<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Neurobiol</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol. Neurobiol</journal-id>
<journal-title-group>
<journal-title>Molecular Neurobiology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0893-7648</issn>
<issn pub-type="epub">1559-1182</issn>
<publisher>
<publisher-name>Springer US</publisher-name>
<publisher-loc>New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29307081</article-id>
<article-id pub-id-type="pmc">6061181</article-id>
<article-id pub-id-type="publisher-id">822</article-id>
<article-id pub-id-type="doi">10.1007/s12035-017-0822-x</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Immune Abnormalities in Autism Spectrum Disorder—Could They Hold Promise for Causative Treatment?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gładysz</surname>
<given-names>Dominika</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Krzywdzińska</surname>
<given-names>Amanda</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Hozyasz</surname>
<given-names>Kamil K.</given-names>
</name>
<address>
<email>khozyasz@verco.com.pl</email>
<email>kamil.hozyasz@imid.med.pl</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0621 4763</institution-id><institution-id institution-id-type="GRID">grid.418838.e</institution-id><institution>Department of Pediatrics, </institution><institution>Institute of Mother and Child, </institution></institution-wrap>Warsaw, Poland </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>6</day>
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>6</day>
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2018</year>
</pub-date>
<volume>55</volume>
<issue>8</issue>
<fpage>6387</fpage>
<lpage>6435</lpage>
<history>
<date date-type="received">
<day>19</day>
<month>6</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>11</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2018</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Autism spectrum disorders (ASD) are characterized by impairments in language and communication development, social behavior, and the occurrence of stereotypic patterns of behavior and interests. Despite substantial speculation about causes of ASD, its exact etiology remains unknown. Recent studies highlight a link between immune dysfunction and behavioral traits. Various immune anomalies, including humoral and cellular immunity along with abnormalities at the molecular level, have been reported. There is evidence of altered immune function both in cerebrospinal fluid and peripheral blood. Several studies hypothesize a role for neuroinflammation in ASD and are supported by brain tissue and cerebrospinal fluid analysis, as well as evidence of microglial activation. It has been shown that immune abnormalities occur in a substantial number of individuals with ASD. Identifying subgroups with immune system dysregulation and linking specific cellular immunophenotypes to different symptoms would be key to defining a group of patients with immune abnormalities as a major etiology underlying behavioral symptoms. These determinations would provide the opportunity to investigate causative treatments for a defined patient group that may specifically benefit from such an approach. This review summarizes recent insights into immune system dysfunction in individuals with ASD and discusses the potential implications for future therapies.</p>
<sec>
<title>Electronic supplementary material</title>
<p>The online version of this article (10.1007/s12035-017-0822-x) contains supplementary material, which is available to authorized users.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>ASD</kwd>
<kwd>Autism</kwd>
<kwd>Cytokine</kwd>
<kwd>Chemokine</kwd>
<kwd>Lymphocytes</kwd>
<kwd>Immune system</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer Science+Business Media, LLC, part of Springer Nature 2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<p id="Par2">
<disp-quote><p id="Par3">“The human body is a machine which winds its own springs”</p><p id="Par4">Julien Offray de La Mettrie (eighteenth-century French physician and philosopher)</p></disp-quote>
</p>
<p id="Par5">Autism spectrum disorders (ASD), according to the International Statistical Classification of Diseases and Related Health Problems and the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>] criteria, belong to pervasive developmental disorders (PDD) and are characterized by the coexistence of primary symptoms across several areas: improper or impaired language and communication development, difficulties in social attachment and interactions, and occurrence of rigid, stereotypic and repetitive patterns of behavior and interests. ASD children require comprehensive care and the support of specialists from various fields [<xref ref-type="bibr" rid="CR2">2</xref>–<xref ref-type="bibr" rid="CR5">5</xref>]. Incidence rates of ASD are controverted and dependent on diagnostic criteria. The Centers for Disease Control and Prevention calculated that the overall prevalence of ASD in children aged 8 years in the USA equaled 1 out of 68 children [<xref ref-type="bibr" rid="CR6">6</xref>]. It is a serious social problem and an increasing global burden with implications for public health services [<xref ref-type="bibr" rid="CR7">7</xref>].</p>
<p id="Par6">Numerous attempts to determine the etiology of ASD have been conducted; nonetheless, it remains largely elusive. It is considered that genetic, neurological, immunological, and environmental factors play a role in the development of ASD. Growing attention is being paid to neuroimmunology as dysregulation of immune responses may lead to impairments in neurodevelopment and numerous findings of altered immune system function in ASD individuals have been reported [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
<sec id="Sec1">
<title>Immunological background of ASD</title>
<p id="Par7">The first suggestion of a link between the immune system and ASD was formed by Stubbs in 1976 because of undetectable rubella antibody titers after a rubella vaccine challenge in autistic children [<xref ref-type="bibr" rid="CR9">9</xref>]. Several studies in animal models confirmed that an immune challenge during pregnancy results in behavioral abnormalities. Maternal immune activation was shown to activate a macrophage inflammatory state with increased M1 polarization [<xref ref-type="bibr" rid="CR10">10</xref>], lead to up-regulation of interferon-gamma (IFN-γ) and interleukin (IL) 17a secreted by CD4<sup>+</sup> T cells [<xref ref-type="bibr" rid="CR11">11</xref>], and cause a systemic deficit of T regulatory cells (Tregs) [<xref ref-type="bibr" rid="CR12">12</xref>].</p>
<p id="Par8">Mice injected with valproic acid during their gestational period were found to have reduced social interactions and therefore are proposed as a mouse model of ASD. They have chronic glial activation and present with an inflammatory response as evidenced by increasing numbers of microglia and production of higher levels of proinflammatory cytokines when stimulated with lipopolysaccharides (LPS) [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
<p id="Par9">Presence of maternal anti-fetal brain autoantibodies has been reported to play a role in ASD as well [<xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR20">20</xref>]. Monkeys exposed prenatally to human immunoglobulin G (IgG) derived from mothers of ASD children were found to exhibit stereotypies, hyperactivity [<xref ref-type="bibr" rid="CR21">21</xref>], or impaired social behavior [<xref ref-type="bibr" rid="CR22">22</xref>]. Similar results were observed in mice [<xref ref-type="bibr" rid="CR23">23</xref>]. BTBR mice (as a mouse model of ASD) were found to have higher levels of serum IgG, immunoglobulin E (IgE), and anti-brain antibodies along with up-regulation of several cytokines [<xref ref-type="bibr" rid="CR24">24</xref>].</p>
<p id="Par10">Family history of autoimmunity has been reported as a risk factor for ASD in multiple studies [<xref ref-type="bibr" rid="CR25">25</xref>–<xref ref-type="bibr" rid="CR39">39</xref>]. A meta-analysis on this topic identified hypothyroidism, type 1 diabetes, rheumatoid arthritis, and psoriasis as a major family history burden [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Maternal autoimmune diseases beginning during pregnancy can strongly impact risk of ASD in offspring as well [<xref ref-type="bibr" rid="CR39">39</xref>].</p>
<p id="Par11">An association between some alleles of human leukocyte antigens (HLA) and autoimmune diseases has been established. Several studies have revealed links between HLA and ASD, where autistic children were found to have a higher frequency of HLA-DRB1*11 allele and lower frequency of HLA-DRB1*03 allele [<xref ref-type="bibr" rid="CR40">40</xref>]. Several other investigators reported on an association between HLA and ASD in different populations including Caucasian [<xref ref-type="bibr" rid="CR41">41</xref>–<xref ref-type="bibr" rid="CR45">45</xref>], Thai [<xref ref-type="bibr" rid="CR46">46</xref>], Saudi Arabian [<xref ref-type="bibr" rid="CR47">47</xref>], and Chinese [<xref ref-type="bibr" rid="CR48">48</xref>]. An interesting association of HLA-G polymorphism with ASD, likely a consequence of prenatal immune activation, was reported by Guerini et al. [<xref ref-type="bibr" rid="CR49">49</xref>]. HLA-DR4 in mothers was also reported as the ASD risk factor for their offspring [<xref ref-type="bibr" rid="CR50">50</xref>]. Consideration of genetic polymorphisms in the HLA region is advised when studying immunopathology of the disease [<xref ref-type="bibr" rid="CR51">51</xref>].</p>
<p id="Par12">A presence of brain autoantibodies in children with ASD also suggests immunological involvement [<xref ref-type="bibr" rid="CR52">52</xref>–<xref ref-type="bibr" rid="CR63">63</xref>]. Severity of ASD, measured with Childhood Autism Rating Scale (CARS), was found to be correlated with serum anti-neuronal [<xref ref-type="bibr" rid="CR54">54</xref>] and anti-ganglioside M1 antibodies [<xref ref-type="bibr" rid="CR63">63</xref>]. Anti-brain antibodies have been found to correlate with more impaired cognitive functions, motor stereotypies [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR57">57</xref>], irritability, and lower expressive language skills [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR57">57</xref>].</p>
<p id="Par13">An accumulation of evidence in favor of an immune pathomechanism has led to studies of neonatal and mid-gestational cytokines as early markers of ASD (Table <xref ref-type="table" rid="Tab1">1</xref>). In a population-based case–control study, monocyte chemotactic protein-1 (MCP-1) was elevated and the chemokine RANTES (for regulated upon activation, normal T-cell expressed and secreted) was decreased in newborn peripheral blood retrieved from archives that collected dried bloodspots for screening purposes (obtained 24–48 h after birth). RANTES was also found to be down-regulated in children with developmental delays other than ASD along with macrophage inflammatory protein-1α (MIP-1α) [<xref ref-type="bibr" rid="CR66">66</xref>]. Another approach to identify children at risk for ASD was proposed by Goines et al. [<xref ref-type="bibr" rid="CR71">71</xref>], who showed that increased IFN-γ, IL-4, and IL-5 in pregnant women at 15 to 19 weeks of gestation was associated with increased risk of bearing a child with ASD. A study from the same center revealed that mid-gestational concentration of cytokines and chemokines (especially granulocyte macrophage colony-stimulating factor—GM-CSF, IFN-γ, IL-1α, and IL-6) was highest in mothers of ASD children with intellectual disability [<xref ref-type="bibr" rid="CR64">64</xref>]. A high concentration of IL-4 was found to be associated with increased risk of severe ASD, while IL-1β correlated with mild to moderate ASD [<xref ref-type="bibr" rid="CR65">65</xref>]. A series of studies by Abdallah et al. [<xref ref-type="bibr" rid="CR67">67</xref>–<xref ref-type="bibr" rid="CR70">70</xref>] demonstrated a strong association of multiple cytokines detected in material from newborn screening, as well as several chemokines (MCP-1, MIP-1α, RANTES) and growth factors (brain-derived neurotrophic factor—BDNF, neurotrophin—NT, transforming growth factor-beta—TGF-β), in both neonatal dried bloodspots and amniotic fluid [<xref ref-type="bibr" rid="CR70">70</xref>]. Down-regulation of NT in dried bloodspots of ASD children was confirmed by Nelson et al. [<xref ref-type="bibr" rid="CR72">72</xref>]. The search for potential ASD biomarkers is well underway [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]; for an excellent review, see Anderson [<xref ref-type="bibr" rid="CR75">75</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of studies on neonatal and gestational ASD immune-specific biomarkers</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Number</th><th>Study</th><th>Country</th><th>Time of sample collection</th><th>Study group maternal age (years)</th><th>Study group gestational age</th><th>Groups</th><th>Females (%)</th><th>Perinatal history</th><th>Psychological tools</th><th>Study material</th><th>Cytokines</th><th>Chemokines</th><th>Growth factors</th><th>Other analytes</th><th>Main results</th></tr></thead><tbody><tr><td>1</td><td>Jones et al. 2017 [<xref ref-type="bibr" rid="CR64">64</xref>]</td><td>USA, Mexico</td><td>2000–2003</td><td>M: 30.01, SD: 5.67</td><td>x</td><td>ASD (<italic>n</italic> = 415), DD (<italic>n</italic> = 188), HC (<italic>n</italic> = 428)</td><td>ASD (17.3), DD (43.6), HC (17.1)</td><td>Unknown, apart from plurality and parity</td><td>DSM-IV</td><td>Mid-gestational serum</td><td>IL-1RA, IL-1β, IL-2, IL-6, IL-9, IL-10, IL-12, IL-18, IFN-γ, TNF-α</td><td>CXCL1 (GRO-α), CXCL8 (IL-8)</td><td>GM-CSF</td><td>x</td><td>ASD+ID vs. DD: ↑GM-CSF, TNF-α, IL-1α, IL-1β, IL-6, IFN-γ, IL-10, IL-1Ra, MCP-1</td></tr><tr><td>2</td><td>Krakowiak et al. 2017 [<xref ref-type="bibr" rid="CR65">65</xref>]</td><td>USA</td><td>2003–2005, mean 7.8 ± 1.4 years from collection to analysis</td><td>No data</td><td>39.3 ± 1.8, 31–45</td><td>ASD (<italic>n</italic> = 214), DD (<italic>n</italic> = 27), HC (<italic>n</italic> = 62)</td><td>ASD (12), DD (41), HC (19)</td><td>Unknown</td><td>DSM-V, ADI-R, ADOS, ABC, MSEL, SCQ, VABS</td><td>Dried bloodspots, routine newborn screening</td><td>IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IFN-γ, TNF-α</td><td>CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), CCL11 (eotaxin), CXCL8 (IL-8), CXCL10 (IP-10)</td><td>x</td><td>x</td><td>severe ASD vs. mild ASD: ↑IL-4; severe ASD vs. HC: ↑IL-4; mild ASD vs. HC: ↑IL-1β</td></tr><tr><td>3</td><td>Zerbo et al. 2014 [<xref ref-type="bibr" rid="CR66">66</xref>]</td><td>USA, Mexico</td><td>2000–2001</td><td>Mdn: 31, IQR: 28–34</td><td>Preterm (<italic>n</italic> = 9), term (<italic>n</italic> = 75)</td><td>ASD (<italic>n</italic> = 84), DD (<italic>n</italic> = 49), HC (<italic>n</italic> = 159)</td><td>ASD (13.1), DD (40.8), HC (12.6)</td><td>Unknown</td><td>DSM-IV</td><td>Dried bloodspots, routine newborn screening</td><td>IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p40, IFN-γ, TNF-α</td><td>CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), CCL11 (eotaxin), CXCL8 (IL-8), CXCL10 (IP-10)</td><td>GM-CSF</td><td>x</td><td>ASD vs. HC: ↑MCP-1 ↓RANTES; DD vs. HC: ↓MIP-1α, RANTES</td></tr><tr><td>4</td><td>Abdallah et al. 2013 [<xref ref-type="bibr" rid="CR67">67</xref>]</td><td>Denmark</td><td>1982–2000</td><td>&lt; 30 (<italic>n</italic> = 95), 30–35 (<italic>n</italic> = 101), &gt; 35 (<italic>n</italic> = 163)</td><td>Preterm (<italic>n</italic> = 32), term (<italic>n</italic> = 324), postterm (<italic>n</italic> = 3)</td><td>ASD (<italic>n</italic> = 359), HC (<italic>n</italic> = 741)</td><td>ASD (18.9), HC (19.7)</td><td>Parity, Apgar score, birth weight, congenital malformations</td><td>ICD-8, ICD-10</td><td>Dried bloodspots, routine newborn screening.</td><td>x</td><td>x</td><td>BDNF, NT-4, TGF-β</td><td>x</td><td>ASD children—BDNF around 10th percentile and NT-4 less likely in upper percentiles, female ASD children—TGF-β around 10th percentile,</td></tr><tr><td>5</td><td>Abdallah et al. 2013 [<xref ref-type="bibr" rid="CR68">68</xref>]</td><td>Denmark</td><td>1982–2000</td><td>&lt; 30 (<italic>n</italic> = 95), 30–35 (<italic>n</italic> = 101), &gt; 35 (<italic>n</italic> = 163)</td><td>Preterm (<italic>n</italic> = 32), term (<italic>n</italic> = 324), postterm (<italic>n</italic> = 3)</td><td>ASD (<italic>n</italic> = 359), HC (<italic>n</italic> = 741)</td><td>ASD (18.9), HC (19.7)</td><td>Parity, Apgar score, birth weight, congenital malformations</td><td>ICD-8, ICD-10</td><td>Dried bloodspots, routine newborn screening.</td><td>x</td><td>CCL2 (MCP-1), CCL3 (MIP-1α), CCL5 (RANTES)</td><td>x</td><td>x</td><td>Females with ASD: ↑RANTES</td></tr><tr><td>6</td><td>Abdallah et al. 2013 [<xref ref-type="bibr" rid="CR68">68</xref>]</td><td>Denmark</td><td>1982–2000</td><td>&lt; 30 (<italic>n</italic> = 109), 30–35 (<italic>n</italic> = 120), &gt; 35 (<italic>n</italic> = 185)</td><td>Preterm (<italic>n</italic> = 43), term (<italic>n</italic> = 368), postterm (<italic>n</italic> = 3)</td><td>ASD (<italic>n</italic> = 331), HC (<italic>n</italic> = 698)</td><td>ASD (19.1), HC (19.5)</td><td>Parity, Apgar score, birth weight, congenital malformations</td><td>ICD-8, ICD-10</td><td>Amniotic fluid</td><td>x</td><td>CCL2 (MCP-1), CCL3 (MIP-1α), CCL5 (RANTES)</td><td>x</td><td>x</td><td>ASD vs. HC: ↑MCP-1</td></tr><tr><td>7</td><td>Abdallah et al. 2012 [<xref ref-type="bibr" rid="CR69">69</xref>]</td><td>Denmark</td><td>1982–2000</td><td>&lt; 30 (<italic>n</italic> = 109), 30–35 (<italic>n</italic> = 120), &gt; 35 (<italic>n</italic> = 185)</td><td>Preterm (<italic>n</italic> = 43), term (<italic>n</italic> = 368), postterm (<italic>n</italic> = 3)</td><td>ASD (<italic>n</italic> = 331), HC (<italic>n</italic> = 698)</td><td>ASD (19.1), HC (19.5)</td><td>Parity, Apgar score, birth weight, congenital malformations</td><td>ICD-8, ICD-10</td><td>Amniotic fluid</td><td>x</td><td>x</td><td>BDNF, NT-4, TGF-β</td><td>MMP-9</td><td>ASD vs. HC: ↑MMP-9</td></tr><tr><td>8</td><td>Abdallah et al. 2012 [<xref ref-type="bibr" rid="CR70">70</xref>]</td><td>Denmark</td><td>1982–2000</td><td>&lt; 30 (<italic>n</italic> = 95), 30–35 (<italic>n</italic> = 101), &gt; 35 (<italic>n</italic> = 163)</td><td>Preterm (<italic>n</italic> = 32), term (<italic>n</italic> = 324), postterm (<italic>n</italic> = 3)</td><td>ASD (<italic>n</italic> = 359), HC (<italic>n</italic> = 741)</td><td>ASD (18.9), HC (19.7)</td><td>Parity, Apgar score, birth weight, congenital malformations</td><td>ICD-8, ICD-10</td><td>Dried bloodspots, routine newborn screening.</td><td>IL-1β, IL-2, IL-4, IL-5, IL-6, sIL-6rα, IL-10, IL-12, IL-17, IL-18, IFN-γ, TNF-α, TNF-β</td><td>CXCL8 (IL-8)</td><td>GM-CSF</td><td>TREM-1</td><td>ASD vs. HC: ↓ IL-1β, IL-10; ASD children had GM-CSF, IFN-γ, IL-2, IL-4, IL-6 more likely around 10th percentile and IL-8 more likely around 90th percentile</td></tr><tr><td>9</td><td>Goines et al. 2011 [<xref ref-type="bibr" rid="CR71">71</xref>]</td><td>USA, Mexico</td><td>x</td><td>M: 30.9, SD: 5.2</td><td>x</td><td>ASD (<italic>n</italic> = 84), DD (<italic>n</italic> = 49), HC (<italic>n</italic> = 159)</td><td>ASD (13.1), DD (40.8), HC (12.6)</td><td>Unknown, apart from plurality and parity</td><td>DSM-IV</td><td>Mid-gestational serum</td><td>IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p40, IFN-γ, TNF-α</td><td>CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), CCL11 (eotaxin), CXCL8 (IL-8), CXCL10 (IP-10)</td><td>GM-CSF</td><td>x</td><td>ASD vs. HC: ↑IFN-γ, IL-4, IL-5; DD vs. HC: ↑IL-2, IL-4, IL-6</td></tr><tr><td>10</td><td>Nelson et al. 2006 [<xref ref-type="bibr" rid="CR72">72</xref>]</td><td>USA</td><td>1998–1995</td><td>No data</td><td>No exact data</td><td>ASD (<italic>n</italic> = 47), DS (<italic>n</italic> = 46), HC (<italic>n</italic> = 90, including 28 preterm, 50 term, and 12 adults)</td><td>No data</td><td>Unknown</td><td>DSM-IV</td><td>Amniotic fluid</td><td>x</td><td>CXCL8 (IL-8)</td><td>BDNF</td><td>VIP, CGRP, NT-3, NT-4/5</td><td>ASD vs. HC: ↓NT-3</td></tr></tbody></table><table-wrap-foot><p><italic>M</italic> mean, <italic>SD</italic> standard deviation, <italic>Mdn</italic> median, <italic>IQR</italic> interquartile range, <italic>ASD</italic> autism spectrum disorders, <italic>DD</italic> developmental delay, <italic>HC</italic> healthy controls, <italic>DSM</italic> Diagnostic and Statistical Manual of Mental Disorders, <italic>ADI-R</italic> Autism Diagnostic Interview–Revised, <italic>ADOS</italic> Autism Diagnostic Observation Schedule, <italic>CARS</italic> Childhood Autism Rating Scale, <italic>MSEL</italic> Mullen Scales of Early Learning, <italic>SCQ</italic> Social Communication Questionnaire, <italic>VABS</italic> Vineland Adaptive Behavior Scale, <italic>ICD</italic> International Statistical Classification of Diseases and Related Health Problems, <italic>IL</italic> interleukin, <italic>IFN</italic> interferon, <italic>TNF</italic> tumor necrosis factor, <italic>TGF</italic> transforming growth factor, <italic>s</italic> soluble, <italic>R</italic> receptor, <italic>CXCL</italic> C-X-C motif chemokine ligand, <italic>GRO</italic> growth-regulated oncogene, <italic>MIP</italic> macrophage inflammatory protein, <italic>MCP</italic> monocyte chemoattractant protein, <italic>RANTES</italic> regulated upon activation normal T-cell expressed and secreted, <italic>CCL</italic> C-C motif chemokine ligand, <italic>IP-10</italic> IFN-γ-inducible protein 10, <italic>GM-CSF</italic> granulocyte-macrophage colony-stimulating factor, <italic>BDNF</italic> brain-derived neurotrophic factor, <italic>NT</italic> neurotrophin, <italic>MMP</italic> matrix metalloproteinase, <italic>TREM</italic> triggering receptor expressed on myeloid cells, <italic>VIP</italic> vasoactive intestinal peptide, <italic>CGRP</italic> calcitonin gene-related peptide</p></table-wrap-foot></table-wrap></p>
<p id="Par14">ASD is very complex and heterogeneous. The question of whether immune dysregulation is a primary cause or secondary consequence is still open. Even if immune system integrity turns out to be a key player in ASD pathogenesis, it surely will not be the sole factor responsible for behavioral abnormalities. However, evidence for an immunological component is strong. It is worth noting that all published studies on neonatal and gestational immune mediators have succeeded in detecting some abnormalities in comparison to typically developing controls. However, attention should be given to some methodological concerns, such as lengthy times from sample collection to analysis, incomplete perinatal histories, lack of details on behavioral abnormalities, and cases of no clinical confirmation of ASD. Only the Krakowiak et al. study [<xref ref-type="bibr" rid="CR65">65</xref>] confirmed ASD diagnoses and made an effort to evaluate behavioral traits. Interestingly, besides mediators classically associated with inflammation, an elevation of Th-2 cytokines was noted. An up-regulated concentration of serum mid-gestational IL-10 in mothers of autistic children was reported by Jones et al. [<xref ref-type="bibr" rid="CR64">64</xref>]. These results should be interpreted with caution, however, as IL-10 is known to be physiologically elevated during pregnancy [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>] and its concentration was normal in another study from the same biological sample [<xref ref-type="bibr" rid="CR71">71</xref>], and was not elevated [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>] or even down-regulated [<xref ref-type="bibr" rid="CR70">70</xref>] in three other studies that utilized dried bloodspots from newborn screening. Surprisingly, another Th2 cytokine, IL-4, was found to be elevated in newborn dried bloodspots (acquired from children that were determined to have ASD) by Krakowiak et al. [<xref ref-type="bibr" rid="CR65">65</xref>] who conducted the study with the best methodological quality. Moreover, high IL-4 level was connected with severe ASD. Another study found elevated IL-4 concentration in mid-gestational serum from mothers of children with ASD, which could be partially attributed to changes during pregnancy [<xref ref-type="bibr" rid="CR76">76</xref>]. One of two experiments based on dried bloodspots did not detect any abnormalities [<xref ref-type="bibr" rid="CR66">66</xref>], while another revealed tendency toward lower IL-4 concentrations in neonates that developed ASD [<xref ref-type="bibr" rid="CR70">70</xref>]. Clearly, the purpose of these studies was to identify biomarkers that could precede occurrence of autistic traits. However, this task is very hard or nearly impossible due to several other perinatal factors that can alter results and due to methodological difficulties, particularly in confirming ASD diagnosis and finding connections between behavioral abnormalities and immune disturbances.</p>
</sec>
<sec id="Sec2">
<title>Lymphocytes</title>
<p id="Par15">One of the first clues concerning lymphocyte pathology in ASD was described by Stubbs and Crawford who found decreased lymphocyte response to stimulation with phytohemagglutinin (PHA) in children with ASD [<xref ref-type="bibr" rid="CR78">78</xref>]. One of the first studies on lymphocyte subsets in ASD was carried out by Warren et al. in 1986 [<xref ref-type="bibr" rid="CR79">79</xref>]. The investigators found a decreased number of T lymphocytes, reduced response to stimulation with PHA, concanavalin A, and pokeweed mitogen, and an imbalanced ratio of helper/suppressor cells. Another study confirmed lower helper/suppressor ratio with a decreased percentage of helper–inducer cells and decreased percentage of cells with expression of IL-2R after mitogenic stimulation being inversely correlated with severity of autistic traits [<xref ref-type="bibr" rid="CR80">80</xref>].</p>
<p id="Par16">Another early study on lymphocytes in ASD showed lower numbers of total lymphocytes in peripheral blood of ASD children compared to sibling and healthy controls, along with a significantly lower percentage and number of CD4<sup>+</sup> helper T cells [<xref ref-type="bibr" rid="CR81">81</xref>]. Ashwood et al. [<xref ref-type="bibr" rid="CR82">82</xref>] reported significantly higher number of B cells in children with ASD aged 4–6 years in comparison with age- and sex-matched typically developing controls. The study protocol involved 64 three-color cellular assays that revealed higher counts of activated and mature B cells and higher numbers of cellular activation markers such as HLA-DR and CD26. The investigators further divided children into low and high functioning individuals according to intelligence quotient (IQ) measured with Stanford–Binet Intelligence Scale; however, there were no differences within subgroups. Ferrante et al. [<xref ref-type="bibr" rid="CR83">83</xref>] observed a significant increase in CD4<sup>+</sup> memory and decrease in CD4<sup>+</sup> naïve T cells associated with HLA A2-DR11. Warren et al.’s studies [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>] on lymphocyte subpopulations revealed incomplete T cell activation, decreased numbers of lymphocytes and CD4<sup>+</sup>CD45RA<sup>+</sup> cells, and normal levels of B, NK, and other T cells. Abnormalities regarding suppressor–inducer T cells have shifted researchers’ attention to T-cell biology in ASD.</p>
<p id="Par17">Tregs play a key role in regulation of immune responses. A study on Egyptian children [<xref ref-type="bibr" rid="CR86">86</xref>] revealed lower numbers of CD4<sup>+</sup>CD25<sup>high</sup> Tregs in the blood of autistic children. Moreover, allergic problems and family history of autoimmunity turned out to be risk factors for the lowest number of CD4<sup>+</sup>CD25<sup>high</sup> Tregs. The study was conducted on 30 patients and 30 age- and sex-matched healthy controls.</p>
<p id="Par18">Dysregulation of Th1, Th2, Th17, and Treg-related transcription factors has also been described. Mononuclear cells derived from peripheral blood (PB-MNC) of autistic children and typically developing controls were stimulated and subsequently assessed for expression of mRNA and proteins of major transcription factors involved in neurodevelopment and differentiation of T cells. A deficit of forkhead box protein 3<sup>+</sup> Tregs was found along with up-regulation of Th1/Th2/Th17-related transcription factors [<xref ref-type="bibr" rid="CR87">87</xref>].</p>
<p id="Par19">An imbalance of cytokines produced by CD4<sup>+</sup> and CD8<sup>+</sup> T cells with skewing toward Th2 response was found in 1997 by Gupta et al. [<xref ref-type="bibr" rid="CR88">88</xref>]. Proportions of CD4<sup>+</sup> and CD8<sup>+</sup> T cells producing IFN-γ and IL-2 were reduced in opposition to T cells that produced IL-4. Further insight into Th2 response was provided by a study that concentrated on Th2 lymphocyte receptor ligands of 56 ASD children with 32 matched controls. Serum levels of macrophage-derived chemokine (MDC) and thymus and activation-regulated chemokine (TARC) were elevated and significantly correlated with intensification of autistic behaviors [<xref ref-type="bibr" rid="CR89">89</xref>]. A higher percentage of CD8<sup>+</sup> T cells (21.68% vs. 16.48%) and B cells (8.17% vs. 6.97%) and a decrease of CD4<sup>+</sup>/CD8<sup>+</sup> ratio (3.01 vs. 3.97) was reported in 59 adult patients with ASD with a mean age of about 24 years versus a control group composed of 26 individuals, two of which were first-degree relatives, with no significant differences regarding age and gender of study participants [<xref ref-type="bibr" rid="CR90">90</xref>].</p>
<p id="Par20">Immune dysfunction is also observed in healthy siblings of ASD children, their immunophenotype is closer to their relatives than to typically developing matched controls. They have been found to have a higher concentration of cytokine-producing lymphocytes and CD8<sup>+</sup> naïve T lymphocytes along with a down-regulation of CD8<sup>+</sup> effector memory and CD4<sup>+</sup> terminally differentiated lymphocytes [<xref ref-type="bibr" rid="CR91">91</xref>].</p>
<p id="Par21">Th17 CD4<sup>+</sup> T cells are thought to be important players in autoimmune and neuroinflammatory diseases. Their product, IL-17A, is known to be up-regulated in several autoimmune diseases such as multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis [<xref ref-type="bibr" rid="CR92">92</xref>]. A cross-sectional study by Al-Ayadhi and Mostafa [<xref ref-type="bibr" rid="CR93">93</xref>] on 45 children with ASD aged 6–11 years revealed a positive correlation of IL-17A with ASD severity. Nearly 50% of autistic children had elevated serum IL-17A levels, including 67.9% of children with severe and 17% of children with mild to moderate ASD. Up-regulation of IL-17 was also found in ASD children with concomitant asthma after T-cell stimulation with PHA [<xref ref-type="bibr" rid="CR94">94</xref>]. A strong association of ASD with Th17 cells has also been demonstrated in animal studies, where effector cytokine IL-17a was essential for maternal immune activation and subsequent behavioral abnormalities [<xref ref-type="bibr" rid="CR95">95</xref>]. IL-23, known to increase Th17 cell production of IL-17, was found to be down-regulated, especially in children with new-onset ASD, with no concomitant differences in IL-17 levels. Stimulation with PHA altered secretion of IL-23, which was found to be significantly lower than in typically developing controls and associated with more impaired behavioral scores [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>].</p>
<p id="Par22">A BTBR mouse model of ASD was found to have up-regulated IgG production with IgG brain deposits and anti-brain IgG antibodies [<xref ref-type="bibr" rid="CR98">98</xref>]. Several studies in humans have assessed concentrations of serum immunoglobulins and their subclasses in ASD individuals with discrepant results. A study on 15 subjects with ASD, 5 of whom underwent cerebrospinal fluid (CSF) immunoglobulin analysis, found no abnormalities [<xref ref-type="bibr" rid="CR99">99</xref>]. Serum immunoglobulin A (IgA) deficiency was found by Warren et al. [<xref ref-type="bibr" rid="CR100">100</xref>] in 40 individuals with ASD, both children and adults. Eight of 40 studied ASD patients had IgA levels below normal range adjusted for age, while in control groups there were no abnormalities. Mean serum IgA level of autistic individuals was significantly lower than in the control group (105 mg/100 mL vs. 143 mg/100 mL). Similar observations were made by Wasilewska et al. [<xref ref-type="bibr" rid="CR101">101</xref>] who reported on lower IgA levels and up-regulated expression of CD23 on B lymphocytes derived from children with regressive ASD aged 3–6 years old. The studied groups consisted of 24 age- and gender-matched individuals with no differences regarding demographics and perinatal history.</p>
<p id="Par23">In a study on 31 patients with selective IgA deficiency, 1 had a diagnosis of ASD [<xref ref-type="bibr" rid="CR102">102</xref>]. The researchers focused on the offspring and siblings of the abovementioned group. Out of 87 children born to individuals with IgA deficiency, 3 had a diagnosis of ASD in comparison to 1 child out of 193 children born to subjects with normal IgA concentration. ASD was diagnosed in 2% of siblings (2/99 individuals) of IgA-deficient patients in contrast with 0.5% of siblings (1/217 individuals) in the control group. However, the abovementioned results did not reach statistical significance [<xref ref-type="bibr" rid="CR102">102</xref>].</p>
<p id="Par24">Analysis of plasma levels of immunoglobulins in over 100 individuals with ASD revealed reduced levels of IgG and immunoglobulin M (IgM) that inversely correlated with scores on the Aberrant Behavior Checklist (ABC), with lethargy being especially pronounced in children with the lowest IgG [<xref ref-type="bibr" rid="CR103">103</xref>]. The mean IgG level in ASD individuals equaled 5.39 mg/mL in contrast to 7.72 mg/mL in typically developing co6ntrols, and 8.23 mg/mL in children with developmental delay. IgM level was less evident; however, it was statistically significant (0.67 mg/mL in comparison to 0.79 mg/mL in healthy controls).</p>
<p id="Par25">Further in-depth studies revealed that the detected abnormalities were not a result of B-cell dysfunction. There were no differences in the number of naïve, memory IgG or IgM cells, no abnormalities in response to antigenic stimulation, and production of immunoglobulins after in vitro stimulation was detected. The authors hypothesized that the lower level of immunoglobulins is caused by either a defect in another immune cell type that takes part in immunoglobulin production or a defect during immune system development [<xref ref-type="bibr" rid="CR104">104</xref>].</p>
<p id="Par26">Plasma concentration of IgM as well as IgG, especially IgG4, was reported to be increased in ASD patients in comparison to healthy siblings. Moreover, IgG1 subclass was found to be increased in comparison with healthy siblings of the same gender [<xref ref-type="bibr" rid="CR105">105</xref>]. Higher concentrations of IgA, IgG, and IgE food-specific antibodies in individuals with ASD in comparison to their siblings were also described [<xref ref-type="bibr" rid="CR106">106</xref>]. Spiroski et al.’s study [<xref ref-type="bibr" rid="CR107">107</xref>] of immunoglobulins in Macedonian children with ASD revealed alterations in concentration of IgA, IgG2, and IgG3 between ASD children and healthy family members. The study was a retrospective analysis that included 30 autistic children with mean age of 10; the control groups consisted of mothers, fathers, and siblings of affected children. No exact demographical data was given. Because of multiple comparison testing and lack of precise characteristics of examined subjects, study results should be interpreted with caution.</p>
<p id="Par27">According to Croonenberghs et al. [<xref ref-type="bibr" rid="CR108">108</xref>], autistic individuals had higher concentrations of total serum proteins with increased concentrations of albumin and gamma-globulins, especially IgG2 (305 md/dL vs. 216 md/dL) and IgG4 (76 md/dL vs. 48 md/dL). The authors hypothesize that alteration of IgG subclasses may be associated with a cytokine-related influence on autoimmune B cells. Unfortunately, the study was carried out on a small number of subjects (18 with ASD and 22 controls). However, increased IgG4 levels in ASD children in comparison to typically developing controls and children with non-autistic developmental delay were confirmed in another study [<xref ref-type="bibr" rid="CR109">109</xref>].</p>
<p id="Par28">A higher frequency of D8/17 B lymphocytes was found in ASD subjects, especially in subjects with repetitive behaviors [<xref ref-type="bibr" rid="CR110">110</xref>]. This antigen is associated with Tourette syndrome, rheumatic fever, and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections [<xref ref-type="bibr" rid="CR111">111</xref>–<xref ref-type="bibr" rid="CR114">114</xref>]. B cells were found to be hypersensitive to thimerosal [<xref ref-type="bibr" rid="CR115">115</xref>]. Wei et al.’s study [<xref ref-type="bibr" rid="CR116">116</xref>] on B-lymphocyte function in eight ASD individuals found altered cell migration and adhesion as well as improper immunoglobulin formation and secretion. The authors concluded that B-cell abnormalities were caused by disturbed integrin-FAK-Src signaling and reduced paxillin activity. However, the majority of studies assessing B-cell number and function did not detect any abnormalities [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR117">117</xref>].</p>
<p id="Par29">Overall data is suggestive that altered lymphocyte function, especially T-cell subpopulations, occurs in a substantial number of ASD individuals. Multiple studies have reported on lymphocyte pathology and imbalances between lymphocyte subpopulations. The key consistent findings include decreased response to stimulation [<xref ref-type="bibr" rid="CR78">78</xref>–<xref ref-type="bibr" rid="CR80">80</xref>], abnormal activation [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>], improper ratio of T helper and suppressor cells [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR83">83</xref>], down-regulation of Th cells [<xref ref-type="bibr" rid="CR81">81</xref>], and systemic deficit of Tregs [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>] in ASD subjects. These results, along with cytokine abnormalities, provide a broader view of a possible basis for observed ASD aberrations.</p>
</sec>
<sec id="Sec3">
<title>Natural killer cells</title>
<p id="Par30">Natural killer (NK) cells constitute about 15% of circulating lymphocytes and play a pivotal role in the innate immune system [<xref ref-type="bibr" rid="CR118">118</xref>]. They are characterized by a lack of CD3 surface antigen, expression of CD56, and their function is exerted by production of immunomodulatory cytokines such as IFN-γ, tumor necrosis factor-alpha (TNF-α), and IL-10. They also have cytolytic activity and mediate cellular cytotoxicity and surveillance immune function through crosstalk with dendritic cells [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR120">120</xref>]. Imbalances between their activation and inhibitory states could play a role in autoimmune diseases; however, the specific underlying mechanisms are not yet fully understood [<xref ref-type="bibr" rid="CR121">121</xref>]. Roles for NK cells have already been described in the pathogenesis of neurological disorders such as multiple sclerosis [<xref ref-type="bibr" rid="CR122">122</xref>], schizophrenia [<xref ref-type="bibr" rid="CR123">123</xref>], Tourette syndrome [<xref ref-type="bibr" rid="CR124">124</xref>], and Rett syndrome [<xref ref-type="bibr" rid="CR125">125</xref>].</p>
<p id="Par31">A previously described study by Ashwood et al. [<xref ref-type="bibr" rid="CR82">82</xref>] reported higher absolute numbers of NK cells in peripheral blood of autistic individuals (161 cells/μL vs. 117 cells/μL). Reduced NK cell activity associated with ASD was first reported by Warren et al. in 1987 [<xref ref-type="bibr" rid="CR126">126</xref>]. The study was carried out using K562 tumor cells, from 31 patients with ASD, as target cells and found that cells from 12 of the ASD patients had significantly reduced cytotoxic activity. Enstrom et al.’s study [<xref ref-type="bibr" rid="CR127">127</xref>] on NK cells revealed an increased expression of NK cell receptor RNA, along with an up-regulated number of NK cells (21.24 ± 3.40 × 10<sup>4</sup>cells/mL vs. 14.45 ± 1.98 × 10<sup>4</sup> cells/mL), and production of perforin, granzyme B, and IFN-γ in blood samples from ASD children compared to typically developing controls. Cellular studies were carried out on 17 autistic individuals aged 2–5 years, and 16 age- and sex-matched controls, while gene expression profile was conducted on 35 ASD children and 11 healthy controls. Cytotoxicity in response to stimulation was reduced in the ASD group. Similar abnormalities were not found in typically developing children. No differences in frequency of CD56<sup>Dim</sup> (cytotoxic properties) or CD56<sup>Bright</sup> (interleukin-producing cells) cells were noted. These results are concordant with previous studies that reported abnormalities in NK cell activity [<xref ref-type="bibr" rid="CR126">126</xref>, <xref ref-type="bibr" rid="CR128">128</xref>] and molecular changes in differentially expressed genes [<xref ref-type="bibr" rid="CR129">129</xref>]. According to Vojdani et al. [<xref ref-type="bibr" rid="CR128">128</xref>], who analyzed peripheral blood samples from over 1000 children, NK cell activity is decreased due to low levels of its stimulants, IL-2 and IL-15. They found no correlation between NK cell absolute number and cytotoxic activity, in opposition to the previously mentioned hypothesis. However, the investigators found a relationship between cell function and low intracellular level of glutathione. They also showed that NK cell activity was higher after co-culture with glutathione, IL-2, and IL-15. However, serum concentrations of those interleukins and subpopulations of CD56<sup>Dim</sup> and CD56<sup>Bright</sup> were not assessed. In 59 adult ASD patients, significantly lower numbers of NKT cells, with normal numbers of NK cells, and increased numbers of stimulated NKT and NK cells expressing CD25<sup>+</sup> were described [<xref ref-type="bibr" rid="CR90">90</xref>].</p>
<p id="Par32">Another approach for NK cell analysis was proposed by Torres et al. [<xref ref-type="bibr" rid="CR130">130</xref>] and Guerini et al. [<xref ref-type="bibr" rid="CR131">131</xref>] who focused on molecular changes by studying killer immunoglobulin receptors (KIR), MHC I class-binding receptors, that are expressed on NK cell surfaces and modulate NK cell function [<xref ref-type="bibr" rid="CR132">132</xref>]. Both activation and inhibition states of KIR have been associated with various diseases including autoimmune disorders [<xref ref-type="bibr" rid="CR133">133</xref>]. Torres et al. [<xref ref-type="bibr" rid="CR130">130</xref>] found up-regulation of KIR-activating genes in patients with ASD. Another study [<xref ref-type="bibr" rid="CR131">131</xref>] suggested that KIR might play a role in in utero ASD pathogenesis as activating KIR/HLA complexes were found to be increased in ASD, detectable in both children with ASD and their mothers.</p>
<p id="Par33">The implications of NK cell pathology in ASD remain unknown, and they seem to be a secondary cause of proinflammatory processes and immune imbalances. Chronic inflammation at the cellular level could lead to persistent activation of NK cells, subsequent reduction of their cytotoxic activity, and compensatory up-regulation of their total number. Increased numbers of NK cells associated with ASD was confirmed in two [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR127">127</xref>] out of five studies [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR126">126</xref>–<xref ref-type="bibr" rid="CR128">128</xref>, <xref ref-type="bibr" rid="CR134">134</xref>]. One study demonstrated the opposite result; however, the study and control group were broader in age demographics (respectively from 3 to 22 years old and from 1 to 12 years old). Abnormal NK cell functional activity was confirmed in both experiments that utilized cytotoxic ability analysis [<xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR128">128</xref>]. One might suspect that either unnaturally low levels of NK cell stimulants (such as IL-15, IL-2, IL-12, IL-18, and IL-21) or that excessively high levels of the stimulants would be observed if the inflammatory milieu leads to NK cell pathogenic activation and loss of cytotoxic properties through exhaustion. Interestingly, abnormalities of these cytokines were scarcely, if ever, found. A major NK cell stimulant, IL-15, was explored in 7 of 57 conducted studies [<xref ref-type="bibr" rid="CR135">135</xref>–<xref ref-type="bibr" rid="CR141">141</xref>] and found significantly up-regulated only in children with ASD who presented with gastrointestinal (GI) disturbances [<xref ref-type="bibr" rid="CR137">137</xref>]. IL-2 was more well studied [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR138">138</xref>–<xref ref-type="bibr" rid="CR149">149</xref>] and turned out to be significantly altered in 4 out of 16 experiments. It was found to be up-regulated in comparison to control group in two studies [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR149">149</xref>] and in one study it was increased among ASD children with GI issues and correlated with impaired adaptive behavior [<xref ref-type="bibr" rid="CR138">138</xref>]. CD-4<sup>+</sup> IL-2-secreting cells were found decreased in one of the earliest studies [<xref ref-type="bibr" rid="CR88">88</xref>]. IL-12 was vastly explored in nearly half of the conducted studies [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR138">138</xref>–<xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR150">150</xref>–<xref ref-type="bibr" rid="CR160">160</xref>] and found frequently increased in ASD subjects in comparison to healthy controls [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR140">140</xref>, <xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR157">157</xref>, <xref ref-type="bibr" rid="CR160">160</xref>]. Interestingly, stimulation in different conditions down-regulated IL-12 concentration [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR153">153</xref>, <xref ref-type="bibr" rid="CR154">154</xref>] apart from stimulation with dietary proteins [<xref ref-type="bibr" rid="CR157">157</xref>]. IL-12 high concentration turned out to be associated with abnormal EEG [<xref ref-type="bibr" rid="CR135">135</xref>], GI complaints [<xref ref-type="bibr" rid="CR158">158</xref>], low IQ [<xref ref-type="bibr" rid="CR138">138</xref>], and prominent aberrant behavior [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]. IL-18 was explored in four studies [<xref ref-type="bibr" rid="CR140">140</xref>–<xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR159">159</xref>] and found elevated in adult males with ASD in comparison to neurotypical controls [<xref ref-type="bibr" rid="CR140">140</xref>], while IL-21 was studied in one experiment and found significantly increased in autistic children compared to normal controls [<xref ref-type="bibr" rid="CR162">162</xref>]. None of the studies assessed NK cell count and function in addition to cytokine levels.</p>
</sec>
<sec id="Sec4">
<title>Monocytes</title>
<p id="Par34">Abnormal monocyte count or function was described in ASD by several investigators [<xref ref-type="bibr" rid="CR151">151</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR161">161</xref>]. Sweeten et al. [<xref ref-type="bibr" rid="CR161">161</xref>] reported a high monocyte count in children with ASD, which was not confirmed in later studies. The difference was small (0.588 × 10<sup>3</sup> cells/mm<sup>3</sup> vs. 0.491 × 10<sup>3</sup> cells/mm<sup>3</sup>), but statistically significant. Monocytes in children with ASD were also found to be positive for a surface receptor that is thought to be expressed on cells susceptible to apoptosis [<xref ref-type="bibr" rid="CR90">90</xref>]. Enstrom et al. [<xref ref-type="bibr" rid="CR155">155</xref>], in a small study on 17 ASD children and 16 healthy controls, stimulated monocytes with Toll-like receptor (TLR) ligands and observed differences between cytokine profiles in autistic and healthy children. Following different LTR stimulations, several cytokines were increased (IL-1β, IL-6, TNF-α) or decreased (IL-1β, IL-6, GM-CSF, and TNF-α) in ASD individuals. However, no difference in number of monocytes was observed. In children with ASD, stimulation with TLR2 and TLR4 led to a high proinflammatory response, while TLR9-induced stimulation resulted in poor production of cytokines and ineffective reaction. Authors concluded that such abnormalities may have an impact on neuronal activity and developing autoimmunity. Jyonouchi et al. [<xref ref-type="bibr" rid="CR151">151</xref>] proposed an interesting study on monocyte cytokine profiles in six groups of patients with and without ASD, including an “inflammatory subtype of ASD” group—patients who presented with symptoms indicating immune dysregulation and GI complaints (other groups included ASD children without non-IgE-mediated food allergy, typically developing controls with non-IgE-mediated food allergy, children with pediatric acute-onset neuropsychiatric syndrome, and healthy controls). The proinflammatory cytokine profile in this group was up-regulated both before and after stimuli. Additionally, children who manifested irritability, lethargy, or hyperactivity were found to produce higher amounts of proinflammatory and lower amounts of anti-inflammatory cytokines (Tables <xref ref-type="table" rid="Tab2">2</xref> and <xref ref-type="table" rid="Tab3">3</xref>). It is worth underlying that cytokine pattern in acute-onset neuropsychiatric syndrome was different than that observed in ASD.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Concentration of cytokines, chemokines, and growth factors in peripheral blood of ASD patients: study participants’ description</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Number</th><th>Study</th><th>Country</th><th>Study group age (years)</th><th>Groups</th><th>Females (%)</th><th>Medication (%)</th><th>ADHD (%)</th><th>Intellectual disability (%)</th><th>Epilepsy (%)</th><th>Psychological tools</th><th>Study material</th></tr></thead><tbody><tr><td>1</td><td>Ahmad et al. 2017 [<xref ref-type="bibr" rid="CR162">162</xref>]</td><td>Saudi Arabia</td><td>M: 7.69, SD: 2.26, R: 3–11</td><td>ASD (<italic>n</italic> = 50), HC (<italic>n</italic> = 45)</td><td>ASD (20), HC (22)</td><td>No</td><td>No data</td><td>No data</td><td>No</td><td>DSM-V, CARS</td><td>PBMNC, stimulation with PMA and ionomycin</td></tr><tr><td>2</td><td>Bryn et al. 2017 [<xref ref-type="bibr" rid="CR142">142</xref>]</td><td>Norway</td><td>M: 11.2, SD: 2.02</td><td>ASD (<italic>n</italic> = 65) including ASD-C <italic>n</italic> = 30, ASD-A <italic>n</italic> = 12, ASD-AS <italic>n</italic> = 16, RS <italic>n</italic> = 1 and another ASD <italic>n</italic> = 6, HC (<italic>n</italic> = 30)</td><td>ASD (20), HC (53)</td><td>No data</td><td>Yes (18.5)</td><td>Yes (39)</td><td>Abnormal EEG (31)</td><td>ICD-10, ADI-R, ADOS, SCQ</td><td>Serum</td></tr><tr><td>3</td><td>Careaga et al. 2017 [<xref ref-type="bibr" rid="CR150">150</xref>]</td><td>USA</td><td>Mdn: 3.21, IQR: 2.80–3.52</td><td>ASD (<italic>n</italic> = 50), HC (<italic>n</italic> = 16)</td><td>ASD (0), HC (0)</td><td>Not relevant</td><td>No data</td><td>No data</td><td>No</td><td>DSM-IV, ICD-10, ADOS, ADI-R, CBCL, MSEL, SCQ</td><td>Plasma, PBMNC supernatants, stimulation with PHA and LPS</td></tr><tr><td>4</td><td>Guloksuz et al. 2017 [<xref ref-type="bibr" rid="CR163">163</xref>]</td><td>Turkey</td><td>M: 7.13, SD: 3.89</td><td>ASD (<italic>n</italic> = 28), PDD-NOS (<italic>n</italic> = 12), HC (<italic>n</italic> = 35)</td><td>ASD and PDD-NOS (25), HC (37)</td><td>No</td><td>No data</td><td>No data</td><td>No</td><td>DSM-IV, CARS</td><td>Plasma</td></tr><tr><td>5</td><td>Han et al. 2017 [<xref ref-type="bibr" rid="CR164">164</xref>]</td><td>China</td><td>ASD-only—M: 9.38, SD: 2.84; ASD + ADHD—M: 9.67, SD: 2.18; HC—M: 10.92, SD: 3.95</td><td>ASD-only (<italic>n</italic> = 13), ASD + ADHD (<italic>n</italic> = 9), HC (<italic>n</italic> = 13)</td><td>ASD-only (0), ASD + ADHD (22), HC (31)</td><td>No immunosuppressive drugs</td><td>Yes (41)</td><td>None</td><td>No data</td><td>DSM-V, ADI-R, CCTT, SRS-2, WISC, CRS-R, FPT, Rey-O, TOL-DX</td><td>Serum</td></tr><tr><td>6</td><td>Jyonouchi et al. 2017<sup>A</sup> [<xref ref-type="bibr" rid="CR165">165</xref>]</td><td>USA</td><td>No data</td><td>ASD (<italic>n</italic> = 71)</td><td>No data</td><td>No data</td><td>No data</td><td>No data</td><td>No data</td><td>No data</td><td>Monocytes, stimulation with TLR agonists</td></tr><tr><td>7</td><td>Makinodan et al. 2017 [<xref ref-type="bibr" rid="CR166">166</xref>]</td><td>Japan</td><td>M: 11.6, SD: 2.7</td><td>ASD (<italic>n</italic> = 30), HC (<italic>n</italic> = 30)</td><td>ASD (0), HC (0)</td><td>No psychoactive medications</td><td>No</td><td>No data</td><td>No</td><td>DSM-IV, ADI-R</td><td>PBMNC</td></tr><tr><td>8</td><td>El-Ansary et al. 2016 [<xref ref-type="bibr" rid="CR73">73</xref>]</td><td>Saudi Arabia</td><td>R: 2–12</td><td>ASD (<italic>n</italic> = 35/29), HC (<italic>n</italic> = 38/16)</td><td>Gender-matched groups</td><td>No data</td><td>No data</td><td>No data</td><td>No</td><td>ADOS, ADI-R, 3DI, SSP</td><td>Plasma</td></tr><tr><td>9</td><td>Ferguson et al. 2016 [<xref ref-type="bibr" rid="CR167">167</xref>]</td><td>USA</td><td>M: 11.8, SD: 3.8, R: 6–18</td><td>ASD (<italic>n</italic> = 120)</td><td>ASD (10)</td><td>No data</td><td>No data</td><td>Yes</td><td>No data</td><td>DSM-IV, ADOS, ABC, WISC/SB, VABS</td><td>Serum</td></tr><tr><td>10</td><td>Jácome et al. 2016 [<xref ref-type="bibr" rid="CR135">135</xref>]</td><td>Cuba</td><td>M: 6.17, SD: 2.08, R: 3–9</td><td>ASD (<italic>n</italic> = 17), HC (<italic>n</italic> = 15)</td><td>ASD (29), HC (47)</td><td>No data</td><td>No data</td><td>No data</td><td>Yes (37.5), all ASD children had abnormal EEG</td><td>DSM-IV, CARS</td><td>Plasma</td></tr><tr><td>11</td><td>Pecorelli et al. 2016 [<xref ref-type="bibr" rid="CR136">136</xref>]</td><td>Italy</td><td>M: 17.7, SD: 7.2, R: 9–37</td><td>ASD (<italic>n</italic> = 12), RTT (<italic>n</italic> = 10), HC (<italic>n</italic> = 8)</td><td>No data</td><td>No data</td><td>No data</td><td>No data</td><td>No data</td><td>DSM-V, ADOS, ABC</td><td>Serum</td></tr><tr><td>12</td><td>Rose et al. 2016<sup>A</sup> [<xref ref-type="bibr" rid="CR137">137</xref>]</td><td>USA</td><td>No data</td><td>ASD, HC</td><td>No data</td><td>No data</td><td>No data</td><td>No data</td><td>No data</td><td>No data</td><td>PBMNC, stimulation with TLR4 agonists</td></tr><tr><td>13</td><td>Akintunde et al. 2015 [<xref ref-type="bibr" rid="CR94">94</xref>]</td><td>USA</td><td>M: 3.56, R: 2–5</td><td>ASD (<italic>n</italic> = 45), HC (<italic>n</italic> = 69)</td><td>ASD (18), HC (13)</td><td>No</td><td>No data</td><td>No data</td><td>No data</td><td>DSM-IV, ADI-R, ADOS,MSEL, SCQ, VABS</td><td>Plasma, PBMNC, stimulation with PHA</td></tr><tr><td>14</td><td>Barbosa et al. 2015 [<xref ref-type="bibr" rid="CR168">168</xref>]</td><td>Brazil</td><td>M: 9.71, SD: 4.99</td><td>ASD (<italic>n</italic> = 30), HC (<italic>n</italic> = 18)</td><td>ASD (17), HC (17)</td><td>Risperidone (40), antidepressants (17), methylphenidate (17)</td><td>Yes</td><td>No data</td><td>No data</td><td>DSM-IV, SRS</td><td>Plasma</td></tr><tr><td>15</td><td>Tonhajzerova et al. 2015 [<xref ref-type="bibr" rid="CR169">169</xref>]</td><td>Slovakia</td><td>M: 9.3, SD: 0.7</td><td>ASD (<italic>n</italic> = 15), HC (<italic>n</italic> = 20)</td><td>ASD (13)</td><td>No</td><td>No data</td><td>No data</td><td>No data</td><td>No data available</td><td>Plasma</td></tr><tr><td>16</td><td>Tsilioni et al. 2015 [<xref ref-type="bibr" rid="CR170">170</xref>]</td><td>Greece</td><td>R: 4–10</td><td>ASD (<italic>n</italic> = 38), HC (<italic>n</italic> = 13)</td><td>ASD (15), HC (no data)</td><td>No psychoactive medications</td><td>No data</td><td>No data</td><td>No focal epilepsy</td><td>DSM, ADOS, VABS</td><td>Serum</td></tr><tr><td>17</td><td>Yang et al. 2015 [<xref ref-type="bibr" rid="CR171">171</xref>]</td><td>China</td><td>M: 12.21, SD: 2.67</td><td>ASD (<italic>n</italic> = 35), HC (<italic>n</italic> = 31)</td><td>ASD (18), HC (22)</td><td>Not relevant</td><td>No</td><td>Yes (100)</td><td>No</td><td>DSM-IV, CARS</td><td>Plasma</td></tr><tr><td>18</td><td>El-Ansary et al. 2014 [<xref ref-type="bibr" rid="CR172">172</xref>]</td><td>Saudi Arabia</td><td>R: 4–12</td><td>ASD (<italic>n</italic> = 20), HC (<italic>n</italic> = 19)</td><td>Gender-matched groups</td><td>No data</td><td>No data</td><td>No data</td><td>No</td><td>ADOS, ADI-R, 3DI</td><td>Plasma</td></tr><tr><td>19</td><td>Jyonouchi et al. 2014 [<xref ref-type="bibr" rid="CR151">151</xref>]</td><td>USA</td><td>ASD-I—Mdn: 11.8, R: 6.0–27.0; ASD-NFA—Mdn: 7.5, R: 3.3–22, ASD-only—Mdn: 12.9, R: 3.6–20.5</td><td>ASD-I (<italic>n</italic> = 24), ASD-NFA (<italic>n</italic> = 20), ASD-only (<italic>n</italic> = 20), HC-NFA (<italic>n</italic> = 16), PANS (<italic>n</italic> = 18), HC (<italic>n</italic> = 16)</td><td>ASD-I (21), ASD-NFA (10), ASD-only (15), HC-NFA (44), PANS (10), HC (37)</td><td>Yes, no exact data</td><td>No data</td><td>Yes, no exact data</td><td>Yes (11)</td><td>ADOS, ADI-R, ABC, CSHQ, NCCPC, VABS</td><td>Monocytes, stimulation with TLR agonists</td></tr><tr><td>20</td><td>Al-Ayadhi et al. 2013 [<xref ref-type="bibr" rid="CR89">89</xref>]</td><td>Saudi Arabia</td><td>M: 7.54, SD: 1.96, R: 4–12</td><td>ASD (<italic>n</italic> = 56), HC (<italic>n</italic> = 32)</td><td>ASD (18), HC (19)</td><td>No</td><td>No data</td><td>No data</td><td>No</td><td>DSM-IV, CARS</td><td>Serum</td></tr><tr><td>21</td><td>Napolioni et al. 2013 [<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>USA</td><td>M: 8.11, SD: 3.65</td><td>ASD (<italic>n</italic> = 25), HC (<italic>n</italic> = 25)</td><td>No data</td><td>No</td><td>No data</td><td>No exact data</td><td>No data</td><td>DSM-IV, ADI-R, ADOS, SB, SRS, VABS</td><td>Plasma</td></tr><tr><td>22</td><td>Ricci et al. 2013 [<xref ref-type="bibr" rid="CR152">152</xref>]</td><td>Italy</td><td>R: 2–21</td><td>ASD (<italic>n</italic> = 29, including PDD-NOS <italic>n</italic> = 6), HC (<italic>n</italic> = 29)</td><td>ASD (6), HC (gender-matched)</td><td>Yes, no exact data</td><td>No</td><td>No exact data</td><td>No</td><td>DSM-IV, CARS</td><td>Serum</td></tr><tr><td>23</td><td>Al-Ayadhi et al. 2012 [<xref ref-type="bibr" rid="CR93">93</xref>]</td><td>Saudi Arabia</td><td>M: 8.44, SD: 1.73, R: 6–11</td><td>ASD (<italic>n</italic> = 45), HC (<italic>n</italic> = 40)</td><td>ASD (20), HC (20)</td><td>No data</td><td>No data</td><td>No</td><td>No</td><td>DSM-IV, CARS</td><td>Serum</td></tr><tr><td>24</td><td>El-Ansary et al. 2012 [<xref ref-type="bibr" rid="CR173">173</xref>]</td><td>Saudi Arabia</td><td>R: 3–16</td><td>ASD (<italic>n</italic> = 20), HC (<italic>n</italic> = 19)</td><td>ASD (0), HC (0)</td><td>No data</td><td>No data</td><td>No exact data</td><td>No</td><td>ADI-R, ADOS, 3DI</td><td>Plasma</td></tr><tr><td>25</td><td>Jyonouchi et al. 2012 [<xref ref-type="bibr" rid="CR153">153</xref>]</td><td>USA</td><td>ASD-SPAD - Mdn:12.3, R:8.3-17.5, ASD-only - Mdn:8.1, R:5-17</td><td>ASD-SPAD (<italic>n</italic> = 8 including PDD-NOS <italic>n</italic> = 2), ASD-only (<italic>n</italic> = 39), HC (<italic>n</italic> = 37), HC-SPAD (<italic>n</italic> = 12)</td><td>ASD-SPAD (25), ASD-only (10), HC (22), HC-SPAD (50)</td><td>IVIG (all ASD-SPAD), multiple medications including antiepileptics</td><td>no data</td><td>no data</td><td>ASD-SPAD (50)</td><td>ADI-R, ADOS</td><td>PBMNC, cell culture supernatant, stimulation with ConA, PHA, recall Ag, IFN-γ-inducing cytokines</td></tr><tr><td>26</td><td>Manzardo et al. 2012 [<xref ref-type="bibr" rid="CR139">139</xref>]</td><td>USA</td><td>Males—M: 7.82, SD: 1.47; females—M: 7.72, SD: 1.85</td><td>ASD (<italic>n</italic> = 99), unrelated SIB (<italic>n</italic> = 40)</td><td>ASD (25), unrelated SIB (30)</td><td>No data</td><td>No data</td><td>No data</td><td>No data</td><td>ADI-R, ADOS, SRS</td><td>Plasma</td></tr><tr><td>27</td><td>Onore et al. 2012 [<xref ref-type="bibr" rid="CR175">175</xref>]</td><td>USA</td><td>Mdn: 2.88, IQR: 2.66–3.14</td><td>ASD (<italic>n</italic> = 49), HC (31)</td><td>ASD (14), HC (35)</td><td>No data</td><td>No data</td><td>No data</td><td>No data</td><td>ADI-R, ADOS, MSEL, SCQ</td><td>Plasma</td></tr><tr><td>28</td><td>Tostes et al. 2012 [<xref ref-type="bibr" rid="CR143">143</xref>]</td><td>Brazil</td><td>No data available</td><td>ASD (<italic>n</italic> = 24), HC (<italic>n</italic> = 24)</td><td>No data available</td><td>No data available</td><td>No data available</td><td>No data available</td><td>No data available</td><td>DSM-IV</td><td>Plasma</td></tr><tr><td>29</td><td>Ashwood et al. 2011 [<xref ref-type="bibr" rid="CR144">144</xref>]</td><td>USA</td><td>Mdn: 3.8, IQR: 3.2–4.3</td><td>ASD (66), HC (73)</td><td>ASD (11), HC (30)</td><td>No</td><td>No data</td><td>No data</td><td>No data</td><td>DSM-IV, ADI-R, ADOS, ABC, MSEL, SCQ, VABS</td><td>PBMNC, stimulation with PHA, tetanus toxoid, cell culture supernatants</td></tr><tr><td>30</td><td>Ashwood et al. 2011[<xref ref-type="bibr" rid="CR174">174</xref>]</td><td>USA</td><td>ASD—Mdn: 3.6, IQR: 3.0–4.5; DD—Mdn: 3.5, IQR: 3.0–4.0</td><td>ASD (80), DD (27), HC (58)</td><td>ASD (16), DD (27), HC (33)</td><td>No</td><td>No data</td><td>No data</td><td>No data</td><td>DSM-IV, ADI-R, ADOS, ABC, MSEL, SCQ, VABS</td><td>Plasma</td></tr><tr><td>31</td><td>Ashwood et al. 2011 [<xref ref-type="bibr" rid="CR145">145</xref>]</td><td>USA</td><td>ASD—Mdn:3.4, IQR: 2.9–4.3; DD—Mdn: 3.5, IQR: 3.0–4.1</td><td>ASD (<italic>n</italic> = 97), DD (<italic>n</italic> = 39), HC (<italic>n</italic> = 87)</td><td>ASD (13), DD (28), HC (18)</td><td>No</td><td>No data</td><td>No data</td><td>No data</td><td>DSM-IV, ADI-R, ADOS, ABC, MSEL, SCQ, VABS</td><td>Plasma</td></tr><tr><td>32</td><td>El-Ansary et al. 2011 [<xref ref-type="bibr" rid="CR165">165</xref>]</td><td>Saudi Arabia</td><td>R: 4–12</td><td>ASD (<italic>n</italic> = 25), HC (<italic>n</italic> = 16)</td><td>ASD (0), HC (0)</td><td>No</td><td>No exact data</td><td>No data</td><td>No</td><td>ADI-R, ADOS</td><td>Plasma</td></tr><tr><td>33</td><td>Jyonouchi et al. 2011 [<xref ref-type="bibr" rid="CR154">154</xref>]</td><td>USA</td><td>ASD-I—Mdn: 7.5, R: 3.0–15.6; ASD-only—Mdn: 5.9, R: 3.0–17.9</td><td>ASD-I (<italic>n</italic> = 30), ASD (<italic>n</italic> = 28), HC (<italic>n</italic> = 26)</td><td>ASD-I (10), ASD (<italic>n</italic> = 21), HC (<italic>n</italic> = 14)</td><td>No data</td><td>No data</td><td>No data</td><td>Yes (5)</td><td>DSM-IV, ADI-R, ADOS</td><td>PBMNC, stimulation with TLR agonists, T-cell mitogens, luminal Ag</td></tr><tr><td>34</td><td>Malik et al. 2011 [<xref ref-type="bibr" rid="CR146">146</xref>]</td><td>USA</td><td>M: 8.4, SD: 0.27</td><td>ASD (<italic>n</italic> = 6), HC (<italic>n</italic> = 6)</td><td>No data</td><td>No data</td><td>No exact data</td><td>No data</td><td>No</td><td>DSM-IV, ADI-R</td><td>PBMNC</td></tr><tr><td>35</td><td>Schwarz et al. 2011 [<xref ref-type="bibr" rid="CR140">140</xref>]</td><td>USA</td><td>M: 31.8, SD: 8.7</td><td>ASD (<italic>n</italic> = 45, only ASD-AS), HC (<italic>n</italic> = 50)</td><td>ASD (51), HC (48)</td><td>No data</td><td>No data</td><td>No data</td><td>No data</td><td>DSM-IV, AQ, EQ, SQ-R, WISC</td><td>Serum</td></tr><tr><td>36</td><td>Suzuki et al. 2011 [<xref ref-type="bibr" rid="CR141">141</xref>]</td><td>Japan</td><td>M: 12.1, SD: 3.3, R: 7–15</td><td>ASD-HF (<italic>n</italic> = 28, including PDD-NOS <italic>n</italic> = 7), HC (<italic>n</italic> = 28)</td><td>ASD-HF (0), HC (0)</td><td>Not relevant</td><td>No exact data</td><td>No</td><td>No</td><td>DSM-IV, ADI-R, WISC</td><td>Plasma</td></tr><tr><td>37</td><td>Emanuele et al. 2010 [<xref ref-type="bibr" rid="CR176">176</xref>]</td><td>Italy</td><td>M: 28.1, SD: 7.7, R: 18–44</td><td>Severe ASD (<italic>n</italic> = 22), HC (<italic>n</italic> = 28)</td><td>Severe ASD (18), HC (25)</td><td>No</td><td>No data</td><td>No exact data</td><td>No data</td><td>DSM-IV, ADI-R, AQ, CARS, RPM, VABS</td><td>Serum</td></tr><tr><td>38</td><td>Enstrom et al. 2010 [<xref ref-type="bibr" rid="CR155">155</xref>]</td><td>USA</td><td>M: 3.9, R: 2.2–5.0</td><td>ASD (<italic>n</italic> = 17), HC (<italic>n</italic> = 16)</td><td>ASD (18), HC (19)</td><td>No immunomodulatory or antipsychotic drugs</td><td>No data</td><td>No data</td><td>No data</td><td>DSM-IV, ADI-R, ADOS, ABC, MSEL, SCQ, VABS</td><td>Monocytes, stimulation with TLR, cell culture supernatants</td></tr><tr><td>39</td><td>Kajizuka et al. 2010 [<xref ref-type="bibr" rid="CR185">185</xref>]</td><td>Japan</td><td>M: 12.3, SD: 3.2, R: 6–19</td><td>ASD (<italic>n</italic> = 31), HC (<italic>n</italic> = 16)</td><td>ASD (0), HC (0)</td><td>No relevant</td><td>No exact data</td><td>No data</td><td>No</td><td>DSM-IV, ADI-R, WAIS</td><td>Serum</td></tr><tr><td>40</td><td>Ashwood et al. 2009 [<xref ref-type="bibr" rid="CR147">147</xref>]</td><td>USA</td><td>Mdn: 3.42, R: 2.42–5</td><td>ASD (<italic>n</italic> = 18), HC (<italic>n</italic> = 19)</td><td>ASD (17), HC (5)</td><td>No antibiotics or anti-inflammatory drugs</td><td>No data</td><td>No data</td><td>No data</td><td>ADOS, ADI-R, SCQ</td><td>PBMNC, pretreatment with BDE-47, stimulation with LPS</td></tr><tr><td>41</td><td>Onore et al. 2009 [<xref ref-type="bibr" rid="CR96">96</xref>]</td><td>USA</td><td>PHA stimulation—Mdn: 3.83, IQR: 3.17–4.25; PMA stimulation—Mdn: 4.25, IQR: 3.08–4.07</td><td>ASD (<italic>n</italic> = 34), HC (<italic>n</italic> = 26)</td><td>ASD (15), HC (19)</td><td>No data</td><td>No data</td><td>No data</td><td>No data</td><td>DSM-IV, ADI-R, ADOS, ABC, MSEL, SCQ, VABS</td><td>PBMNC, stimulation with PHA/PMA</td></tr><tr><td>42</td><td>Saresella et al. 2009 [<xref ref-type="bibr" rid="CR91">91</xref>]</td><td>Italy</td><td>ASD—Mdn: 13, R: 5–17; SIB—Mdn: 15; R: 3–16</td><td>ASD (<italic>n</italic> = 20), SIB (<italic>n</italic> = 15), HC (<italic>n</italic> = 20)</td><td>ASD (<italic>n</italic> = 30), SIB (16), HC (45)</td><td>Not relevant</td><td>No data</td><td>No data</td><td>No data</td><td>DSM-IV, SRS</td><td>PBMNC, stimulation with staphylococcal enterotoxin B, IL-2</td></tr><tr><td>43</td><td>Ashwood et al. 2008 [<xref ref-type="bibr" rid="CR177">177</xref>]</td><td>USA</td><td>ASD—Mdn: 3.4, IQR: 3.0–4.2; DD—Mdn: 3.9, IQR: 3.1–4.5</td><td>ASD (<italic>n</italic> = 75), DD (<italic>n</italic> = 32), HC (<italic>n</italic> = 36)</td><td>ASD (9), DD (12)</td><td>No data</td><td>No data</td><td>No data</td><td>No data</td><td>DSM-IV, ADI-R, ADOS, ABC, MSEL, SCQ, VABS</td><td>Plasma</td></tr><tr><td>44</td><td>Enstrom et al. 2008 [<xref ref-type="bibr" rid="CR178">178</xref>]</td><td>USA</td><td>M: 3.5, R: 2–5</td><td>ASD (<italic>n</italic> = 40), HC (<italic>n</italic> = 20)</td><td>ASD (10), HC (20)</td><td>No data</td><td>No data</td><td>No data</td><td>No data</td><td>ADI-R, ADOS, MSEL, SCQ, MSEL, VABS</td><td>Plasma</td></tr><tr><td>45</td><td>Grigorenko et al. 2008 [<xref ref-type="bibr" rid="CR179">179</xref>]</td><td>Netherlands</td><td>No exact data</td><td>ASD (<italic>n</italic> = 10/29 including ASD-AS, PDD-NOS and CDD), SIB (<italic>n</italic> = 10)</td><td>No exact data</td><td>No data</td><td>No data</td><td>No data</td><td>No data</td><td>ADOS, ADI</td><td>Plasma</td></tr><tr><td>46</td><td>Jyonouchi et al. 2008 [<xref ref-type="bibr" rid="CR156">156</xref>]</td><td>USA</td><td>ASD-I—Mdn: 7.6, R: 2.3–13.4; ASD-only—Mdn: 4.8, R: 1.5–17.3</td><td>ASD-I (<italic>n</italic> = 26), ASD (<italic>n</italic> = 107), HC-FA (<italic>n</italic> = 24), HC (<italic>n</italic> = 43)</td><td>ASD-I (4), ASD (14), HC-FA (28), HC (28)</td><td>No data</td><td>No data</td><td>No data</td><td>Yes (4.5)</td><td>DSM-IV, ADOS, ADI-R</td><td>PBMNC, stimulation with TLR agonists</td></tr><tr><td>47</td><td>Molloy et al. 2006 [<xref ref-type="bibr" rid="CR148">148</xref>]</td><td>USA</td><td>M: 6.9, SD: 2.0, R: 3.7–10.7</td><td>ASD (<italic>n</italic> = 20), HC (<italic>n</italic> = 20)</td><td>ASD (15), HC (15)</td><td>Psychotropic medications (65)</td><td>No data</td><td>No data</td><td>No data</td><td>DSM-IV, ADOS</td><td>PBMNC, stimulation with PHA, house dust mite, tetanus toxoid</td></tr><tr><td>48</td><td>Al-Ayadhi 2005 [<xref ref-type="bibr" rid="CR180">180</xref>]</td><td>Saudi Arabia</td><td>M: 8.8, SD: 0.5, R: 3.5–14</td><td>ASD (<italic>n</italic> = 77, including ADD <italic>n</italic> = 8, RTT <italic>n</italic> = 2, ASD-AS <italic>n</italic> = 2), HC (<italic>n</italic> = 77)</td><td>ASD (8), HC (gender-matched)</td><td>No data</td><td>No data</td><td>No data</td><td>No exact data</td><td>E2</td><td>Serum</td></tr><tr><td>49</td><td>Jyonouchi et al. 2005 [<xref ref-type="bibr" rid="CR157">157</xref>]</td><td>USA</td><td>ASD-GI—M: 4.7, R: 1.8–10.6, ASD-only—M: 5.4, R: 2.1–10.2, NFH—M: 2.8, R: 1.3–7.8</td><td>ASD-GI (<italic>n</italic> = 75, including PDD-NOS <italic>n</italic> = 27), ASD-only (<italic>n</italic> = 34, including PDD-NOS <italic>n</italic> = 1), NFH (<italic>n</italic> = 15), HC (<italic>n</italic> = 19)</td><td>ASD-GI (19), ASD-only (6), NFH (40), HC (42)</td><td>No exact data</td><td>No data</td><td>No data</td><td>No data</td><td>DSM-IV, ICD-10, ADI-R, ADOS</td><td>PBMNC, stimulation with gliadin, cow’s milk protein, soy, cell culture supernatants</td></tr><tr><td>50</td><td>Jyonouchi et al. 2005 [<xref ref-type="bibr" rid="CR158">158</xref>]</td><td>USA</td><td>Mdn: 4.8</td><td>ASD (<italic>n</italic> = 177, including 77 on ED), NFH (<italic>n</italic> = 30, including 16 on ED), HC (<italic>n</italic> = 13)</td><td>No data</td><td>No data</td><td>No data</td><td>No data</td><td>No data</td><td>No data</td><td>PBMNC, stimulation with LPS</td></tr><tr><td>51</td><td>Sweeten et al. 2004 [<xref ref-type="bibr" rid="CR181">181</xref>]</td><td>USA</td><td>M: 6.1, SD: 2.8, R: 2–12</td><td>ASD (<italic>n</italic> = 29), HC (<italic>n</italic> = 27)</td><td>ASD (14), HC (14)</td><td>No</td><td>No data</td><td>No data</td><td>No data</td><td>DSM-IV, ADI-R, ADOS</td><td>Plasma</td></tr><tr><td>52</td><td>Croonenberghs et al. 2002 [<xref ref-type="bibr" rid="CR182">182</xref>]</td><td>Netherlands</td><td>R: 12–18</td><td>ASD (<italic>n</italic> = 13), HC (<italic>n</italic> = 13)</td><td>ASD (0)</td><td>Not relevant</td><td>No data</td><td>Yes (7)</td><td>No active seizure disorder</td><td>DSM-IV</td><td>Serum, whole blood culture supernatant</td></tr><tr><td>53</td><td>Jyonouchi et al. 2002 [<xref ref-type="bibr" rid="CR183">183</xref>]</td><td>USA</td><td>Mdn: 5, R: 1–17</td><td>ASD (<italic>n</italic> = 72, including PDD-NOS <italic>n</italic> = 9, ASD-AS <italic>n</italic> = 1), DPI (<italic>n</italic> = 24), SIB (<italic>n</italic> = 26), HC (<italic>n</italic> = 15)</td><td>ASD (18), DPI (29), SIB (31), HC (20)</td><td>Valproic acid (4)</td><td>No data</td><td>No data</td><td>Yes (4)</td><td>DSM-IV, ICD-10, ADI-R, ADOS</td><td>PBMNC, stimulation with gliadin, cow’s milk protein, soy, cell culture supernatants</td></tr><tr><td>54</td><td>Jyonouchi et al. 2001 [<xref ref-type="bibr" rid="CR159">159</xref>]</td><td>USA</td><td>Mdn: 6, R: 2–14</td><td>ASD (<italic>n</italic> = 71, including PDD-NOS <italic>n</italic> = 6), SIB (<italic>n</italic> = 23), HC (<italic>n</italic> = 17)</td><td>ASD (21), SIB (30), HC (59)</td><td>Valproic acid (7)</td><td>No data</td><td>No data</td><td>Yes (7)</td><td>DSM-IV</td><td>PBMNC, stimulation with LPS, PHA, tetanus, dust mite, IL-12p70, IL-18</td></tr><tr><td>55</td><td>Gupta et al. 1998 [<xref ref-type="bibr" rid="CR88">88</xref>]</td><td>USA</td><td>R: 3–7</td><td>ASD (<italic>n</italic> = 20), HC (<italic>n</italic> = 20)</td><td>ASD (20), HC (15)</td><td>No data</td><td>No data</td><td>No data</td><td>No data</td><td>DSM-IV</td><td>PBMNC</td></tr><tr><td>56</td><td>Singh et al. 1996 [<xref ref-type="bibr" rid="CR160">160</xref>]</td><td>USA</td><td>M: 10.7</td><td>ASD (<italic>n</italic> = 20), HC (<italic>n</italic> = 20)</td><td>ASD (20), HC (35)</td><td>Not relevant</td><td>No data</td><td>No data</td><td>No data</td><td>DSM-III</td><td>Plasma</td></tr><tr><td>57</td><td>Singh et al. 1991 [<xref ref-type="bibr" rid="CR149">149</xref>]</td><td>USA</td><td>No data available</td><td>ASD, TD, DD</td><td>No data available</td><td>No data available</td><td>No data available</td><td>No data available</td><td>No data available</td><td>No data available</td><td>Serum</td></tr></tbody></table><table-wrap-foot><p><italic>M</italic> mean, <italic>SD</italic> standard deviation, <italic>R</italic> range, <italic>Mdn</italic> median, <italic>IQR</italic> interquartile range, <italic>ASD</italic> autism spectrum disorder, <italic>ADHD</italic> attention deficit hyperactivity disorder, <italic>RTT</italic> Rett syndrome, <italic>HC</italic> healthy controls, <italic>I</italic> inflammatory subtype (defined as fluctuating behavioral symptoms following immune insults), <italic>NFA</italic> non-IgE-mediated food allergy, <italic>SPAD</italic> specific polysaccharide antibody deficiency, <italic>LF</italic> low functioning, <italic>HF</italic> high functioning, <italic>DD</italic> developmental delay, <italic>PHA</italic> phytohemagglutinin, <italic>PMA</italic> phorbol myristate acetate, <italic>SIB</italic> siblings, <italic>GI</italic> gastrointestinal symptoms, <italic>PDD-NOS</italic> pervasive developmental disorder not otherwise specified, <italic>PANS</italic> pediatric acute-onset neuropsychiatric syndrome, <italic>FA</italic> food allergy, <italic>NHF</italic> non-allergic food hypersensitivity, <italic>ASD-C</italic> childhood autism, <italic>ASD-A</italic> atypical autism, <italic>ASD-AS</italic> Asperger syndrome, <italic>ADD</italic> attention deficit disorder, <italic>ED</italic> elimination diet, <italic>DPI</italic> dietary protein intolerance, <italic>CDD</italic> childhood disintegrative disorder, <italic>IVIG</italic> intravenous immunoglobulins, <italic>DSM</italic> Diagnostic and Statistical Manual of Mental Disorders, <italic>CARS</italic> Childhood Autism Rating Scale, <italic>ICD</italic> International Statistical Classification of Diseases and Related Health Problems, <italic>ADI-R</italic> Autism Diagnostic Interview–Revised, <italic>ADOS</italic> Autism Diagnostic Observation Schedule, <italic>SCQ</italic> Social Communication Questionnaire, <italic>CBCL</italic> Child Behaviour Checklist, <italic>MSEL</italic> Mullen Scales of Early Learning, <italic>CCTT</italic> Children’s Color Trail Test, <italic>CRS-R</italic> Conners’ Rating Scales–Revised, <italic>FPT</italic> Five Point Test, <italic>Rey-O</italic> Rey–Osterrieth Complex Figure Test, <italic>TOL-DX</italic> Tower of London Test–Drexel Version, <italic>3DI</italic> Developmental, Dimensional Diagnostic Interview, <italic>SSP</italic> Short Sensory Profile, <italic>ABC</italic> Aberrant Behavior Checklist, <italic>WISC</italic> Wechsler Intelligence Scale for Children, <italic>SB</italic> Stanford–Binet, <italic>VABS</italic> Vineland Adaptive Behavior Scale, <italic>SRS</italic> Social Responsiveness Scale, <italic>CSHQ</italic> Children’s Sleep Habits Questionnaires, <italic>NCCPC</italic> Non-communicating Children’s Pain Checklist, <italic>RBSR</italic> Repetitive Behavior Scale–Revised, <italic>AQ</italic> Autism-Spectrum Quotient, <italic>EG</italic> Empathy Quotient, <italic>SQ-R</italic> Systemizing Quotient–Revised, <italic>RPM</italic> Raven’s Progressive Matrices, <italic>WAIS</italic> Wechsler Adult Intelligence Scale, <italic>ADI</italic> Autism Diagnostic Interview, <italic>E2</italic> Diagnostic Checklist Form E-2, <italic>LIPS</italic> Leiter International Performance Scale, <italic>YSR</italic> Youth Self-Report, <italic>PBMNC</italic> peripheral blood mononuclear cells, <italic>LPS</italic> lipopolysaccharides, <italic>TLR</italic> Toll-like receptors, <italic>ConA</italic> concanavalin A, <italic>Ag</italic> antigen, <italic>IFN</italic> interferon, <italic>BDE-47</italic> 2,2′,4,4′-tetrabromodiphenyl ether, <italic>IL</italic> interleukin</p><p><sup>A</sup>Abstract</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Concentration of cytokines, chemokines, and growth factors in peripheral blood of ASD patients: immune abnormalities description</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Number</th><th>Study</th><th>Cytokines</th><th>Chemokines</th><th>Growth factors</th><th>Other analytes</th><th>Main results</th><th>Relation to psychological symptoms</th><th>Excluded correlations</th></tr></thead><tbody><tr><td>1</td><td>Ahmad et al. 2017 [<xref ref-type="bibr" rid="CR162">162</xref>]</td><td>IL-21, IL-22, IL-27</td><td>x</td><td>x</td><td>CTLA-4 (CD152)</td><td>ASD vs. HC: ↑IL-21 and IL-22 CD4<sup>+</sup> cells and mRNA expression, ↓IL-27 CD14<sup>+</sup> cells and CTLA-4 CD4<sup>+</sup> cells and mRNA</td><td>Not studied</td><td>x</td></tr><tr><td>2</td><td>Bryn et al. 2017 [<xref ref-type="bibr" rid="CR142">142</xref>]</td><td>IL-1RA, IL-1β, IL-2, IL-6, IL-9, IL-10, IL-12, IL-18, IFN-γ, TNF-α</td><td>CXCL1 (GRO-α), CXCL8 (IL-8)</td><td>x</td><td>x</td><td>ASD-C vs. HC: ↑IL-8, ↓IL-10; ASD-C vs. ASD-AS: ↑IL-8</td><td>Not studied</td><td>No differences between ASD and HC children</td></tr><tr><td>3</td><td>Careaga et al. 2017 [<xref ref-type="bibr" rid="CR150">150</xref>]</td><td>IL-1β, IL-6, IL-10, IL-12p40, IL-13, IL-17, IFN-γ, TNF-α</td><td>CCL2 (MCP-1)</td><td>GM-CSF</td><td>x</td><td>ASD children divided into 2 groups according to the response to LPS stimulation, ASD-high vs. ASD-low: ↑IL-1β, IL-6, IL-10, MCP-1</td><td>Social and developmental impairment, sleep disturbances, aggression in ASD-high group: ↑IL-1β, IL-6, IL-10, MCP-1; developmental impairment more severe in children with Th1-skewed response to stimulation</td><td>x</td></tr><tr><td>4</td><td>Guloksuz et al. 2017 [<xref ref-type="bibr" rid="CR163">163</xref>]</td><td>IL-1β, IL-4, IL-6, IL-10, IL-17A, IFN-γ, TNF-α</td><td>x</td><td>x</td><td>S100B</td><td>ASD vs. HC: ↑S100B, TNF-α</td><td>Severe ASD: ↑S100B</td><td>No association with regression, no association of S100B concentration and ASD severity after adjustment for age, gender, and BMI</td></tr><tr><td>5</td><td>Han et al. 2017 [<xref ref-type="bibr" rid="CR164">164</xref>]</td><td>TGF-β1, MIF</td><td>CCL2 (MCP-1), CCL5 (RANTES), CXCL8 (IL-8), CXCL-9 (MIG), CXCL10</td><td>x</td><td>x</td><td>ASD vs. HC: ↑CCL2 and CCL5 ↓CXCL9; ASD + ADHD vs. ASD-only: ↑MIF ↓CXCL8</td><td>Poor executive functioning: ↑MIF ↓CXCL10; impaired short-term memory: ↑CXCL9; severe inattention and hyperactivity: ↓CXCL5</td><td>No association with social domain and repetitive, restricted behaviors and interests</td></tr><tr><td>6</td><td>Jyonouchi et al. 2017<sup>A</sup> [<xref ref-type="bibr" rid="CR184">184</xref>]</td><td>IL-1β, IL-10</td><td>x</td><td>x</td><td>Oxygen consumption rate in PBMNC</td><td>Altered IL-1β and mitochondrial function may be associated with chronic GI symptoms</td><td>No data</td><td>x</td></tr><tr><td>7</td><td>Makinodan et al. 2017 [<xref ref-type="bibr" rid="CR166">166</xref>]</td><td>IL-1β, IL-6, TNF-α (mRNA levels)</td><td>x</td><td>x</td><td>x</td><td>ASD vs. HC: ↓TNF-α</td><td>Impaired social interactions: ↓TNF-α</td><td>No association with impairment of communication, restricted behaviors, and interests</td></tr><tr><td>8</td><td>El-Ansary et al. 2016 [<xref ref-type="bibr" rid="CR73">73</xref>]</td><td>IL-10, IL-12</td><td>x</td><td>x</td><td>NF-κB, 8-isoprostane, PE, PS, PC, MAP2K1, PGE2, PGE2-EP2, mPGES-1, cPLA2, COX-2</td><td>Biomarker sets effective in distinguishing ASD from HC subjects</td><td>Sensory impairment: PE, PGES, mPGES-1</td><td>No association with cognitive and social impairment</td></tr><tr><td>9</td><td>Ferguson et al. 2016 [<xref ref-type="bibr" rid="CR167">167</xref>]</td><td>IL-6, TNF-α</td><td>x</td><td>x</td><td>Salivary cortisol</td><td>ASD with more prominent upper GI symptoms: ↑TNF-α</td><td>Higher IQ: ↓IL-6, socialization impairment: ↑IL-6, irritability: ↓TNF-α, anxiety: ↑TNF-α, regression: ↑TNF-α</td><td>No association of IL-6 with GI symptoms, no correlation with depression and seizures</td></tr><tr><td>10</td><td>Jácome et al. 2016 [<xref ref-type="bibr" rid="CR135">135</xref>]</td><td>IL-1α, IL-1RA, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-6sR, IL-7, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-16, IL-17, IFN-γ, TNF-α, TNF-β, TNF-sRI, TNF-sRII</td><td>CCL1 (I-309), CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), CCL9 (MIP-1γ), CCL11 (eotaxin), CCL24 (eotaxin-2), CXCL8 (IL-8), CXCL-9 (MIG), CXCL13 (BLC)</td><td>G-CSF, M-CSF, GM-CSF, PDGF-BB</td><td>ICAM-1, TIMP1, TIMP2</td><td>ASD vs. HC: ↑IL-1β, IL-6, IL-17, IL-12p40, and IL-12p70; mild ASD vs. HC: ↑IL-1β, IL-6, IL-12p40, IL-17; ASD + abnormal EEG: ↑IL-12p40 ↑IL-6</td><td>Moderate ASD vs. HC: ↑IL-1β, IL-6, IL-12p70, IL-17, TNF-α; moderate ASD vs. mild ASD: ↑IL-6, IL-12p70, TNF-α and ↓IL-12p40</td><td>x</td></tr><tr><td>11</td><td>Pecorelli et al. 2016 [<xref ref-type="bibr" rid="CR136">136</xref>]</td><td>IL-1RA, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, IFN-γ, TNF-α</td><td>CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), CCL11 (eotaxin), CXCL8 (IL-8), CXCL10 (IP-10)</td><td>G-CSF, GM-CSF, FGF, PDGF-BB, VEGF</td><td>x</td><td>ASD vs. RTT: ↓IL-1β, VEGF</td><td>Not studied</td><td>ASD vs. HC: no significant differences</td></tr><tr><td>12</td><td>Rose et al. 2016<sup>A</sup> [<xref ref-type="bibr" rid="CR137">137</xref>]</td><td>i.a. IL-1α, IL-1β, IL-5, IL-15, IL-17, TNF-α</td><td>x</td><td>x</td><td>x</td><td>ASD-only vs. HC: ↑IL-1α, IL-1β, TNF-α; ASD-GI vs. ASD-only: ↑IL-5, IL-15, IL-17, ↓TGF-β; ASD-GI vs. HC: ↓TGF-β</td><td>Worse score on ABC: ASD with GI symptoms</td><td>x</td></tr><tr><td>13</td><td>Akintunde et al. 2015 [<xref ref-type="bibr" rid="CR94">94</xref>]</td><td>IL-4, IL-13, IL-17</td><td>x</td><td>x</td><td>x</td><td>ASD vs. HC after PHA: ↑IL-17; ASD + asthma vs. HC + asthma after PHA: ↑IL-17, IL-13</td><td>Not studied</td><td>No differences in baseline levels of cytokines between ASD and HC, no differences in IL-17 in children with and without asthma, no association with allergies</td></tr><tr><td>14</td><td>Barbosa et al. 2015 [<xref ref-type="bibr" rid="CR168">168</xref>]</td><td>IL-1β, IL-33</td><td>x</td><td>x</td><td>sST2</td><td>Positive correlation of IL-33 and sST2</td><td>No correlations</td><td>No differences in baseline levels, no differences in relation to medications</td></tr><tr><td>15</td><td>Tonhajzerova et al. 2015 [<xref ref-type="bibr" rid="CR169">169</xref>]</td><td>IL-1β, TNF-α,</td><td>CXCL8 (IL-8)</td><td>x</td><td>TBARS</td><td>ASD vs. HC: ↑IL-8</td><td>Not studied</td><td>X</td></tr><tr><td>16</td><td>Tsilioni et al. 2015 [<xref ref-type="bibr" rid="CR170">170</xref>]</td><td>IL-6, IL-9, IL-31, IL-33, TNF</td><td>x</td><td>x</td><td>x</td><td>ASD vs. HC: ↑TNF, authors distinguished two subgroups of ASD children: with initially low or high IL-6 and TNF level</td><td>Not studied at baseline level of cytokines</td><td>No significant difference in baseline IL-6, IL-9, IL-31, IL-33</td></tr><tr><td>17</td><td>Yang et al. 2015 [<xref ref-type="bibr" rid="CR171">171</xref>]</td><td>IL-6</td><td>x</td><td>x</td><td>5-HT</td><td>ASD vs. HC: ↑IL-6, 5-HT</td><td>ASD severity: ↑IL-6, 5-HT</td><td>x</td></tr><tr><td>18</td><td>El-Ansary et al. 2014 [<xref ref-type="bibr" rid="CR172">172</xref>]</td><td>IL-6, IFN-γ, TNF-α</td><td>x</td><td>x</td><td>GABA, glutamate/GABA ratio, IFI-16</td><td>ASD vs. HC: ↑GABA, glutamate, IFN-γ, IFI-16; ↓glutamate/GABA ratio, IL-6, TNF-α</td><td>Not studied</td><td>x</td></tr><tr><td>19</td><td>Jyonouchi et al. 2014 [<xref ref-type="bibr" rid="CR151">151</xref>]</td><td>IL-1β, IL-6, IL-10, IL-12p40, IL-17a, IL-23, TGF-β, TNF-α, sTNFRII</td><td>x</td><td>x</td><td>x</td><td>ASD-I-flare vs. ASD-NFA, ASD, HC: ↑IL-1β, IL-6</td><td>Worsening of irritability, lethargy, and hyperactivity in ASD-I: ↑IL-1β, IL-6 ↓IL-10</td><td>x</td></tr><tr><td>20</td><td>Al-Ayadhi et al. 2013 [<xref ref-type="bibr" rid="CR89">89</xref>]</td><td>x</td><td>CCL17 (TARC), CCL22 (MDC)</td><td>x</td><td>x</td><td>ASD vs. HC: ↑TARC, MDC</td><td>Severe ASD vs. mild–moderate ASD: ↑TARC, MDC</td><td>x</td></tr><tr><td>21</td><td>Napolioni et al. 2013 [<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>IL-1α, IL-1RA, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-6sR, IL-7, IL-10, IL-11, IL-12p40, IL-12p70, IL-13, IL-15, IL-16, IL-17, IFN-γ, TNF-α, TNF-β, TNF-sRI, TNF-sRII</td><td>CCL1 (I-309), CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), CCL11 (eotaxin), CCL15 (MIP-1δ), CCL24 (eotaxin-2), CXCL8 (IL-8), CXCL9 (MIG), CXCL13 (BLC)</td><td>G-CSF, M-CSF, GM-CSF, PDGF-BB</td><td>ICAM-1, TIMP-2</td><td>Head circumference: ↓BLC, TIMP-2; GI issues: ↑IL-1β, IL-2, IL-6</td><td>Regression: ↑IL-1β, IL-5, IL-17; non-verbal: ↑GM-CSF, M-CSF, IL-10; VABS score: ↓GM-CSF, IL-1β, IL-2, IL-6, MCP-1, ↑MIP-1δ; social responsiveness: ↓IL-6sR, MIP-1β, MIP-1δ; IQ: ↓IL-1β, IL-6, IL-7, IL-11, IL-12p70, IL-13, IL-16, IL-17, M-CSF, GM-CSF, TNF-sRII</td><td>No association with allergy</td></tr><tr><td>22</td><td>Ricci et al. 2013 [<xref ref-type="bibr" rid="CR152">152</xref>]</td><td>IL-1β, IL-6, IL-12, IL-13, IL-23, TNF-α</td><td>x</td><td>BDNF</td><td>x</td><td>ASD vs. HC: ↑IL-1β, IL-6, IL-12, IL-23, TNF-α, BDNF</td><td>ASD severity: ↑IL-1β</td><td>No correlation with IL-13</td></tr><tr><td>23</td><td>Al-Ayadhi et al. 2012 [<xref ref-type="bibr" rid="CR93">93</xref>]</td><td>IL-17A</td><td>x</td><td>x</td><td>x</td><td>ASD vs. HC: ↑IL-17A</td><td>ASD severity: ↑IL-17A</td><td>x</td></tr><tr><td>24</td><td>El-Ansary et al. 2012 [<xref ref-type="bibr" rid="CR173">173</xref>]</td><td>IFN-γ, TGF-β2</td><td>x</td><td>x</td><td>HSP70, caspase 7</td><td>ASD vs. HC: ↑IFN-γ, TGF-β2, HSP70, caspase 7</td><td>Not studied</td><td>x</td></tr><tr><td>25</td><td>Jyonouchi et al. 2012 [<xref ref-type="bibr" rid="CR153">153</xref>]</td><td>IL-1β, IL-6, IL-10, IL-12p40, IL-23, TGF-β, TNF-α, sTNFRII</td><td>x</td><td>x</td><td>Monocyte transcription profiling</td><td>ASD-SPAD vs. HC: ↓IL-1β (baseline), IL-6 (baseline, after TLR7/8, TLR2/6), IL-10 (after <italic>Candida</italic> antigen), IL-12p40 (after TLR4, T-cell mitogens, <italic>Candida</italic> antigen), IL-17 (after T-cell mitogens), IL-23 (after TLR7/8), TNF-α (baseline), IFN-γ (after T-cell mitogens). ASD-SPAD vs. ASD-only: ↑gene expression of TGFBR, Notch, EGFR1 pathways</td><td>Not studied</td><td>ASDnoSPAD vs. HC: no significant differences</td></tr><tr><td>26</td><td>Manzardo et al. 2012 [<xref ref-type="bibr" rid="CR139">139</xref>]</td><td>IL-1α, IL-1β, IL1-RA, IL-2, IL-2RA, IL-3,IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15; IL-17, IFN-α2, IFN-γ, TGF-α, TNF-α, TNF-β</td><td>CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL7 (MCP-3), CCL11 (eotaxin), CCL22 (MDC), CXCL1 (GRO-α), CXCL8 (IL-8), CXCL10 (IP-10)</td><td>EGF, FGF-2, G-CSF, GM-CSF, VEGF</td><td>CD40L, Flt3 ligand</td><td>ASD vs. unrelated SIB: ↓IL-1α, IL-6, G-CSF, EGF, fractalkine, MCP3, MIP1, MIP1</td><td>Not studied</td><td>x</td></tr><tr><td>27</td><td>Onore et al. 2012 [<xref ref-type="bibr" rid="CR175">175</xref>]</td><td>x</td><td>x</td><td>EGF, HGF</td><td>x</td><td>ASD vs. HC: ↓EGF</td><td>Not studied</td><td>No differences in HGF concentration</td></tr><tr><td>28</td><td>Tostes et al. 2012 [<xref ref-type="bibr" rid="CR143">143</xref>]</td><td>IL-1β, IL-2, IL-4, IL-6, IL-10, IFN-γ, TNF-α</td><td>x</td><td>x</td><td>VIP, NT-3, NO</td><td>ASD vs. HC: ↑IFN-γ, VIP, NO ↓NT-3</td><td>Not studied</td><td>x</td></tr><tr><td>29</td><td>Ashwood et al. 2011 [<xref ref-type="bibr" rid="CR144">144</xref>]</td><td>IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p40, IL-13, IFN-γ, TNF-α</td><td>CXCL8 (IL-8)</td><td>GM-CSF</td><td>Lymphocyte subpopulations and markers of cellular activation CD134, CD25, CD69, CD95, HLA-DR</td><td>ASD vs. HC: high response to PHA stimulation ↑IL-8 (baseline), GM-CSF, TNF-α, IL-13 (PHA) ↓IL-12p40 (PHA), IFN-γ (tetanus toxoid); ↓CD134<sup>+</sup> and CD25<sup>+</sup> cells after PHA stimulation</td><td>Increased hyperactivity: high response to PHA stimulation, ↑IL-12p40, ↓IL-13; increased lethargy: high response to PHA stimulation; stereotypy: ↑TNF-α, IFN-γ, ↓GM-CSF; impaired communication: ↑IL-8, IFN-γ; inappropriate speech: ↑IL-12p40; impaired expressive language: ↓IL-5, IL-10; impaired fine motor skills: ↓IL-5; impaired visual reception: ↑IL-8; impaired expressive language: ↓IL-5; impaired adaptive behavior: ↓GM-CSF</td><td>No association with regression, no differences after tetanus toxoid stimulation, no differences in number of CD3<sup>+</sup>, CD4<sup>+</sup> and CD8<sup>+</sup> T cells, no differences in CD69<sup>+</sup>, CD137<sup>+</sup>, and HLA-DR<sup>+</sup> cells</td></tr><tr><td>30</td><td>Ashwood et al. 2011 [<xref ref-type="bibr" rid="CR174">174</xref>]</td><td>x</td><td>CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), CCL11 (eotaxin), CXCL10 (IP-10)</td><td>x</td><td>x</td><td>ASD vs. DD, HC: ↑MCP-1, RANTES, eotaxin; ASD vs. DD: ↑MIP-1β</td><td>Impaired communication: ↑MIP-1α, RANTES; impaired behaviors: ↑MCP-1, RANTES and eotaxin; impaired adaptive and cognitive functions: ↑MCP-1, RANTES, eotaxin; lethargy: ↑RANTES, eotaxin; hyperactivity: ↑RANTES, eotaxin; stereotypy: ↑RANTES, eotaxin; impaired visual reception: ↑MCP-1, RANTES, eotaxin; impaired fine motor skills: ↑MCP-1, RANTES, eotaxin; impaired expressive language: ↑MCP-1, RANTES, eotaxin; worse daily living scores: ↑MCP-1, eotaxin; impaired adaptive behavior: ↑RANTES, eotaxin</td><td>No differences in MIP-1α and IP10 concentrations</td></tr><tr><td>31</td><td>Ashwood et al. 2011 [<xref ref-type="bibr" rid="CR145">145</xref>]</td><td>IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p40, IL-13, IFN-γ, TNF-α</td><td>CXCL8 (IL-8)</td><td>GM-CSF</td><td>x</td><td>ASD vs. DD, HC: ↑IL-6, IL-12p40; ASD vs. HC: ↑IL-1β, IL-8; regressive ASD vs. early-onset ASD: ↑IL-1β, GM-CSF; regressive ASD vs. HC: ↑IL-1β, IL-6, IL-8, GM-CSF</td><td>Impaired non-verbal communication: ↑IL-4; stereotypies: ↑IL-1β, IL-6, IL-8, IL12p40; lethargy: ↑IL-8, IL-12; hyperactivity: ↑IL-8, impaired visual reception: ↑IL-8; impaired receptive and expressive language: ↑IL-8; impaired daily living: ↑IL-8</td><td>No association with IQ, no psychological differences in children with and without regression</td></tr><tr><td>32</td><td>El-Ansary et al. 2011 [<xref ref-type="bibr" rid="CR165">165</xref>]</td><td>IL-6, TNF-α</td><td>x</td><td>x</td><td>Caspase 3</td><td>ASD vs. HC: ↓caspase3, IL-6, TNF-α</td><td>Not studied</td><td>x</td></tr><tr><td>33</td><td>Jyonouchi et al. 2011 [<xref ref-type="bibr" rid="CR154">154</xref>]</td><td>IL-1β, IL-5, IL-6, IL-10, IL-12p40, IL-17A, IL-23, TGF-β, TNF-α, sTNFRII</td><td>x</td><td>x</td><td>Transcription profiling</td><td>ASD-I-GI vs. HC: ↓IL-1β, IL-6, IL-10; ASD-I-GI vs. HC after TLR stimulation: ↓IL-1β, IL-10, IL-12, IL-23, TNF-α; ASD-I-GI vs. HC after luminal Ags stimulation: ↓IFN-γ, TNF-α; 7 pts from ASD-I diagnosed with immunodeficiency: 1-CVID, 6-SPAD</td><td>Not studied</td><td>No differences between ASD-I without GI and HC apart from lower IL-23 production, no difference after stimulation with T-cell mitogens</td></tr><tr><td>34</td><td>Malik et al. 2011 [<xref ref-type="bibr" rid="CR146">146</xref>]</td><td>IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, IFN-γ, TNF-α</td><td>CXCL8 (IL-8)</td><td>GM-CSF</td><td>Bcl2 concentration and expression</td><td>ASD vs. HC: ↑IL-6, TNF-α, cathepsin D expression; ↓ Bcl2 expression</td><td>Not studied</td><td>No differences in concentration of Blc2, IL-1β, IL-2, IL-4, IL-5, IL-8, IL-10, IFN-γ, GM-CSF</td></tr><tr><td>35</td><td>Schwarz et al. 2011 [<xref ref-type="bibr" rid="CR140">140</xref>]</td><td>IL-1α, IL-1β, IL-1RA, IL-2, IL-23, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-11, IL-12p40, IL-12p70, IL-13, IL-15, IL-16, IL-17, IL-18, IFN-γ, MIF, TGF-α, TGF-β3, TNF-α, TNF-β, TNFRII</td><td>CCL1 (I-309), CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), CCL7 (MCP-3), CCL11 (eotaxin), CCL22 (MDC), CCL26 (eotaxin-3) CXCL1 (GRO-α), CXCL8 (IL-8)</td><td>EGF, EGF-R, HB-EGF, FGF basic, FGF-4, M-CSF, G-CSF, GM-CSF, HGF, NGF-β, SCF, IGF-I, IGF-BP, PDGF, VEGF</td><td>Multiple analytes including IgA, IgM, IgE, CD40, CD40L, ICAM-1, MMP-2, MMP-3, MMP-9, s100B, TIMP-1</td><td>Female ASD vs. HC: ↑IL-1β, IL-7, IL-12p40, NARG1, FAI, LH, TF, BDNF; ↓GOT1, Apo-CIII, IgM, sRAGE, Apo-A1, Tenascin-C, Eotaxin-3, Endothelin-1, GH, male ASD vs. HC: ↑IL-1β, IL-3, IL-4, IL-5, IL-10, IL-12p40, IL-12p70, IL-18, fatty acid binding protein, EPO, G-CSF, chromogranin A, neuronal cell adhesion molecule, tenascin-C, TNF-α, ENA-78, factor VII, connective tissue growth factor,  thrombopoietin, stem cell factor, sortilin 1, ICAM-1 ↓GOT-1</td><td>Not studied</td><td>x</td></tr><tr><td>36</td><td>Suzuki et al. 2011 [<xref ref-type="bibr" rid="CR141">141</xref>]</td><td>IL-1α, IL-2Rα, IL-1RA, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-16, IL-17, IL-18, IFN-γ, LIF, TNF-α, TNF-β, TRAIL, SCF</td><td>CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), CCL7 (MCP-3), CCL11 (eotaxin), CXCL1 (GRO-α), CXCL8 (IL-8), CXCL9 (MIG), CXCL10 (IP-10), CXCL12 (SDF-1α), CTACK</td><td>HGF, M-CSF, G-CSF, GM-CSF, VEGF, basic FGF, PDGF-BB, β-NGF, SCGF-β</td><td>x</td><td>ASD vs. HC: ↑IL-1β, IL-1RA, IL-5, IL-8, IL-12p70, IL-13, IL-17, GRO-α</td><td>Not studied</td><td>x</td></tr><tr><td>37</td><td>Emanuele et al. 2010 [<xref ref-type="bibr" rid="CR176">176</xref>]</td><td>IL-1β, IL-6, IL-10</td><td>x</td><td>x</td><td>Endotoxin, sCD14</td><td>ASD vs. HC: ↑endotoxins, IL-1β, IL-6</td><td>Impaired social interaction: ↑endotoxins</td><td>No differences in concentrations of sCD14 and IL-10, no association with IQ</td></tr><tr><td>38</td><td>Enstrom et al. 2010 [<xref ref-type="bibr" rid="CR155">155</xref>]</td><td>IL-1β, IL-4, IL-5, IL-6, IL-10, IL-12p70, IFN-γ, TNF-α</td><td>CCL2 (MCP-1), CXCL8 (IL-8)</td><td>GM-CSF</td><td>Monocyte counts and subsets (CD14<sup>+</sup>CD16<sup>+</sup> and CD14<sup>+</sup>CD15<sup>−</sup>), plasma</td><td>ASD vs. HC: ↑IL-1β (TLR2-LTA, TLR4-LPS), IL-6 (TLR2-LTA), TNF-α (TLR2-LTA), CD14<sup>+</sup>HLA-DR<sup>+</sup> (baseline, TLR2-LTA) ↓MCP-1 (TLR4-LPS, TLR3-poly I:C, TLR9-CpG-B), IL-1β (TLR9-CpG-B), IL-6 (TLR9-CpG-B), TNF-α (TLR9-CpG-B), GM-CSF (TLR9-CpG-B)</td><td>Impaired social interaction: ↑IL-1β (TLR4-LPS), IL-6 (TLR-4-LPS); impaired non-verbal communication: ↑IL-1β (TLR4-LPS), IL-6 (TLR-4-LPS)</td><td>No differences in total number of monocytes and it subsets, no association with GI symptoms. TLR stimulation showed no association with Th1 (IL-12p70, IFN-γ) and Th2 (IL-4, IL-5, IL-10) cytokines in plasma</td></tr><tr><td>39</td><td>Kajizuka et al. 2010 [<xref ref-type="bibr" rid="CR185">185</xref>]</td><td>x</td><td>x</td><td>PDGF-AA, PDGF-AB, PDGF-BB, VEGF</td><td>x</td><td>ASD vs. HC: ↑PDGF-BB</td><td>Restricted behaviors and interests: ↑PDGF-BB</td><td>No association with IQ, impairment of social interaction and communication</td></tr><tr><td>40</td><td>Ashwood et al. 2009 [<xref ref-type="bibr" rid="CR147">147</xref>]</td><td>IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p40, IFN-γ, TNF-α</td><td>CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), CCL11 (eotaxin), CXCL8 (IL-8)</td><td>GM-CSF</td><td>x</td><td>ASD vs. HC: ↑MIP-1β after pretreatment with BDE-47; ASD vs. HC: ↓IL-6, GM-CSF and ↑IL-1β, IL-8 after pretreatment with BDE-47 and stimulation with LPS</td><td>Not studied</td><td>Undetectable basal levels of IL-2, IL-4, IL-5, IFN-γ, MCP-1, RANTES, and eotaxin, pretreatment with BDE-47—no effect on cytokine production</td></tr><tr><td>41</td><td>Onore et al. 2009 [<xref ref-type="bibr" rid="CR96">96</xref>]</td><td>IL-17, IL-23</td><td>x</td><td>x</td><td>x</td><td>ASD vs. HC: ↓IL-23</td><td>Impaired social interactions: ↓IL-23 after PHA stimulation</td><td>No differences in total numbers of T cells, B cells, or monocytes, undetectable levels of IL-17 and 23 without stimulation, no differences in IL-17 following stimulation with PHA, no differences in the frequency of Th17 cells, no association with ADI-R, MSEL, VABS, and ABC scores</td></tr><tr><td>42</td><td>Saresella et al. 2009 [<xref ref-type="bibr" rid="CR91">91</xref>]</td><td>IL-1β, IL-2, IL-6, IL-10, IL-12, IFN-γ, TNF-α</td><td>x</td><td>x</td><td>Perforin, granzyme</td><td>ASD vs. HC: ↑CD4<sup>+</sup>IFN-γ, CD4<sup>+</sup>IL-6, CD4<sup>+</sup>IL-10, CD8<sup>+</sup>IFN-γ, CD8<sup>+</sup>IL-2, CD8<sup>+</sup>IL-6, CD8<sup>+</sup>IL-10, CD14<sup>+</sup>IL-10, ↓CD14<sup>+</sup>IL-6, CD14<sup>+</sup>IL-1β; ASD vs. SIB: ↑CD4<sup>+</sup>TNF-α, CD8<sup>+</sup>IFN-γ; SIB vs. HS: ↑CD4<sup>+</sup>IL-6, CD4<sup>+</sup>IL-10, CD8<sup>+</sup>IL-2, CD8<sup>+</sup>TNF-α, CD8<sup>+</sup>IL8, CD8<sup>+</sup>IL-10 ↓CD14<sup>+</sup>TNF-α; ASD and SIB vs. HC: ↑naive CD8<sup>+</sup>CD45RA-CCR7<sup>+</sup> lymphocytes, ↓effector memory CD8<sup>+</sup>CD45RA-CCR7<sup>−</sup> and terminally differentiated CD4<sup>+</sup>CD45RA<sup>+</sup>CCR7<sup>−</sup> lymphocytes</td><td>Not studied</td><td>No statistically significant differences in granzyme and perofin-producing CD8<sup>+</sup> lymphocytes, no differences in basic lymphocyte subpopulations</td></tr><tr><td>43</td><td>Ashwood et al. 2008 [<xref ref-type="bibr" rid="CR177">177</xref>]</td><td>TGF-β1</td><td>x</td><td>x</td><td>x</td><td>ASD vs. HC: ↓TGF-β1, ASD vs. DD: ↓TGF-β1</td><td>Irritability, lethargy, stereotypy, and hyperactivity: ↓TGF-β1, impaired adaptive behavior, social interaction: ↓TGF-β1, especially in early-onset ASD; regressive ASD and irritability: ↓TGF-β1</td><td>No differences in concentration of TGF-β1 and psychological parameters within ASD regressive and early-onset subtypes, no correlation with ADI-R, ADOS, MSEL, or VABS scores</td></tr><tr><td>44</td><td>Enstrom et al. 2008 [<xref ref-type="bibr" rid="CR178">178</xref>]</td><td>IL-17, IL-23</td><td>x</td><td>x</td><td>x</td><td>ASD vs. HC: ↓IL-23; early-onset ASD vs. HC: ↓IL-23; early-onset ASD vs. regressive ASD: ↓IL-23</td><td>Not studied</td><td>No significant difference in IL-17 concentration, no significant difference in IL-23 in regressive ASD vs. HC</td></tr><tr><td>45</td><td>Grigorenko et al. 2008 [<xref ref-type="bibr" rid="CR179">179</xref>]</td><td>MIF</td><td>x</td><td>x</td><td>x</td><td>ASD vs. SIB: ↑MIF</td><td>ASD severity, social impairment, imaginative skills: ↑MIF</td><td>x</td></tr><tr><td>46</td><td>Jyonouchi et al. 2008 [<xref ref-type="bibr" rid="CR156">156</xref>]</td><td>IL-1β, IL-6, IL-10, IL-12p40, IL-23, TGF-β, TNF-α, sTNFRII</td><td>x</td><td>x</td><td>x</td><td>ASD-I vs. ASD, HC : ↓IL-1β (TLR4/7/8), IL-10 (TLR2/6) ↑IL-23 (TLR4)</td><td>Not studied</td><td>x</td></tr><tr><td>47</td><td>Molloy et al. 2006 [<xref ref-type="bibr" rid="CR148">148</xref>]</td><td>IL-2, IL-4, IL-5, IL-10, IL-13, IFN-γ</td><td>x</td><td>x</td><td>Eosinophil count</td><td>ASD vs. HC: ↑IL-4, IL-5, IL-13, IL-13/IL-10 ratio, IFN-γ/IL-10 ratio, eosinophil count; ASD without medication vs. TD: ASD vs. TD: ↑IL-4, IL-13</td><td>Not studied</td><td>No differences in IL-10 baseline concentration, no significant differences between ASD and HC following stimulation, no differences in cytokine concentration in relation to medication</td></tr><tr><td>48</td><td>Al-Ayadhi 2005 [<xref ref-type="bibr" rid="CR180">180</xref>]</td><td>IL-1, IL-6, TNF-α</td><td>x</td><td>x</td><td>x</td><td>ASD vs. HC: ↑TNF-α, IL-1, IL-6</td><td>No correlations with ASD severity</td><td>x</td></tr><tr><td>49</td><td>Jyonouchi et al. 2005 [<xref ref-type="bibr" rid="CR157">157</xref>]</td><td>IL-5, IL-10, IL-12p40, IFN-γ, TNF-α, sTNFRII</td><td>x</td><td>x</td><td>x</td><td>ASD vs. HC after stimulation: ↑TNF-α, IL-12; NFH vs. HC: ↑IFN-γ, TNF-α, IL-10, IL-12</td><td>Not studied</td><td>No differences in IL-5 concentration after stimulation, no significant differences between groups without stimulation</td></tr><tr><td>50</td><td>Jyonouchi et al. 2005 [<xref ref-type="bibr" rid="CR158">158</xref>]</td><td>IL-1RA, IL-1β, IL-6, IL-10, IL-12, TNF-α, sTNFRII</td><td>x</td><td>x</td><td>x</td><td>ASD vs. HC: ↑TNF-α (LPS); ASD-GI without diet vs. ASD: ↑IL-12 (LPS), ↓IL-10 (LPS)</td><td>Not studied</td><td>No significant difference in cytokine production after T-cell mitogens</td></tr><tr><td>51</td><td>Sweeten et al. 2004 [<xref ref-type="bibr" rid="CR181">181</xref>]</td><td>IL-1β, IFN-y, TNF-α</td><td>x</td><td>x</td><td>NO</td><td>ASD vs. HC: ↑NO</td><td>Not studied</td><td>No differences in IL-1β, IFN-y, TNF-α concentrations between study and control groups</td></tr><tr><td>52</td><td>Croonenberghs et al. 2002 [<xref ref-type="bibr" rid="CR182">182</xref>]</td><td>IL-1RA, IL-2R (serum only), IL-6, IL-10 (supernatant), IFN-γ (supernatant), TNF-α (supernatant)</td><td>x</td><td>x</td><td>x</td><td>ASD vs. HC: ↑IL-1RA, IFN-γ (culture supernatants)</td><td>Not studied</td><td>No differences in serum cytokine concentrations</td></tr><tr><td>53</td><td>Jyonouchi et al. 2002 [<xref ref-type="bibr" rid="CR183">183</xref>]</td><td>IL-1β, IL-4, IL-5, IL-6, IFN-γ, TNF-α, sTNFRI, sTNFRII</td><td>x</td><td>x</td><td>x</td><td>ASD vs. HC without stimulation: ↑ IL-5; ASD vs. HC after gliadin or milk stimulation: ↑ IFN-γ, TNF-α; ASD vs. HC after soy stimulation: ↑IFN-γ; SIB vs. HC after milk stimulation: ↑IFN-γ, TNF-α; DPI vs. HC after stimulation: ↑IFN-γ, TNF-α</td><td>Not studied</td><td>No differences in IL-5 concentration after stimulation; differences between ASD, SIB and DPI children not studied</td></tr><tr><td>54</td><td>Jyonouchi et al. 2001 [<xref ref-type="bibr" rid="CR159">159</xref>]</td><td>IL-1RA, IL-1β, IL-4, IL-5, IL-6, IL-10, IL-12p40, IL-18, IFN-γ, TGF-β, TNF-α, sTNFRI, sTNFRII</td><td>x</td><td>x</td><td>x</td><td>ASD vs. HC: ↑IL-1β, IL-6 (only without stimulation), TNF-α, sTNFRI, sTNFRII (only without stimulation), ASD vs. SIB: ↑TNF-α, sTNFRI (only without stimulation)</td><td>Not studied</td><td>No differences in IL-1RA concentrations between groups, no differences in IL-1β, IL-6, and sTNFRII between ASD children and their healthy siblings</td></tr><tr><td>55</td><td>Gupta et al. 1998 [<xref ref-type="bibr" rid="CR88">88</xref>]</td><td>IL-2, IL-4, IL-6, IL-10, IFN-γ</td><td>x</td><td>x</td><td>x</td><td>ASD vs. HC: ↑IL-4<sup>+</sup>CD4<sup>+</sup>, IL-4<sup>+</sup>CD8<sup>+</sup>, ↓IFN-γ<sup>+</sup>CD4<sup>+</sup>, IL-2<sup>+</sup>CD4<sup>+</sup>, IFN-γ<sup>+</sup>CD8<sup>+</sup>, IL-2<sup>+</sup>CD8<sup>+</sup></td><td>Not studied</td><td>x</td></tr><tr><td>56</td><td>Singh et al. 1996 [<xref ref-type="bibr" rid="CR160">160</xref>]</td><td>IL-6, IL-12, IFN-α, IFN-γ, TNF-α</td><td>x</td><td>x</td><td>sICAM-1</td><td>ASD vs. HC: ↑IL-12, IFN-γ</td><td>Not studied</td><td>No differences in concentrations of IFN-α, IL-6, TNF-α, sICAM-1</td></tr><tr><td>57</td><td>Singh et al. 1991 [<xref ref-type="bibr" rid="CR149">149</xref>]</td><td>IL-1, IL-2, IL-2R</td><td>x</td><td>x</td><td>T8 antigen</td><td>ASD vs. HC, DD: ↑IL-2, T8 antigen</td><td>Not studied</td><td>No differences in concentrations of IL-1 and IL-2R</td></tr></tbody></table><table-wrap-foot><p><italic>IL</italic> interleukin, <italic>IFN</italic> interferon, <italic>TNF</italic> tumor necrosis factor, <italic>TGF</italic> transforming growth factor, <italic>MIF</italic> macrophage migration inhibitory factor, <italic>sR</italic> soluble receptor, <italic>TRAIL</italic> TNF-related apoptosis-inducing ligand, <italic>LIF</italic> leukemia inhibitory factor, <italic>SCF</italic> stem cell factor, <italic>CXCL</italic> C-X-C motif chemokine ligand, <italic>GRO</italic> growth-regulated oncogene, <italic>MCP</italic> monocyte chemoattractant protein, <italic>CCL</italic> C-C motif chemokine ligand, <italic>RANTES</italic> regulated on activation, normal T-cell expressed and secreted, <italic>I-309</italic> T-lymphocyte activation, <italic>MIP</italic> macrophage inflammatory protein, <italic>MIG</italic> monokine induced by interferon-gamma, <italic>BCL</italic> B lymphocyte chemoattractant <italic>TARC</italic> thymus and activation-regulated chemokine, <italic>MDC</italic> macrophage-derived chemokine, <italic>IP-10</italic> IFN-γ-inducible protein 10, <italic>SDF</italic> stromal cell-derived factor, <italic>CTACK</italic> cutaneous T-cell-attracting chemokine, <italic>GM-CSF</italic> granulocyte-macrophage colony-stimulating factor, <italic>G-CSF</italic> granulocyte colony-stimulating factor, <italic>M-CSF</italic> macrophage colony-stimulating factor, <italic>PDGF</italic> platelet-derived growth factor, <italic>FGF</italic> fibroblast growth factor, <italic>VEGF</italic> vascular endothelial growth factor, <italic>BDNF</italic> brain-derived neurotrophic factor, <italic>EGF</italic> epidermal growth factor, <italic>HGF</italic> hepatocyte growth factor, <italic>EGF-R</italic> epidermal growth factor receptor, <italic>HB-EGF</italic> heparin-binding epidermal growth factor, <italic>NGF</italic> nerve growth factor, <italic>IGF</italic> insulin-like growth factor, <italic>BP</italic> binding protein, <italic>SCGF</italic> stem cell growth factor, <italic>CTLA</italic> cytotoxic T-lymphocyte-associated protein, <italic>S100B</italic> calcium-binding protein B, <italic>PBMNC</italic> peripheral blood mononuclear cells<italic>, NFκBp65</italic> nuclear factor kappa-light-chain enhancer of activated B cells p65 subunit, <italic>PE</italic> phosphatidyl ethanolamine, <italic>PS</italic> phosphatidyl serine, <italic>PC</italic> phosphatidyl choline, <italic>MAP2K1</italic> dual specificity mitogen-activated protein kinase kinase 1, <italic>PGE</italic> prostaglandin E2, <italic>EP</italic> E-prostanoid, <italic>mPGES</italic> microsomal prostaglandin synthase E, <italic>cPLA</italic> cytosolic phospholipase A, <italic>COX</italic> cyclo-oxygenase, <italic>ICAM</italic> cell adhesion molecule, <italic>TIMP</italic> tissue inhibitors of metalloproteinases, <italic>sST</italic> suppressor of T-cell receptor signaling, <italic>TBARS</italic> thiobarbituric acid reactive substance, <italic>HT</italic> hydroxytryptamine, <italic>GABA</italic> gamma-aminobutyric acid, <italic>IFI</italic> interferon-γ-inducible protein, <italic>HSP</italic> heat shock proteins, <italic>CD</italic> cluster of differentiation, <italic>L</italic> ligand, <italic>Flt3</italic> Fms-related tyrosine kinase, <italic>VIP</italic> vasoactive intestinal peptide, <italic>NT</italic> neurotrophin, <italic>NO</italic> nitric oxide, <italic>MMP</italic> matrix metalloproteinase, <italic>ASD</italic> autism spectrum disorder, <italic>HC</italic> healthy controls, <italic>ASD-C</italic> childhood autism, <italic>ASD-AS</italic> Asperger syndrome, <italic>LPS</italic> lipopolysaccharides, <italic>GI</italic> gastrointestinal symptoms, <italic>RTT</italic> Rett syndrome, <italic>PHA</italic> phytohemagglutinin, <italic>I</italic> inflammatory subtype (defined as fluctuating behavioral symptoms following immune insults), <italic>NFA</italic> non-IgE-mediated food allergy, <italic>SPAD</italic> specific polysaccharide antibody deficiency, <italic>TLR</italic> Toll-like receptors, <italic>SIB</italic> siblings, <italic>DD</italic> developmental delay, <italic>NHF</italic> non-allergic food hypersensitivity, <italic>DPI</italic> dietary protein intolerance, <italic>ABC</italic> Aberrant Behavior Checklist, <italic>BMI</italic> body mass index, <italic>IQ</italic> intelligence quotient, <italic>ADI-R</italic> Autism Diagnostic Interview–Revised, <italic>MSEL</italic> Mullen Scales of Early Learning, <italic>VABS</italic> Vineland Adaptive Behavior Scale, <italic>BDE-47</italic> 2,2′,4,4′-tetrabromodiphenyl ether, <italic>ADOS</italic> Autism Diagnostic Observation Schedule</p><p><sup>A</sup>Abstract</p></table-wrap-foot></table-wrap></p>
<p id="Par35">Monocytes are a part of an innate immune system that differentiate into macrophages and migrate into the surrounding tissue where they present antigens to lymphocytes [<xref ref-type="bibr" rid="CR186">186</xref>]. State-of-the-art research has shown that current understanding of monocyte and macrophage biology is insufficient and should undergo revision [<xref ref-type="bibr" rid="CR167">187</xref>]. Monocytes in an inflammatory milieu have been known to secrete proinflammatory mediators such as IL-1β, IL-8, or TNF-α, and their prolonged activation has been found to be relevant in the course of rheumatoid arthritis [<xref ref-type="bibr" rid="CR188">188</xref>], Alzheimer’s [<xref ref-type="bibr" rid="CR189">189</xref>], and Parkinson’s disease [<xref ref-type="bibr" rid="CR190">190</xref>]. Changes in monocyte function observed in ASD may not be causative, as studies suggest that monocytes are in an activated state and their proinflammatory activity could add on to existing immune imbalances, exacerbating behavioral symptoms.</p>
</sec>
<sec id="Sec5">
<title>Microglia</title>
<p id="Par36">Microglia, resident innate immune cells of the brain, are specialized tissue macrophages of the CNS that monitor brain homeostasis [<xref ref-type="bibr" rid="CR191">191</xref>]. They are known to play an important role in the pathogenesis of neuropsychiatric disorders including ASD [<xref ref-type="bibr" rid="CR192">192</xref>–<xref ref-type="bibr" rid="CR195">195</xref>]. During brain development, microglia take part in synaptic and neuronal development and regulation of stem cell proliferation [<xref ref-type="bibr" rid="CR196">196</xref>]. In autistic children, microglia are located closer to neurons and activated in several regions of brain, especially in cerebellum [<xref ref-type="bibr" rid="CR196">196</xref>, <xref ref-type="bibr" rid="CR197">197</xref>]. Morgan et al.’s study [<xref ref-type="bibr" rid="CR198">198</xref>] of dorsolateral prefrontal cortex microglia revealed marked activation in 5 of 13 studied individuals with ASD (especially in children under age of 6) and marginal activation in 4. Moreover, microglial volume and cell density were increased in ASD subjects, which is in accordance with other studies [<xref ref-type="bibr" rid="CR199">199</xref>]. Activation of microglia may be linked to abnormal brain connectivity reported in children with ASD [<xref ref-type="bibr" rid="CR200">200</xref>, <xref ref-type="bibr" rid="CR201">201</xref>]. Studies in mouse models of obsessive compulsive disorder and trichotillomania with microglial abnormalities revealed that after transplantation of bone marrow-derived stem cells, key symptoms of the disease were ameliorated [<xref ref-type="bibr" rid="CR202">202</xref>]. This result suggests that modulation of immune system can lead to behavioral improvements.</p>
<p id="Par37">Microglial abnormality is a promising area that should be more intensively researched. Resident immune cells have been found to play a role in white matter abnormalities in the brain of schizophrenia patients [<xref ref-type="bibr" rid="CR204">204</xref>, <xref ref-type="bibr" rid="CR205">205</xref>]. The interplay between the peripheral immune system and microglia [<xref ref-type="bibr" rid="CR205">205</xref>–<xref ref-type="bibr" rid="CR207">207</xref>] as well as abnormal white matter connectivity found in ASD [<xref ref-type="bibr" rid="CR208">208</xref>, <xref ref-type="bibr" rid="CR209">209</xref>] makes microglia an interesting target for further studies in this field. Finding explicit connections between microglial activation and peripheral immune abnormalities in ASD could uncover new possibilities for targeted interventions.</p>
</sec>
<sec id="Sec6">
<title>Cytokines and chemokines in brain tissue and cerebrospinal fluid</title>
<p id="Par38">A tremendous insight into ASD pathogenesis was achieved through cytokine studies on autistic brains. Frozen tissue lysates of front cerebral cortex from eight ASD patients and matched individuals were compared for concentrations of several cytokines. The subjects were aged 4–37 years (mean age of 12) and included five males and three females with moderate to severe ASD. The control group was age- and sex-matched and included individuals that had been diagnosed with asthma, heart disease, or other injuries. TNF-α, IL-6, granulocyte colony-stimulating factor (G-CSF), IFN-γ, and IL-8 were increased in the brain of ASD patients. There were no differences in IL-1β, IL-2, IL-4, IL-5, or IL-10. The study revealed that proinflammatory and Th1 cytokines as well as Th1/Th2 ratio (measured as IFN-γ/IL-10 ratio) and IL-8 were up-regulated in comparison with control group [<xref ref-type="bibr" rid="CR210">210</xref>]. Vargas et al. [<xref ref-type="bibr" rid="CR211">211</xref>] studied cytokine profiles in both brain and CSF. The brain tissue was sampled from middle frontal gyrus, anterior cingulate gyrus, and cerebellar hemisphere. The study group was composed of 15 patients (3 females) aged 5–44; most had been diagnosed with mental retardation (12/15) and some with epilepsy (6/15). The control group consisted of 12 individuals, including 3 females, aged 5–46, with no neurological disorders. The causes of death in both groups were non-neurological. The expression of 79 proteins, including cytokines, chemokines, and growth and differentiation factors, was measured on seven autistic brains and controls by protein array studies and confirmed with ELISA array for the most significant proteins. The most prominent changes were captured in anterior cingulate gyrus; however, several proteins turned out to be up-regulated in all studied regions (MCP-1, TARC,TGF-β1) and one in CSF as well (MCP-1). Proteins up-regulated in CSF included IL-6, INF-γ, and IL-10. Interestingly, immunocytochemical staining was carried out to detect structures responsible for increased cytokine concentration and revealed that astrocytes localized in the cerebellum and cortical and subcortical white matter regions were the main source of MCP-1 and IL-6. Moreover, Vargas et al. [<xref ref-type="bibr" rid="CR211">211</xref>] found that microglia and astroglia activation was most prominent in the cerebellum. However, interpretation of this study should be careful due to the co-existing pathologies of epilepsy and mental retardation. Elevated concentration of IL-6 was also found by another study that examined cerebellar brain tissue derived from six ASD individuals compared to six control subjects [<xref ref-type="bibr" rid="CR212">212</xref>]. Zimmerman et al.’s study [<xref ref-type="bibr" rid="CR213">213</xref>] aimed to examine CSF. They obtained CSF and serum from 12 patients with moderate to severe ASD, including 2 females, aged 2.7–10 years, most with regression, and some with epilepsy or abnormal EEG results. The study revealed an increased concentration of biopterin and a decreased concentration of quinolinic acid and neopterin (indicators for immune activation) in comparison with control group; however, those changes could be due to the fact that control group was composed of patients with central nervous system diseases. Cytokine profile showed a higher serum soluble TNF-α receptor II concentration in children with ASD compared with siblings, normal children, and patients with central nervous system diseases. No other abnormalities were detected. No correlation between serum and CSF concentration was observed and presence of regression did not seem to influence results in any manner. The authors concluded that decreased quinolinic acid and neopterin along with increased biopterin in CSF might be a result of metabolic pathway dysmaturation in the absence of co-existing infection or due to expression localized to microglia. Another study [<xref ref-type="bibr" rid="CR214">214</xref>] that examined pterin compounds in CSF found 7,8-dihydroneopterin and 6R-5,6,7,8-tetrahydrobiopterin to be significantly down-regulated in comparison with controls. Several other investigators have raised the issue of elevated pterins in both serum and urine as a sign of cellular immunity activation, stimulated by IFN-γ and TNF-α with conflicting results [<xref ref-type="bibr" rid="CR161">161</xref>, <xref ref-type="bibr" rid="CR215">215</xref>–<xref ref-type="bibr" rid="CR218">218</xref>]. The earliest study on 16 ASD children and 12 typically developing controls found decreased plasma and urinary levels of neopterin and monapterin accompanied by normal tetrahydrobiopterin level [<xref ref-type="bibr" rid="CR218">218</xref>]. In contrast, two other studies on urinary pterins revealed that both neopterin and biopterin were elevated in ASD individuals in comparison to healthy controls [<xref ref-type="bibr" rid="CR216">216</xref>, <xref ref-type="bibr" rid="CR217">217</xref>]. High plasma neopterin in ASD individuals was also confirmed in two other studies [<xref ref-type="bibr" rid="CR161">161</xref>, <xref ref-type="bibr" rid="CR215">215</xref>]. Several attempts to treat ASD with tetrahydrobiopterin and sapropterin have been carried out demonstrating potentially positive effects, including three clinical trials [<xref ref-type="bibr" rid="CR219">219</xref>–<xref ref-type="bibr" rid="CR224">224</xref>]. However, molecular studies on ASD individuals revealed only one marginal association with a gene responsible for tetrahydrobiopterin synthesis [<xref ref-type="bibr" rid="CR225">225</xref>]. Currently, there are no open clinical trials in this area.</p>
<p id="Par39">An elevation of NF-κB in neurons and microglia was found to be significant in orbitofrontal cortex of ASD individuals [<xref ref-type="bibr" rid="CR226">226</xref>]. Chez et al. [<xref ref-type="bibr" rid="CR227">227</xref>] evaluated the concentration of TNF-α simultaneously in both serum and CSF of 10 male patients aged 2.5–9.7 with regressive ASD. The study’s results must be interpreted cautiously since 7 out of 10 patients were on medications, including valproic acid and risperidone, which are thought to have anti-inflammatory and potentially immunomodulatory properties [<xref ref-type="bibr" rid="CR228">228</xref>–<xref ref-type="bibr" rid="CR231">231</xref>]. Four patients had received treatment for autoimmunity in the past, but no details concerning timeframe of treatment were provided. The ratio of TNF-α in CSF and serum ranged between 1.7 and 275, with an average value of 41.6, and the concentration of TNF-α in CSF and the CSF/serum ratio were higher in patients who did not undergo immunomodulatory therapy. The authors hypothesized they may have observed a unique CNS response, as no apparent correlation exists between CSF and serum and the CSF/serum ratio described in other diseases (HIV, ischemic stroke, traumatic brain injury, multiple sclerosis, systemic lupus erythematosus, frontotemporal dementia) is close to 1:1. A similar hypothesis concerning lack of association between different protein concentration in CSF and serum was confirmed by Pardo et al. [<xref ref-type="bibr" rid="CR232">232</xref>]. The results of studies conducted on CSF and brain tissue are summarized in Table <xref ref-type="table" rid="Tab4">4</xref>.<table-wrap id="Tab4"><label>Table 4.</label><caption><p>Concentration of cytokines, chemokines, and growth factors in brain tissue and cerebrospinal fluid of ASD patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Number</th><th>Study</th><th>Study group age (years)</th><th>Groups</th><th>Females (%)</th><th>Death causes</th><th>Study material</th><th>Cytokines</th><th>Chemokines</th><th>Growth factors</th><th>Main results</th><th>Excluded correlations</th></tr></thead><tbody><tr><td>1</td><td>Pardo et al. 2017 [<xref ref-type="bibr" rid="CR232">232</xref>]</td><td>R: 2–8</td><td>ASD (<italic>n</italic> = 104, 67 for CSF analysis), HC (<italic>n</italic> = 54)</td><td>ASD (17), HC (24)</td><td>NA</td><td>CSF, serum</td><td>IL-1α, IL-1RA, IL-1β, IL-2, sIL-2RA, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17, IFN-α2, IFN-γ, TNF-α, TNF-β, TGF-α</td><td>CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL7 (MCP-3), CCL11 (eotaxin), CCL22 (MDC), CXCL1 (GRO-α), CXCL8 (IL-8), CXCL10 (IP-10), CX3CL1 (fractalkine)</td><td>EGF, G-CSF, GM-CSF, VEGF, FGF-2, FLT-3L, sCD40L</td><td>ASD vs. TD: ↑EGF, sCD40L (serum), high within-subject variation of studied parameters</td><td>No association between concentrations of studied parameters in blood and CSF</td></tr><tr><td>2</td><td>Wei et al. 2010 [<xref ref-type="bibr" rid="CR212">212</xref>]</td><td>M: 8.3, SD: 3.8</td><td>ASD (<italic>n</italic> = 6), HC (<italic>n</italic> = 6)</td><td>ASD (33), HC (33)</td><td>ASD: drowning (<italic>n</italic> = 4), multiple injuries (<italic>n</italic> = 1), smoke inhalation (<italic>n</italic> = 1); HC: drowning (<italic>n</italic> = 2), multiple injuries (<italic>n</italic> = 1), cardiac arrhythmia (<italic>n</italic> = 1), asthma (<italic>n</italic> = 1), lymphocytic myocarditis (<italic>n</italic> = 1)</td><td>Brain tissue (cerebellum)</td><td>IL-6</td><td>x</td><td>x</td><td>ASD vs. TD: ↑IL-6</td><td>x</td></tr><tr><td>3</td><td>Li et al. 2009 [<xref ref-type="bibr" rid="CR211">210</xref>]</td><td>M: 12.8, R: 4–37</td><td>ASD (<italic>n</italic> = 8), HC (<italic>n</italic> = 8)</td><td>ASD (37), HC (37)</td><td>No data</td><td>Brain tissue (front cerebral cortex)</td><td>IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IFN-γ, TNF-α</td><td>CXCL8 (IL-8)</td><td>GM-CSF</td><td>ASD vs. TD: ↑IL-6, IFN-γ, TNF-α, IL-8, GM-CSF, Th1/Th2 ratio</td><td>No differences in IL-1β, IL-4, IL-5, IL-10 concentration</td></tr><tr><td>4</td><td>Chez et al. 2007 [<xref ref-type="bibr" rid="CR227">227</xref>]</td><td>M: 5.4, SD: 2.1, R: 2.5–9.5</td><td>Regressive ASD (<italic>n</italic> = 10), LGS (<italic>n</italic> = 1)</td><td>ASD (0), LGS (0)</td><td>NA</td><td>CSF, serum</td><td>TNF-α</td><td>x</td><td>x</td><td>CSF vs. serum: ↑TNF-α; ASD + medications: ↑TNF-α, ASD vs. Lennox–Gastaut: ↑TNF-α</td><td>No abnormalities in CSF including protein, glucose, glutamate levels, myelin basic protein, oligoclonal bands</td></tr><tr><td>5</td><td>Zimmerman et al. 2005 [<xref ref-type="bibr" rid="CR213">213</xref>]</td><td>ASD1—M: 6.1, R: 1.4–10; ASD2—M: 7.8, R: 2.8–43</td><td>ASD1 (<italic>n</italic> = 12), ASD2 (<italic>n</italic> = 35, including 1 with ASD-AS, 1 with PDD-NOS, 1 with high functioning ASD), HC1 (<italic>n</italic> = 15), HC2 (<italic>n</italic> = 12), HC3 (<italic>n</italic> = 2), SIB (<italic>n</italic> = 10), ND (<italic>n</italic> = 11)</td><td>ASD1 (17), ASD2 (8), HC1 (60), HC2 (50), HC3 (50), SIB (50), ND (9)</td><td>NA</td><td>CSF (ASD1, HC1, HC2), serum (ASD1, ASD2, HC3, ND, SIB)</td><td>IL-RA, IL-6, IL-1β, IL-2, IFN-γ, TGF-β, sTNFRI, sTNFRII</td><td>x</td><td>x</td><td>ASD vs. TD: ↑quinolinic acid, neopterin ↓biopterin; ASD vs. ND: ↑biopterin ↓quinolinic acid, neopterin; ASD vs. ND and SIB: ↑sTNFRII</td><td>No abnormalities in CSF including protein, glucose, oligoclonal bands. IL-1β, IL-2, IFN-γ, TGF-β not detected in CSF</td></tr><tr><td>6</td><td>Vargas et al. 2005 [<xref ref-type="bibr" rid="CR211">211</xref>]</td><td>Brain tissue—M: 12, R: 5–44; CSF—M: 5.5, R: 4–10</td><td>Brain tissue: ASD (<italic>n</italic> = 15), HC (<italic>n</italic> = 12); CSF: ASD (<italic>n</italic> = 6), HC (<italic>n</italic> = 9)</td><td>Brain tissue: ASD (20), HC (25); CSF: ASD (33), HC (67)</td><td>ASD: drowning (<italic>n</italic> = 5), trauma sudden death (<italic>n</italic> = 3), respiratory failure (<italic>n</italic> = 1), hyperthermia (<italic>n</italic> = 1), trauma (<italic>n</italic> = 1), aspiration (<italic>n</italic> = 1), acute myocardial infarction (<italic>n</italic> = 1), unknown (<italic>n</italic> = 1); HC: drowning (<italic>n</italic> = 1), allograft rejection (<italic>n</italic> = 1), cardiac arrhythmia (<italic>n</italic> = 1), accidental (<italic>n</italic> = 1), asthma (<italic>n</italic> = 1), gunshot (<italic>n</italic> = 1), trauma (<italic>n</italic> = 2), hanging (<italic>n</italic> = 1), asphyxia (<italic>n</italic> = 1), heart disease (<italic>n</italic> = 1), sudden death (<italic>n</italic> = 1)</td><td>Brain tissue (cerebellum, midfrontal, and cingulate gyrus), CSF</td><td>IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, IL-16, IFN-γ, TNF-α, TNF-β, TGF-β1, TGF-β2, TGF-β3</td><td>CCL1 (I-309), CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), CCL7 (MCP-3), CCL8 (MCP-2), CCL9 (MIP-1γ), CCL11 (eotaxin), CCL22 (MDC), CCL24 (eotaxin-2), CCL26 (eotaxin-3), GRO, CXCL1 (GRO-α), CXCL8 (IL-8), CXCL9 (MIG), CXCL10 (IP-10), CX3CL1 (fractalkine), ENA-78, MIP-1gamma, SDF-1, CCL17 (TARC), BLC, GCP-2, MCP-4, MIF, MIP-3alpha, NAP-2, CkBeta8-1</td><td>G-CSF, M-CSF, SCF, EGF, IGF-I, Ang, OSM, Tpo, VEGF, PDGF-B, Leptin, BDNF, FGF-4, FGF-6, FGF-7, FGF-9, Flt-3 ligand, GDNF, HGF, GFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, LIF, LIGHT, NT-3, NT-4, Osteoprotegerin, PARC, PIGF, TIMP-1, TIMP-2</td><td>ASD vs. TD: ↑IL-6, IL-10, CCL2 (MCP-1), CCL7 (MCP-3), CCL8 (MCP-2), TGF-β1, IGFBP1, CCL11 (eotaxin), eotaxin-2, TARC, MDC, Ckβ8.1, MIG, BLC, IGF-1, leptin, Flt3-lig, IGFBP1, osteoprotegerin, microglia and astroglia activation</td><td>No evidence of adaptive immune reactions</td></tr></tbody></table><table-wrap-foot><p><italic>R</italic> range, <italic>M</italic> mean, <italic>SD</italic> standard deviation, <italic>ASD</italic> autism spectrum disorder, <italic>CSF</italic> cerebrospinal fluid, <italic>HC</italic> healthy controls, <italic>LGS</italic> Lennox–Gastaut Syndrome, <italic>SIB</italic> siblings, <italic>ND</italic> neurological disorders, <italic>IL</italic> interleukin, <italic>IFN</italic> interferon, <italic>TNF</italic> tumor necrosis factor, <italic>TGF</italic> transforming growth factor, <italic>sR</italic> soluble receptor, <italic>CCL</italic> C-C motif chemokine ligand, <italic>MCP</italic> monocyte chemoattractant protein, <italic>MIP</italic> macrophage inflammatory protein, <italic>MDC</italic> macrophage-derived chemokine, <italic>CXCL</italic> C-X-C motif chemokine ligand, <italic>GRO</italic> growth-regulated oncogene, <italic>IP-10</italic> IFN-γ-inducible protein 10, <italic>MIG</italic> monokine induced by interferon-gamma, <italic>ENA-78</italic> epithelial cell-derived neutrophil activating peptide-78, <italic>SDF</italic> stromal cell-derived factor, <italic>TARC</italic> thymus and activation-regulated chemokine, <italic>EGF</italic> epidermal growth factor, <italic>G-CSF</italic> granulocyte colony-stimulating factor, <italic>GM-CSF</italic> granulocyte-macrophage colony-stimulating factor, <italic>VEGF</italic> vascular endothelial growth factor, <italic>BDNF</italic> brain-derived neurotrophic factor</p></table-wrap-foot></table-wrap></p>
<p id="Par40">It is worth noting that though all of the described studies detected abnormalities in CSF or brain tissue of ASD patients, high variability between subjects, small samples, and lack of correlation between clinical symptoms and laboratory results hinder interpretation. Only three studies [<xref ref-type="bibr" rid="CR213">213</xref>, <xref ref-type="bibr" rid="CR227">227</xref>, <xref ref-type="bibr" rid="CR232">232</xref>] focused on both CSF and peripheral blood and did not confirm any correlation between the same proteins in those two samples. It would be highly beneficial to conduct larger studies, simultaneously evaluating concentrations of proteins in both CSF and peripheral blood. It is understandable that lumbar puncture for scientific purposes might be unacceptable to some patients’ parents as it is connected with high levels of child stress and/or administration of premedication or anesthetics. However, ASD children often undergo MRI scans under general anesthesia for diagnostic purposes and CSF sampling could be done at that time and preserved for further studies. Understanding differences and interactions between the periphery and CNS is crucial for determining novel therapeutic strategies.</p>
</sec>
<sec id="Sec7">
<title>Peripheral blood cytokines, chemokines, and growth factors</title>
<p id="Par41">The first studies on plasma cytokine levels in individuals with ASD showed increased levels of IFN-γ, IL-2, and IL-12 and thus concluded that ASD may be linked to pathological stimulation of Th1 cells. No difference between the study and control group was found for IFN-α, IL-1, IL-6, TNF-α, or soluble intercellular adhesion molecule-1 [<xref ref-type="bibr" rid="CR149">149</xref>, <xref ref-type="bibr" rid="CR160">160</xref>]. An increase in the Th1 inflammatory response was also found by Croonenberghs et al. [<xref ref-type="bibr" rid="CR182">182</xref>] who studied production of IL-6, IL-10, interleukin-1 receptor antagonist (IL-1RA), IFN-γ, and TNF-α in whole blood and IL-6, interleukin-2 receptor (IL-2R), and IL-1RA in serum of ASD individuals. The study revealed increased levels of IFN-γ and IL-1RA in the supernatant of ASD group whole blood cultures. A relationship between Th1 and Th2 cytokines was also studied by Gupta et al. [<xref ref-type="bibr" rid="CR88">88</xref>]. They found an imbalance between Th1 and Th2 cytokines with increased IL-4<sup>+</sup>CD4<sup>+</sup> T cells and IL-4<sup>+</sup>CD8<sup>+</sup> T cells and decreased proportions of IFN-γ<sup>+</sup>CD4<sup>+</sup> T cells, IL-2<sup>+</sup>CD4<sup>+</sup> T cells, and IFN-γ<sup>+</sup>CD8<sup>+</sup> and IL-2<sup>+</sup>CD8<sup>+</sup> T cells in children with autism. Molloy et al. [<xref ref-type="bibr" rid="CR148">148</xref>] compared production of several cytokines (IL-2, IL-4, IL-5, IL-10, IL-13, IFN-γ) in PB-MNC of ASD children and healthy controls and found a predominance of Th2 response with an imbalance in Th1/Th2 cytokine subsets in the ASD children MNC. Production of TNF-α, IL-1β, and IL-6 by PB-MNC was significantly increased with and without stimuli (PHA, tetanus, IL-12p70, IL-18) [<xref ref-type="bibr" rid="CR159">159</xref>] in the ASD group. The same investigators measured cytokine production against common dietary proteins and found increased proinflammatory cytokine responses (IFN-γ and TNF-α) that might predispose ASD individuals to GI inflammation and worsen disease behavioral symptoms [<xref ref-type="bibr" rid="CR157">157</xref>]. In another study, both children with ASD and non-allergic food hypersensitivity had elevated cytokine production after stimulation with common dietary proteins and similar cytokine profiles. Both groups had high TNF-α and IL-12 concentrations and individuals with non-allergic food hypersensitivity also had elevated IFN-γ and IL-10 levels [<xref ref-type="bibr" rid="CR183">183</xref>] (Table <xref ref-type="table" rid="Tab3">3</xref>).</p>
<p id="Par42">Suzuki et al. [<xref ref-type="bibr" rid="CR141">141</xref>] measured concentration of multiple proteins in plasma of high-functioning male children with ASD aged 7–15. The study included 21 children with ASD disorder and 7 with pervasive developmental disorder–not otherwise specified (PDD-NOS). The investigators found that IL-1β, IL-1RA, IL-5, IL-8, IL-12p70, IL-13, IL-17, and growth-regulated oncogene-α were significantly elevated (1.5–2.5-fold) in comparison to matched controls; however, no correlation between clinical profile and laboratory results was observed. An interesting contribution was made by Han et al. [<xref ref-type="bibr" rid="CR164">164</xref>] who found distinct chemokine and cytokine profiles between ASD individuals and ASD children with comorbid diagnosis of attention deficit hyperactivity disorder (ADHD). The study group consisted of children aged 6–17 years, 9 with ASD and ADHD, 13 with ASD only, and 13 typically developing controls matched by age, gender, and IQ. Investigators compared concentrations of several chemokines and two cytokines (TGFβ1 and macrophage migration inhibitory factor—MIF) of which MCP-1 and Th2-related RANTES were significantly higher and Th1-related C-X-C motif chemokine ligand (CXCL) 9 was lower in all children with ASD, in comparison to healthy controls. Moreover, an increased MIF and decreased CXCL10 concentration was found to correlate with lower executive functioning scores, while CXCL9 was inversely correlated with short-term memory function. Increased concentration of RANTES and decreased CXCL9 were associated with poor behavioral scores (social domain, repetitive behavior, and hyperactivity). Children with co-morbid ADHD had higher MIF and lower IL-8 concentration than ASD-only children. Individuals with ASD and ADHD were different from typically developing controls in concentration of MIF (higher) and in IL-8 and CXCL9 (lower).</p>
<p id="Par43">Frequently, ASD individuals were reported to have a higher concentration of proinflammatory or lower concentration of anti-inflammatory cytokines [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR137">137</xref>, <xref ref-type="bibr" rid="CR141">141</xref>–<xref ref-type="bibr" rid="CR143">143</xref>, <xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR146">146</xref>, <xref ref-type="bibr" rid="CR149">149</xref>, <xref ref-type="bibr" rid="CR151">151</xref>, <xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR157">157</xref>–<xref ref-type="bibr" rid="CR160">160</xref>, <xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR169">169</xref>–<xref ref-type="bibr" rid="CR171">171</xref>, <xref ref-type="bibr" rid="CR182">182</xref>, <xref ref-type="bibr" rid="CR183">183</xref>] in comparison to healthy controls or other developmental delays, although some results are contradictory [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR139">139</xref>, <xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR153">153</xref>, <xref ref-type="bibr" rid="CR154">154</xref>, <xref ref-type="bibr" rid="CR156">156</xref>, <xref ref-type="bibr" rid="CR166">166</xref>, <xref ref-type="bibr" rid="CR172">172</xref>, <xref ref-type="bibr" rid="CR173">173</xref>, <xref ref-type="bibr" rid="CR177">177</xref>]. Interestingly, Tsilioni et al. [<xref ref-type="bibr" rid="CR170">170</xref>] distinguished two autistic groups—with initially low or high IL-6 and TNF levels, whereas another study divided subjects according to response to LPS stimulation and found high levels of IL-1β and IL-6 in LPS responders [<xref ref-type="bibr" rid="CR150">150</xref>]. One recent study focused on several soluble factors that have not previously been studied in ASD. Investigators researched IL-21, IL-22, IL-27, and cytotoxic T-lymphocyte-associated molecule-4 as indicators of pro- and anti-inflammatory balance and revealed dysregulation of immune milieu [<xref ref-type="bibr" rid="CR162">162</xref>]. Other differences between ASD subjects and healthy individuals included high MCP-1, RANTES, eotaxin [<xref ref-type="bibr" rid="CR174">174</xref>], TARC, MDC [<xref ref-type="bibr" rid="CR89">89</xref>], BDNF, and platelet-derived growth factor (PDGF) concentrations [<xref ref-type="bibr" rid="CR140">140</xref>, <xref ref-type="bibr" rid="CR152">152</xref>], low epidermal growth factor (EGF) [<xref ref-type="bibr" rid="CR139">139</xref>, <xref ref-type="bibr" rid="CR175">175</xref>], and altered IL-23 [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR152">152</xref>–<xref ref-type="bibr" rid="CR154">154</xref>, <xref ref-type="bibr" rid="CR156">156</xref>, <xref ref-type="bibr" rid="CR178">178</xref>] and IL-8 [<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR169">169</xref>]. Intriguingly, a few studies included normally developing siblings as one of the control groups and found that their biomarker profile was distinct from other normally developing children [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR179">179</xref>, <xref ref-type="bibr" rid="CR183">183</xref>].</p>
<p id="Par44">Several published studies did not confirm differences between ASD and healthy individuals in baseline or stimulated levels of cytokines, chemokines, or growth factors [<xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR153">153</xref>, <xref ref-type="bibr" rid="CR168">168</xref>, <xref ref-type="bibr" rid="CR170">170</xref>, <xref ref-type="bibr" rid="CR181">181</xref>].</p>
<p id="Par45">Approximately half of the studies tried to correlate behavioral profile with laboratory abnormalities (Table <xref ref-type="table" rid="Tab3">3</xref>). One of them did not find any correlation with clinical measures [<xref ref-type="bibr" rid="CR168">168</xref>]; however, it evaluated only two cytokines (IL-1β, IL-33), scored children with the Social Responsiveness Scale (SRS) alone, and included those also on psychotropic medication. However, there were no differences found between patients on and off medication.</p>
<p id="Par46">A link between ASD severity and cytokine or chemokine abnormalities was sought for extensively. Increased concentration of IL-1β [<xref ref-type="bibr" rid="CR150">150</xref>–<xref ref-type="bibr" rid="CR152">152</xref>], IL-6 [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR171">171</xref>], IL-12p70 [<xref ref-type="bibr" rid="CR135">135</xref>], IL-17A [<xref ref-type="bibr" rid="CR93">93</xref>], TNF-α [<xref ref-type="bibr" rid="CR135">135</xref>], MIF [<xref ref-type="bibr" rid="CR179">179</xref>], MDC, and TARC [<xref ref-type="bibr" rid="CR89">89</xref>] positively correlated with more severe behavioral symptoms. Only one out of seven studies on this topic failed to confirm a connection between peripheral blood cytokines (TNF-α, IL-1, IL-6) and disease severity [<xref ref-type="bibr" rid="CR180">180</xref>].</p>
<p id="Par47">Several investigators identified a relationship between social sphere and concentration of several factors, out of which IL-6 was repeatedly found to be relevant. IL-6 correlated positively with social impairments both at baseline level [<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR167">167</xref>] and after stimulation [<xref ref-type="bibr" rid="CR155">155</xref>]. Up-regulation of IL-1β [<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR155">155</xref>], IL-10 [<xref ref-type="bibr" rid="CR150">150</xref>], MCP-1 [<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR219">219</xref>], MIP-1β [<xref ref-type="bibr" rid="CR138">138</xref>], MIP-1δ [<xref ref-type="bibr" rid="CR138">138</xref>], MIF [<xref ref-type="bibr" rid="CR180">180</xref>], and endotoxins [<xref ref-type="bibr" rid="CR177">177</xref>] and down-regulation of IL-23 [<xref ref-type="bibr" rid="CR96">96</xref>], TGF-β1 [<xref ref-type="bibr" rid="CR177">177</xref>], TNF-α [<xref ref-type="bibr" rid="CR166">166</xref>], and GM-CSF [<xref ref-type="bibr" rid="CR138">138</xref>] were also described in relation to social dysfunction.</p>
<p id="Par48">In opposition to the above-described results, Han et al. [<xref ref-type="bibr" rid="CR164">164</xref>] found no association of social domain with TGF-β1 and MIF. Correlation with social impairment was also negative in two other experiments that focused on IL-10, IL-12 [<xref ref-type="bibr" rid="CR73">73</xref>], PDGF, and vascular endothelial growth factor (VEGF) [<xref ref-type="bibr" rid="CR185">185</xref>]. Poorer performance on Vineland Adaptive Behavior Scale was connected with low GM-CSF, IL-1β, IL-2, IL-6, and MCP-1, with high MIP-1δ [<xref ref-type="bibr" rid="CR138">138</xref>], and no association was found with IL-17, IL-23, and TGF-β1 [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR177">177</xref>].</p>
<p id="Par49">Deficits in communication and language were frequently found to be associated with an impaired protein profile, in particular higher concentration of IL-4, IL-8, IL12p40, IFN-γ [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>], MIP-1α, and RANTES [<xref ref-type="bibr" rid="CR174">174</xref>] and lower concentrations of IL-5 and IL-10 [<xref ref-type="bibr" rid="CR144">144</xref>]. Concentration of PDGF and VEGF [<xref ref-type="bibr" rid="CR185">185</xref>] and mRNA levels of IL-1β, IL-6, and TNF-α [<xref ref-type="bibr" rid="CR166">166</xref>] were found to be independent of communication skills. Poor verbal contact was linked with up-regulation of IL-1β and IL-6 after stimulation [<xref ref-type="bibr" rid="CR155">155</xref>] as well as high concentration of IL-10, GM-CSF, and M-CSF [<xref ref-type="bibr" rid="CR138">138</xref>].</p>
<p id="Par50">Stereotypic behavior seemed to correlate with down-regulation of TGF-β1 [<xref ref-type="bibr" rid="CR177">177</xref>] and GM-CSF [<xref ref-type="bibr" rid="CR144">144</xref>] as well as up-regulation of IL-1β, IL-6, IL-8, IL12p40, TNF-α, and IFN-γ [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]. Restricted patterns of behavior and interests were more pronounced in patients with high concentration of MCP-1, RANTES, eotaxin [<xref ref-type="bibr" rid="CR174">174</xref>], and PDGF-BB [<xref ref-type="bibr" rid="CR185">185</xref>].</p>
<p id="Par51">Surprisingly, exacerbations of both hyperactivity and lethargy were found to be linked to low levels of anti-inflammatory cytokines (IL-10, TGF-β), high levels of proinflammatory cytokines (IL-1β, IL-6) [<xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR151">151</xref>], several chemokines (IL-8, RANTES, eotaxin), and high response to PHA stimulation [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR174">174</xref>]. Hyperactivity was also associated with low levels of CXCL5 [<xref ref-type="bibr" rid="CR164">164</xref>] and IL-13 and high levels of IL-12p40 [<xref ref-type="bibr" rid="CR144">144</xref>]. Irritability was also associated with a similar balance of pro- and anti-inflammatory cytokines [<xref ref-type="bibr" rid="CR151">151</xref>] apart from a low level of TNF-α [<xref ref-type="bibr" rid="CR167">167</xref>] or TGF-β1 [<xref ref-type="bibr" rid="CR178">178</xref>].</p>
<p id="Par52">Most of the studies did not reveal any association between IQ and soluble molecules profile [<xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR176">176</xref>, <xref ref-type="bibr" rid="CR185">185</xref>] apart from low concentration of IL-6 in Ferguson et al. [<xref ref-type="bibr" rid="CR167">167</xref>] study and Napolioni et al. research [<xref ref-type="bibr" rid="CR138">138</xref>] in which a wide range of cytokines inversely correlated with IQ. Impaired short-term memory was associated with high CXCL9 [<xref ref-type="bibr" rid="CR164">164</xref>].</p>
<p id="Par53">An interesting observation about sleep disturbances and aggressive behavior was made by Careaga et al. who found up-regulation of IL-1β, IL-6, IL-10, and MCP-1 in children whose PBMNC responded well to LPS stimulation [<xref ref-type="bibr" rid="CR150">150</xref>]. Interestingly, Th-1 skewed response was associated with more severe developmental impairment.</p>
<p id="Par54">Other studied areas included fine motor skills (down-regulated IL-5, up-regulated MCP-1, RANTES, and eotaxin), visual reception (up-regulated IL-8, MCP-1, RANTES, and eotaxin) [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR175">176</xref>], executive functioning (high MIF, low CXCL10) [<xref ref-type="bibr" rid="CR164">164</xref>], daily living abilities (high MCP-1, eotaxin), and adaptive and cognitive functions (high MCP-1, RANTES, and eotaxin, low TGF-β1 and GM-CSF, and no association with IL-10 or IL-12) [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR174">174</xref>, <xref ref-type="bibr" rid="CR177">177</xref>].</p>
<p id="Par55">When analyzing various developmental patterns of ASD patients it would seem that children who lost abilities would present with different biological conditions. A few studies that researched a wide cytokine profile negated its connection with regression [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR163">163</xref>]. However, Ashwood et al. [<xref ref-type="bibr" rid="CR145">145</xref>] showed that children who regressed expressed higher levels of IL-1β in comparison to other ASD individuals and higher levels of IL-1β, IL-6, IL-8, and GM-CSF in comparison to healthy controls. IL-1β was also found significantly higher by Napolioni et al. [<xref ref-type="bibr" rid="CR138">138</xref>] along with IL-5 and IL-17 in children with regressive ASD. A single study reported a connection between higher TNF-α concentration and occurrence of regression [<xref ref-type="bibr" rid="CR167">167</xref>].</p>
<p id="Par56">GI issues are frequently reported among autistic individuals [<xref ref-type="bibr" rid="CR233">233</xref>]. PB-MNC from ASD individuals with GI problems were found to have altered concentration of several cytokines; however, results are inconsistent [<xref ref-type="bibr" rid="CR137">137</xref>, <xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR154">154</xref>, <xref ref-type="bibr" rid="CR158">158</xref>, <xref ref-type="bibr" rid="CR167">167</xref>, <xref ref-type="bibr" rid="CR184">184</xref>]. ASD children with GI symptoms were also assessed for intracellular cytokines in CD3<sup>+</sup> lymphocytes in both peripheral blood and mucosa. Peripheral blood levels of TNF-α were similar to typically developing children with Crohn disease and were increased in comparison to healthy controls. Similar observations were made for IFN-γ both in peripheral blood and terminal ileum lymphocytes. IL-10 was down-regulated in ASD children with GI symptoms in comparison to both healthy controls and children with Crohn disease in both peripheral blood and terminal ileum mucosa. The observed differences were maintained following stimulation [<xref ref-type="bibr" rid="CR234">234</xref>]. Lymphocytic colitis in ASD children, especially those with GI symptoms and regression, was reported in several papers. A study on immunological aberrations in gut mucosa, based on duodenal, ileal, and colonic biopsies, revealed up-regulation of CD3<sup>+</sup>CD8<sup>+</sup> intraepithelial lymphocytes and CD3<sup>+</sup> lamina propria lymphocytes with proinflammatory cytokine profile [<xref ref-type="bibr" rid="CR234">234</xref>, <xref ref-type="bibr" rid="CR235">235</xref>]. Functional GI disorders in children with ASD were associated with elevation of several proinflammatory cytokines in rectal biopsy mucosa [<xref ref-type="bibr" rid="CR236">236</xref>]. ASD children with GI complaints were found to have comparable levels of CD3<sup>+</sup> lymphocyte intracellular cytokines [<xref ref-type="bibr" rid="CR237">237</xref>] and even higher intraepithelial cell number and CD8<sup>+</sup> density than children with Crohn disease [<xref ref-type="bibr" rid="CR238">238</xref>].</p>
<p id="Par57">Another study revealed epithelial IgG and complement deposition in almost all children with regressive ASD [<xref ref-type="bibr" rid="CR239">239</xref>]. However, not all investigators were successful in determining abnormalities of intestinal biopsy specimens in ASD individuals [<xref ref-type="bibr" rid="CR240">240</xref>].</p>
<p id="Par58">An unusual approach was proposed in a double-blind, placebo-controlled trial with camel milk, assessing whether 2-week administration of raw or boiled camel milk, instead of cow milk, would help to reduce serum levels of TARC and lessen autistic traits. Camel milk is said to have unique properties such as low molecular weight immunoglobulins. Investigators hypothesized that camel milk could down-regulate synthesis and secretion of TARC leading to reduction of inflammatory processes. Best behavioral outcomes were observed with raw camel milk; however, the use of both forms of camel milk led to significant reduction of TARC levels [<xref ref-type="bibr" rid="CR241">241</xref>].</p>
<p id="Par59">Multiple studies have confirmed cytokine, chemokine, and growth factor abnormalities in ASD. For details concerning demographic details and medical history of analyzed patients, please refer to Table <xref ref-type="table" rid="Tab2">2</xref>; for summarized results, please see Table <xref ref-type="table" rid="Tab3">3</xref>. The main results concern proinflammatory cytokines. IL-1 was found to be found up-regulated frequently and its high concentration was connected with regression [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR145">145</xref>], ASD severity [<xref ref-type="bibr" rid="CR152">152</xref>], deficits in social sphere [<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR155">155</xref>], impaired adaptive skills [<xref ref-type="bibr" rid="CR138">138</xref>] and development [<xref ref-type="bibr" rid="CR150">150</xref>], as well as hyperactivity, lethargy, and irritability [<xref ref-type="bibr" rid="CR151">151</xref>]. IL-6 was strongly associated with ASD severity [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR171">171</xref>] and deficits in social sphere [<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR167">167</xref>]. Its up-regulation, analogous to IL-1, was found to be significantly correlated with hyperactivity, lethargy, and irritability [<xref ref-type="bibr" rid="CR151">151</xref>]. Interestingly, higher IQ was connected with lower IL-6 level [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR167">167</xref>]. For detailed summary, please refer to Table <xref ref-type="table" rid="Tab5">5</xref>.<table-wrap id="Tab5"><label>Table 5</label><caption><p>Association between autistic traits, co-occurring symptoms, and immune-specific molecules in peripheral blood of ASD children</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Type of analyte</th><th>Analytes</th><th>ASD severity</th><th>Regression</th><th>Impaired development</th><th>Deficits in social sphere</th><th>Impaired communication</th><th>Repetitive behaviors and interests, stereotypies</th><th>Impaired cognitive sphere</th><th>Impaired adaptive skills</th><th>Impaired imaginative skills</th><th>Aggression</th><th>Hyperactivity</th><th>Irritability</th><th>Lethargy</th><th>Anxiety</th><th>Higher IQ</th><th>Short-term memory</th><th>Attention deficits</th><th>Sleep disturbances</th><th>GI symptoms</th><th>Epilepsy or EEG abnormalities</th><th>Head circumference</th></tr></thead><tbody><tr><td rowspan="19">Cytokines</td><td>1. IL-1<sup>a</sup> [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR135">135</xref>–<xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR149">149</xref>–<xref ref-type="bibr" rid="CR156">156</xref>, <xref ref-type="bibr" rid="CR159">159</xref>, <xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR166">166</xref>, <xref ref-type="bibr" rid="CR168">168</xref>, <xref ref-type="bibr" rid="CR169">169</xref>, <xref ref-type="bibr" rid="CR174">174</xref>, <xref ref-type="bibr" rid="CR179">179</xref>, <xref ref-type="bibr" rid="CR181">181</xref>, <xref ref-type="bibr" rid="CR183">183</xref>, <xref ref-type="bibr" rid="CR184">184</xref>]</td><td>↑ (1/4) [<xref ref-type="bibr" rid="CR152">152</xref>]</td><td>↑ (2/4)[<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR150">150</xref>]</td><td>↑ (2/5)[<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR155">155</xref>]</td><td>↑ (1/4)[<xref ref-type="bibr" rid="CR155">155</xref>]</td><td>↑ (1/2)[<xref ref-type="bibr" rid="CR145">145</xref>]</td><td>x</td><td>↑ (1/3)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>NA</td><td>↑ (1/1) [<xref ref-type="bibr" rid="CR150">150</xref>]</td><td>1. ↑ (1/2)[<xref ref-type="bibr" rid="CR151">151</xref>]</td><td>↑ (1/2)[<xref ref-type="bibr" rid="CR151">151</xref>]</td><td>↑ (1/2)[<xref ref-type="bibr" rid="CR151">151</xref>]</td><td>NA</td><td>↓ (1/2)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>NA</td><td>NA</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR150">150</xref>]</td><td>↑ (1/2)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>x</td><td>NA</td></tr><tr><td>2. IL-2 [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR138">138</xref>–<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR143">143</xref>–<xref ref-type="bibr" rid="CR149">149</xref>, <xref ref-type="bibr" rid="CR156">156</xref>, <xref ref-type="bibr" rid="CR162">162</xref>]</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>x</td><td>x</td><td>x</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>NA</td><td>NA</td><td>2. x</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>NA</td><td>NA</td><td>NA</td><td>↑ (1/2)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>x</td><td>x</td></tr><tr><td>3. IL-4 [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR138">138</xref>–<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR143">143</xref>–<xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR159">159</xref>, <xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR183">183</xref>]</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>↑ (1/4)[<xref ref-type="bibr" rid="CR145">145</xref>]</td><td>x</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>3. x</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>NA</td><td>x</td><td>NA</td><td>x</td><td>x</td><td>x</td></tr><tr><td>4. IL-5 [<xref ref-type="bibr" rid="CR135">135</xref>–<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR144">144</xref>–<xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR154">154</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR157">157</xref>, <xref ref-type="bibr" rid="CR159">159</xref>, <xref ref-type="bibr" rid="CR183">183</xref>]</td><td>x</td><td>↑ (1/3)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>NA</td><td>x</td><td>x</td><td>x</td><td>↓(1/2)[<xref ref-type="bibr" rid="CR144">144</xref>]</td><td>x</td><td>NA</td><td>x</td><td>4. x</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>NA</td><td>x</td><td>NA</td><td>x</td><td>x</td><td>x</td></tr><tr><td>5. IL-6 [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR138">138</xref>–<xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR150">150</xref>–<xref ref-type="bibr" rid="CR156">156</xref>, <xref ref-type="bibr" rid="CR158">158</xref>–<xref ref-type="bibr" rid="CR160">160</xref>, <xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR165">165</xref>–<xref ref-type="bibr" rid="CR167">167</xref>, <xref ref-type="bibr" rid="CR170">170</xref>–<xref ref-type="bibr" rid="CR172">172</xref>, <xref ref-type="bibr" rid="CR174">174</xref>, <xref ref-type="bibr" rid="CR180">180</xref>, <xref ref-type="bibr" rid="CR182">182</xref>, <xref ref-type="bibr" rid="CR183">183</xref>]</td><td>↑ (2/4) [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR171">171</xref>]</td><td>↑ (1/5)[<xref ref-type="bibr" rid="CR145">145</xref>]</td><td>↑ [<xref ref-type="bibr" rid="CR150">150</xref>]</td><td>↑ (3/6)[<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR167">167</xref>]</td><td>↑ (2/5)[<xref ref-type="bibr" rid="CR140">140</xref>, <xref ref-type="bibr" rid="CR171">171</xref>]</td><td>↑ (1/2)[<xref ref-type="bibr" rid="CR145">145</xref>]</td><td>x</td><td>↑ (1/3)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>NA</td><td>↑ (1/3)[<xref ref-type="bibr" rid="CR150">150</xref>]</td><td>5. ↑ (1/3)[<xref ref-type="bibr" rid="CR150">150</xref>]</td><td>↑ (1/2)[<xref ref-type="bibr" rid="CR151">151</xref>]</td><td>↑ (1/3)[<xref ref-type="bibr" rid="CR151">151</xref>]</td><td>x</td><td>↓ (2/4)[<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR167">167</xref>]</td><td>NA</td><td>x</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR150">150</xref>]</td><td>↑ (1/3)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR135">135</xref>]</td><td>x</td></tr><tr><td>6. IL-6sR [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR138">138</xref>]</td><td>x</td><td>x</td><td>NA</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>x</td><td>NA</td><td>NA</td><td>x</td><td>NA</td><td>NA</td><td>6. NA</td><td>NA</td><td>NA</td><td>NA</td><td>x</td><td>NA</td><td>NA</td><td>NA</td><td>x</td><td>x</td><td>x</td></tr><tr><td>7. IL-7 [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR138">138</xref>–<xref ref-type="bibr" rid="CR141">141</xref>]</td><td>x</td><td>x</td><td>NA</td><td>NA</td><td>x</td><td>NA</td><td>NA</td><td>x</td><td>NA</td><td>NA</td><td>7. NA</td><td>NA</td><td>NA</td><td>NA</td><td>↓ (1/1) [<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>NA</td><td>NA</td><td>NA</td><td>x</td><td>x</td><td>x</td></tr><tr><td>8. IL-10 [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR138">138</xref>–<xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR151">151</xref>, <xref ref-type="bibr" rid="CR153">153</xref>–<xref ref-type="bibr" rid="CR159">159</xref>, <xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR174">174</xref>, <xref ref-type="bibr" rid="CR182">182</xref>, <xref ref-type="bibr" rid="CR184">184</xref>]</td><td>x</td><td>x</td><td>↑ [<xref ref-type="bibr" rid="CR150">150</xref>]</td><td>↑ (1/5)[<xref ref-type="bibr" rid="CR150">150</xref>]</td><td>↑ (1/4)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>x</td><td>x</td><td>x</td><td>NA</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR150">150</xref>]</td><td>8. ↓ (1/3)[<xref ref-type="bibr" rid="CR151">151</xref>]</td><td>↓ (1/1)[<xref ref-type="bibr" rid="CR151">151</xref>]</td><td>↓ (1/3)<break></break>[<xref ref-type="bibr" rid="CR139">139</xref>]</td><td>NA</td><td>x</td><td>NA</td><td>x</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR150">150</xref>]</td><td>x</td><td>x</td><td>x</td></tr><tr><td>9. IL-11 [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR140">140</xref>]</td><td>NA</td><td>x</td><td>NA</td><td>x</td><td>x</td><td>NA</td><td>NA</td><td>x</td><td>NA</td><td>NA</td><td>9. NA</td><td>NA</td><td>NA</td><td>NA</td><td>↓ (1/1)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>NA</td><td>NA</td><td>NA</td><td>x</td><td>NA</td><td>x</td></tr><tr><td>10. IL-12 [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR139">139</xref>–<xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR150">150</xref>–<xref ref-type="bibr" rid="CR155">155</xref>]</td><td>↑p70, ↓p40 (1/3)[<xref ref-type="bibr" rid="CR135">135</xref>]</td><td>x</td><td>x</td><td>x</td><td>↑ (1/4)[<xref ref-type="bibr" rid="CR144">144</xref>]</td><td>↑ (1/3)[<xref ref-type="bibr" rid="CR145">145</xref>]</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>10. ↑ (1/3)[<xref ref-type="bibr" rid="CR144">144</xref>]</td><td>x</td><td>↑ (1/2)[<xref ref-type="bibr" rid="CR145">145</xref>]</td><td>NA</td><td>↓ p70 [<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>NA</td><td>x</td><td>x</td><td>x</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR135">135</xref>]</td><td>x</td></tr><tr><td>11. IL-13 [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR138">138</xref>–<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR156">156</xref>–<xref ref-type="bibr" rid="CR160">160</xref>]</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>11. ↓ (1/1)<break></break>[<xref ref-type="bibr" rid="CR80">80</xref>]</td><td>x</td><td>x</td><td>NA</td><td>↓ (1/1)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>NA</td><td>NA</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>12. IL-16 [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR140">140</xref>, <xref ref-type="bibr" rid="CR141">141</xref>]</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>x</td><td>NA</td><td>NA</td><td>x</td><td>NA</td><td>NA</td><td>12. NA</td><td>NA</td><td>NA</td><td>NA</td><td>↓ (1/1)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>NA</td><td>NA</td><td>NA</td><td>x</td><td>x</td><td>x</td></tr><tr><td>13. IL-17 [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR135">135</xref>–<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR151">151</xref>, <xref ref-type="bibr" rid="CR154">154</xref>, <xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR178">178</xref>]</td><td>↑ (1/2)[<xref ref-type="bibr" rid="CR93">93</xref>]</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>x</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>13. x</td><td>x</td><td>x</td><td>NA</td><td>↓ (1/1)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>NA</td><td>NA</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>14. IL-23 [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR140">140</xref>, <xref ref-type="bibr" rid="CR151">151</xref>–<xref ref-type="bibr" rid="CR154">154</xref>, <xref ref-type="bibr" rid="CR156">156</xref>, <xref ref-type="bibr" rid="CR178">178</xref>]</td><td>x</td><td>NA</td><td>NA</td><td>↓ (1/1)[<xref ref-type="bibr" rid="CR96">96</xref>]</td><td>NA</td><td>NA</td><td>x</td><td>x</td><td>NA</td><td>NA</td><td>14. x</td><td>x</td><td>x</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>15. IFN-γ [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR138">138</xref>–<xref ref-type="bibr" rid="CR140">140</xref>, <xref ref-type="bibr" rid="CR142">142</xref>–<xref ref-type="bibr" rid="CR146">146</xref>, <xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR172">172</xref>, <xref ref-type="bibr" rid="CR173">173</xref>]</td><td>x</td><td>x</td><td>x</td><td>x</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR144">144</xref>]</td><td>↑ (1/2)[<xref ref-type="bibr" rid="CR144">144</xref>]</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>15. x</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>NA</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>16. TNF-α [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR137">137</xref>, <xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR150">150</xref>–<xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR166">166</xref>, <xref ref-type="bibr" rid="CR167">167</xref>, <xref ref-type="bibr" rid="CR180">180</xref>]</td><td>↑ (1/2)[<xref ref-type="bibr" rid="CR135">135</xref>]</td><td>x</td><td>x</td><td>↓ (1/4)[<xref ref-type="bibr" rid="CR166">166</xref>]</td><td>x</td><td>↑ (1/2)[<xref ref-type="bibr" rid="CR144">144</xref>]</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>16. x</td><td>↓ (1/2)[<xref ref-type="bibr" rid="CR167">167</xref>]</td><td>x</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR167">167</xref>]</td><td>x</td><td>NA</td><td>x</td><td>x</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR167">167</xref>]</td><td>x</td><td>x</td></tr><tr><td>17. TNF-sRII [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR138">138</xref>]</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>x</td><td>NA</td><td>NA</td><td>x</td><td>NA</td><td>NA</td><td>17. x</td><td>x</td><td>x</td><td>NA</td><td>↓ (1/1)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>NA</td><td>NA</td><td>NA</td><td>x</td><td>NA</td><td>x</td></tr><tr><td>18. TGF-β [<xref ref-type="bibr" rid="CR139">139</xref>, <xref ref-type="bibr" rid="CR151">151</xref>, <xref ref-type="bibr" rid="CR153">153</xref>, <xref ref-type="bibr" rid="CR159">159</xref>, <xref ref-type="bibr" rid="CR164">164</xref>, <xref ref-type="bibr" rid="CR173">173</xref>, <xref ref-type="bibr" rid="CR177">177</xref>]</td><td>NA</td><td>x</td><td>NA</td><td>↓ (1/2)[<xref ref-type="bibr" rid="CR177">177</xref>]</td><td>x</td><td>↓ (1/2)[<xref ref-type="bibr" rid="CR177">177</xref>]</td><td>x</td><td>x</td><td>NA</td><td>NA</td><td>18. ↓ (1/2)[<xref ref-type="bibr" rid="CR177">177</xref>]</td><td>↓ (1/2)[<xref ref-type="bibr" rid="CR177">177</xref>]</td><td>↓ (1/2)[<xref ref-type="bibr" rid="CR177">177</xref>]</td><td>NA</td><td>NA</td><td>x</td><td>x</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>19. MIF [<xref ref-type="bibr" rid="CR140">140</xref>, <xref ref-type="bibr" rid="CR164">164</xref>, <xref ref-type="bibr" rid="CR179">179</xref>]</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR179">179</xref>]</td><td>NA</td><td>NA</td><td>↑ (1/2)[<xref ref-type="bibr" rid="CR179">179</xref>]</td><td>x</td><td>x</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR164">164</xref>]</td><td>NA</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR179">179</xref>]</td><td>NA</td><td>19. x</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>x</td><td>x</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td rowspan="10">Chemokines</td><td>1. CCL2 (MCP-1) [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR138">138</xref>–<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR164">164</xref>, <xref ref-type="bibr" rid="CR175">175</xref>]</td><td>x</td><td>x</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR150">150</xref>]</td><td>↑ (1/2)[<xref ref-type="bibr" rid="CR174">174</xref>]</td><td>x</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR174">174</xref>]</td><td>↑ (1/4)[<xref ref-type="bibr" rid="CR174">174</xref>]</td><td>↑ [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR174">174</xref>]</td><td>NA</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR150">150</xref>]</td><td>1. x</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>x</td><td>x</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR150">150</xref>]</td><td>x</td><td>x</td><td>x</td></tr><tr><td>2. CCL4 (MIP-1β) [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR138">138</xref>–<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR175">175</xref>]</td><td>x</td><td>x</td><td>NA</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>x</td><td>x</td><td>x</td><td>x</td><td>NA</td><td>NA</td><td>2. x</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>NA</td><td>NA</td><td>NA</td><td>x</td><td>x</td><td>x</td></tr><tr><td>3. CCL5 (RANTES) [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR138">138</xref>–<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR164">164</xref>, <xref ref-type="bibr" rid="CR174">174</xref>]</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>↑ (1/2)[<xref ref-type="bibr" rid="CR174">174</xref>]</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR174">174</xref>]</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR174">174</xref>]</td><td>↑ (1/2)[<xref ref-type="bibr" rid="CR174">174</xref>]</td><td>NA</td><td>NA</td><td>3. ↑ (1/1)[<xref ref-type="bibr" rid="CR174">174</xref>]</td><td>x</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR174">174</xref>]</td><td>NA</td><td>x</td><td>x</td><td>↓ (1/1)[<xref ref-type="bibr" rid="CR164">164</xref>]</td><td>NA</td><td>x</td><td>x</td><td>x</td></tr><tr><td>4. CCL11 (eotaxin) [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR138">138</xref>–<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR175">175</xref>]</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>x</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR174">174</xref>]</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR174">174</xref>]</td><td>↑ (1/2)[<xref ref-type="bibr" rid="CR174">174</xref>]</td><td>NA</td><td>NA</td><td>4. ↑ (1/1)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>x</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR174">174</xref>]</td><td>NA</td><td>x</td><td>NA</td><td>NA</td><td>NA</td><td>x</td><td>x</td><td>x</td></tr><tr><td>5. CCL15 (MIP-1δ) [<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>x</td><td>x</td><td>x</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>x</td><td>x</td><td>x</td><td>↓ (1/1)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>NA</td><td>NA</td><td>5. NA</td><td>NA</td><td>NA</td><td>NA</td><td>x</td><td>NA</td><td>NA</td><td>NA</td><td>x</td><td>NA</td><td>x</td></tr><tr><td>6. CCL17 (TARC) [<xref ref-type="bibr" rid="CR89">89</xref>]</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR89">89</xref>]</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>6. NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>7. CCL22 (MDC) [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR139">139</xref>, <xref ref-type="bibr" rid="CR140">140</xref>]</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR89">89</xref>]</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>7. NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>8. CXCL8 (IL-8) [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR138">138</xref>–<xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR144">144</xref>–<xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR164">164</xref>, <xref ref-type="bibr" rid="CR169">169</xref>]</td><td>x</td><td>↑ (1/3)[<xref ref-type="bibr" rid="CR145">145</xref>]</td><td>NA</td><td>x</td><td>↑ (3/5)[<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]</td><td>↑ (2/3)[<xref ref-type="bibr" rid="CR145">145</xref>]</td><td>↑ (2/2)[<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]</td><td>↑ (2/4)[<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]</td><td>NA</td><td>x</td><td>8. ↑ (1/3)[<xref ref-type="bibr" rid="CR145">145</xref>]</td><td>x</td><td>↑ (1/2)[<xref ref-type="bibr" rid="CR145">145</xref>]</td><td>NA</td><td>x</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>x</td><td>x</td></tr><tr><td>9. CXCL9 (MIG) [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR164">164</xref>]</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>NA</td><td>NA</td><td>9. x</td><td>NA</td><td>NA</td><td>NA</td><td>x</td><td>↓ (1/1)[<xref ref-type="bibr" rid="CR164">164</xref>]</td><td>x</td><td>NA</td><td>x</td><td>x</td><td>x</td></tr><tr><td>10. CXCL13 (BLC) [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR138">138</xref>]</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>x</td><td>NA</td><td>NA</td><td>x</td><td>NA</td><td>NA</td><td>10. NA</td><td>NA</td><td>NA</td><td>NA</td><td>x</td><td>NA</td><td>NA</td><td>NA</td><td>x</td><td>x</td><td>↓ (1/1)[<xref ref-type="bibr" rid="CR138">138</xref>]</td></tr><tr><td rowspan="3">Growth factors</td><td>1. M-CSF [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR140">140</xref>]</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>NA</td><td>NA</td><td>x</td><td>NA</td><td>NA</td><td>1. NA</td><td>NA</td><td>NA</td><td>NA</td><td>↓ (1/1)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>NA</td><td>NA</td><td>NA</td><td>x</td><td>x</td><td>x</td></tr><tr><td>2. GM-CSF [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR138">138</xref>–<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR144">144</xref>–<xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR155">155</xref>]</td><td>x</td><td>↑ (1/2)[<xref ref-type="bibr" rid="CR145">145</xref>]</td><td>x</td><td>↑ (1/4)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>↑ (1/4)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>↓ (1/2)[<xref ref-type="bibr" rid="CR144">144</xref>]</td><td>x</td><td>↓ (1/3)[<xref ref-type="bibr" rid="CR144">144</xref>]<break></break>↓ (2/3)[<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR144">144</xref>]</td><td>NA</td><td>x</td><td>2. x</td><td>x</td><td>x</td><td>NA</td><td>↓ (1/1)[<xref ref-type="bibr" rid="CR138">138</xref>]</td><td>NA</td><td>x</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR150">150</xref>]</td><td>x</td><td>NA</td><td>x</td></tr><tr><td>3. PDGF-BB [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR185">185</xref>]</td><td>x</td><td>x</td><td>NA</td><td>x</td><td>x</td><td>↑ (1/1)[<xref ref-type="bibr" rid="CR185">185</xref>]</td><td>NA</td><td>x</td><td>NA</td><td>NA</td><td>3. NA</td><td>NA</td><td>NA</td><td>NA</td><td>x</td><td>NA</td><td>NA</td><td>NA</td><td>x</td><td>x</td><td>x</td></tr></tbody></table><table-wrap-foot><p>No associations were found with IL-1RA, IL-15, IL-33, TNF-β, TNF-sRI, CCL1 (I-309), CCL3 (MIP-1α), CCL9 (MIP-1γ), CCL24 (eotaxin-2), CXCL10 (IP-10), G-CSF, BDNF, PDGF-AA, and VEGF. Allergy and depression were found unrelated to examined analytes. Numbers in brackets stand for number of studies that confirmed analyzed association per total number of studies</p><p><italic>IL</italic> interleukin, <italic>sR</italic> soluble receptor, <italic>IFN</italic> interferon, <italic>TNF</italic> tumor necrosis factor, <italic>TGF</italic> transforming growth factor, <italic>MIF</italic> macrophage migration inhibitory factor, <italic>CCL</italic> C-C motif ligand, <italic>MIP</italic> macrophage inflammatory protein, <italic>MCP</italic> monocyte chemoattractant protein, <italic>RANTES - </italic> regulated on activation, normal T-cell expressed and secreted, <italic>TARC</italic> thymus and activation-regulated chemokine, <italic>MDC</italic> macrophage-derived chemokine, <italic>MIG</italic> monokine induced by interferon-gamma, <italic>IP-10</italic> IFN-γ-inducible protein 10, <italic>BLC-B</italic> lymphocyte chemoattractant, <italic>M-CSF</italic> macrophage colony-stimulating factor, <italic>GM-CSF</italic> granulocyte-macrophage colony-stimulating factor, <italic>PDGF</italic> platelet-derived growth factor, <italic>x</italic> no association, <italic>NA</italic> not applicable (analyte not studied)</p><p><sup>a</sup>IL-β was analyzed in all studies apart from Jácome et al. 2016 [<xref ref-type="bibr" rid="CR135">135</xref>] and Napolioni et al. 2013 [<xref ref-type="bibr" rid="CR138">138</xref>] who studied IL-1α, and Al-Ayadhi et al. 2005 who explored IL-1 [<xref ref-type="bibr" rid="CR180">180</xref>]</p></table-wrap-foot></table-wrap></p>
</sec>
<sec id="Sec8">
<title>Pivotal role of immune system as a potential target for novel therapeutic methods</title>
<p id="Par60">The first attempt to treat ASD on the basis of immunological disturbances came in the form of intravenous immunoglobulin (IVIG) administration. According to current guidelines, such treatment is not recommended due to limited scientific rationale [<xref ref-type="bibr" rid="CR243">243</xref>]. However, several papers reported on improvement after IVIG. Plioplys [<xref ref-type="bibr" rid="CR244">244</xref>] reported on 10 children who received 4 IVIG infusions with 6-week intervals, out of which 5 were considered to have improved. Four children had a partial response to treatment with regard to improved attention span and reduced hyperactivity. One child was reported to have an amelioration of autistic symptoms that regressed after IVIG discontinuation. Gupta et al. [<xref ref-type="bibr" rid="CR245">245</xref>] treated 10 patients out of which 5 had marked improvement in prominent eye contact, echolalia, speech, and behavior. DelGiudice-Asch et al. [<xref ref-type="bibr" rid="CR246">246</xref>] did not find any beneficial effects; however, they carried out their study on seven subjects without previous in-depth immune tests. Another study reported on 26 children who received IVIG and had improved ABC scores, and described that 22 regressed within 2–4 months after IVIG cessation [<xref ref-type="bibr" rid="CR247">247</xref>]. An open-label study with oral encapsulated immunoglobulin therapy in ASD children with GI symptoms revealed that 50% of subjects had behavioral improvement measured with ABC and marked reduction of GI complaints [<xref ref-type="bibr" rid="CR248">248</xref>]. However, a double-blind placebo-controlled trial showed no effectiveness of the abovementioned treatment [<xref ref-type="bibr" rid="CR249">249</xref>]. IVIG exert an immunomodulatory effect and has been reported to be effective in several autoimmune and inflammatory disorders [<xref ref-type="bibr" rid="CR251">250</xref>–<xref ref-type="bibr" rid="CR252">252</xref>]. Although immunoglobulin administration has been shown to have an inhibitory effect on T-cell activation and down-regulate concentration of several cytokines [<xref ref-type="bibr" rid="CR253">253</xref>, <xref ref-type="bibr" rid="CR254">254</xref>], it primarily acts on B-cell function and immunoglobulin repertoire [<xref ref-type="bibr" rid="CR255">255</xref>]. On the basis of cellular mechanism studies and the results of human use, treatment with IVIG does not appear to hold strong potential as a disease-modifying strategy.</p>
<p id="Par61">Interestingly, corticosteroids which have been used to treat other disorders in ASD patients were found to lessen autistic features. A child with ASD who developed autoimmune lymphoproliferative disorder improved greatly in language development and behavior after oral prednisolone therapy [<xref ref-type="bibr" rid="CR242">242</xref>]. A retrospective analysis showed that children with regressive autism benefited from steroid therapy in language development and behavioral spheres [<xref ref-type="bibr" rid="CR256">256</xref>, <xref ref-type="bibr" rid="CR257">257</xref>]. Two other cases of behavioral improvement after corticosteroid therapy were reported in ASD and PDD [<xref ref-type="bibr" rid="CR258">258</xref>, <xref ref-type="bibr" rid="CR259">259</xref>]. Limitations of steroid therapy include well-known side effects and lack of expected significant improvement in core ASD domains. To date, there is only one registered clinical trial registered using pregnenolone in an attempt to lessen irritability, sensory impairment, and social sphere in autistic individuals [NCT02627508].</p>
<p id="Par62">The US Food and Drug Administration has approved two atypical antipsychotic medications for treatment of irritability related to ASD [<xref ref-type="bibr" rid="CR260">260</xref>]. Both risperidone and aripiprazole display interesting immunological properties in in vitro experiments. They were found to reduce proinflammatory cytokines, promote anti-inflammatory pathways, and inhibit microglial activation [<xref ref-type="bibr" rid="CR261">261</xref>–<xref ref-type="bibr" rid="CR265">265</xref>]. However, results from in vivo studies on cytokine changes during treatment of schizophrenia patients are inconsistent [<xref ref-type="bibr" rid="CR266">266</xref>–<xref ref-type="bibr" rid="CR269">269</xref>]. In children with ASD, levels of cytokine after 8 weeks of risperidone therapy were unchanged in one study [<xref ref-type="bibr" rid="CR270">270</xref>], while Choi et al. [<xref ref-type="bibr" rid="CR229">229</xref>] found significant reductions of two chemokines, MCP-1 and eotaxin, that have previously been reported as up-regulated. Multiple clinical trials with risperidone [NCT01171937, NCT00576732, NCT01333072, NCT00080145, NCT00584701, NCT00005014, NCT01624675, NCT00086645, NCT00374764, NCT00166595, NCT0014739] and aripiprazole [NCT00619190, NCT01333072, NCT00468130 NCT00208533 NCT00198107, NCT01028820, NCT01617447, NCT00332241, NCT00308074, NCT01227668, NCT01617460, NCT00337571, NCT00365859, NCT00198055, NCT00870727] were conducted. Other neuroleptics whose potential was explored in ASD include olanzapine [NCT00057408, NCT00183404], lurasidone [NCT01911442, NCT01620060, NCT01914393, NCT01731119], brexipiprazole [NCT03292848], and ziprasidone [NCT00208559]. Effects of neuroleptics on ASD-associated irritability and hyperactivity are promising, and though some studies report improvement in the social sphere or in stereotypy [<xref ref-type="bibr" rid="CR271">271</xref>], most fail to address core ASD symptoms [<xref ref-type="bibr" rid="CR272">272</xref>, <xref ref-type="bibr" rid="CR273">273</xref>]. Their influence on immune abnormalities is probably much more pronounced in in vitro than in vivo conditions, and although MCP-1 was found to be correlated with deficits in social sphere [<xref ref-type="bibr" rid="CR150">150</xref>], improper communication [<xref ref-type="bibr" rid="CR174">174</xref>], and impaired adaptive skills [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR174">174</xref>], none of the fields were influenced with risperidone treatment. The possible adverse effects of neuroleptics, such as increased appetite, weight gain, fatigue, and tremor, have to be taken into consideration before deciding on treatment initiation [<xref ref-type="bibr" rid="CR271">271</xref>–<xref ref-type="bibr" rid="CR274">274</xref>].</p>
<p id="Par63">Donepezil, an acetylcholinesterase inhibitor, was proven to reduce inflammatory cytokine response [<xref ref-type="bibr" rid="CR275">275</xref>] and attenuate M1 microglia polarization [<xref ref-type="bibr" rid="CR276">276</xref>, <xref ref-type="bibr" rid="CR277">277</xref>]. It was also found to be beneficial in the BTBR mouse model of ASD and valproic acid-induced mouse model of ASD [<xref ref-type="bibr" rid="CR278">278</xref>, <xref ref-type="bibr" rid="CR279">279</xref>]. However, despite promising preclinical data, administration of acetylcholinesterase inhibitors such as donepezil, galantamine, or rivastigmine failed to alter concentrations of proinflammatory cytokines in peripheral blood of patients with Alzheimer’s disease [<xref ref-type="bibr" rid="CR280">280</xref>]. In another study, four of eight patients with ASD improved on donepezil; however, the drug influenced only irritability and hyperactivity [<xref ref-type="bibr" rid="CR281">281</xref>]. Donepezil failed to show efficacy in two double-blind, randomized clinical trials in children with ASD and Fragile X syndrome [<xref ref-type="bibr" rid="CR282">282</xref>, <xref ref-type="bibr" rid="CR283">283</xref>]. Currently, there is one clinical trial open to evaluate acetyl-choline esterase inhibitors [NCT01098383].</p>
<p id="Par64">Minocycline, a tetracycline antibiotic that could potentially alter inflammation and microglia activity [<xref ref-type="bibr" rid="CR284">284</xref>], failed to exert clinical effects despite detected changes of hepatocyte growth factor and IL-8 in serum and BDNF changes in both serum and CSF [<xref ref-type="bibr" rid="CR285">285</xref>]. However, in a double-blind placebo-controlled trial, minocycline as an adjunctive therapy to risperidone showed reduction of hyperactivity and irritability [<xref ref-type="bibr" rid="CR286">286</xref>]. One clinical trial with minocycline aimed at measuring microglia activity by PET imagining is currently open [NCT03117530].</p>
<p id="Par65">Several other medications with potent immunomodulatory properties evidenced by in vitro studies are presently under clinical trials. Currently, there are over 60 ongoing interventional clinical trials with different pharmacologic approaches and more than 130 studies already completed with no drug registered for ASD core symptoms [<xref ref-type="bibr" rid="CR287">287</xref>].</p>
<p id="Par66">The most currently available data still fails to reveal the most efficient mechanism of action for addressing immune abnormalities found in ASD. Regulation of cytokine expression seems a natural candidate due to vast preclinical evidence of cytokine correlation with autistic traits. Cytokine administration was also found to induce behavioral abnormalities [<xref ref-type="bibr" rid="CR288">288</xref>, <xref ref-type="bibr" rid="CR289">289</xref>]. INF-α, which is known to elicit proinflammatory mediators such as IL-1, IL-2, IL-6, IL-8, and MCP-1 [<xref ref-type="bibr" rid="CR290">290</xref>, <xref ref-type="bibr" rid="CR291">291</xref>], has been used for treatment of cancer and chronic viral hepatitis [<xref ref-type="bibr" rid="CR292">292</xref>, <xref ref-type="bibr" rid="CR293">293</xref>] with behavioral adverse effects such as depression, anxiety, mania, and psychosis [<xref ref-type="bibr" rid="CR294">294</xref>]. Cytokines as a therapeutic agent should be used with the utmost caution, as in vitro studies are unable to predict immune responses in living organisms due to their complicated, pleiotropic actions. Unnaturally excessive immune activation can lead to cytokine-release syndrome, a potentially life-threatening adverse effect [<xref ref-type="bibr" rid="CR295">295</xref>].</p>
<p id="Par67">Interestingly, a recent study in a valproic acid-exposed rat model of ASD revealed that fingolimod, an immunomodulatory agent used in clinical trials in relapsing–remitting multiple sclerosis, improved learning disturbances, memory deficits, and social impairments. It was found to reduce microglial activation and down-regulate IL-1β and IL-6 in the hippocampus [<xref ref-type="bibr" rid="CR296">296</xref>].</p>
<p id="Par68">Another approach is to explore the potential for utilizing stem cells in inducing immunomodulation. Recent robust research in the stem cell field revealed that stem cells have both immunomodulatory and neuroprotective potential [<xref ref-type="bibr" rid="CR297">297</xref>]. The first clues to such association come from hematopoietic stem cell transplantation (HSCT). Interestingly, behavioral abnormalities are not transferred by bone marrow transplantation (BM-HSCT); however, they can be corrected by BM-HSCT from healthy individuals. Thus, restoring an immunophenotype could alter a disease course [<xref ref-type="bibr" rid="CR12">12</xref>]. Stem cell intervention may be a way to correct immune system abnormalities and alternate core symptom domains of ASD.</p>
<p id="Par69">Specific properties of mesenchymal stromal cells (MSC) make them an attractive cell source for regenerative therapy. MSCs are multipotent non-hematopoietic stem cells that display immunomodulatory properties [<xref ref-type="bibr" rid="CR298">298</xref>]. They have been defined by the International Society for Cellular Therapy [<xref ref-type="bibr" rid="CR299">299</xref>] as a plastic-adherent cell population with particular phenotype (CD105<sup>+</sup>, CD73<sup>+</sup>, CD90<sup>+</sup>, CD45, CD34<sup>−</sup>, CD14, CD11b<sup>−</sup>, CD79a<sup>−</sup>, CD19, HLA<sup>−</sup>DR<sup>−</sup>), able to differentiate into osteoblasts, adipocytes, and chondroblasts. They can be transplanted across allogeneic barriers because of their low immunogenicity, as they do not express major histocompatibility complex class II antigens or co-stimulatory molecules [<xref ref-type="bibr" rid="CR300">300</xref>].</p>
<p id="Par70">Evidence for MSC effectiveness in a mouse model has accumulated. An animal model of maternal immune activation yields offspring with autistic traits that present with increased M1 polarization, up-regulation of inflammatory cytokines and CD4<sup>+</sup> response, as well as systemic Treg deficit [<xref ref-type="bibr" rid="CR10">10</xref>–<xref ref-type="bibr" rid="CR12">12</xref>]. The BTBR mouse strain is considered an adequate animal model for ASD due to behavioral deficits in ASD-related spheres [<xref ref-type="bibr" rid="CR301">301</xref>]. Moreover, similar immune system abnormalities and an inflammatory phenotype are found in BTBR mice [<xref ref-type="bibr" rid="CR302">302</xref>–<xref ref-type="bibr" rid="CR304">304</xref>]. Intraventricular MSC transplantation in young BTBR mice ameliorated stereotypic behaviors and improved deficits in social and cognitive spheres; it is worth noting that it did alter core ASD-related symptoms. Histological analysis revealed increased neurogenesis in the hippocampal area and an elevated level of BDNF were noted. Six weeks after transplantation, MSC cells were detectable in the dorsal third ventricle [<xref ref-type="bibr" rid="CR305">305</xref>]. Intriguingly, MSC cultured to express higher amount of BDNF were found to induce long-term effects on behavioral traits, superior to unmodified cells [<xref ref-type="bibr" rid="CR306">306</xref>]. Intracerebral MSC administration protected mice from a social deficit induced by phencyclidine [<xref ref-type="bibr" rid="CR307">307</xref>, <xref ref-type="bibr" rid="CR308">308</xref>], while adipose-derived stem cells alleviated behavioral abnormalities in a valproic acid-induced ASD model [<xref ref-type="bibr" rid="CR309">309</xref>]. As previously mentioned, microglia in ASD individuals tend to be overly activated. Several investigators found MSC were able to inhibit microglial activation and induce neuroprotective M2 polarization [<xref ref-type="bibr" rid="CR310">310</xref>–<xref ref-type="bibr" rid="CR312">312</xref>]. MSC and microglial crosstalk was also investigated in vitro. MSC were found to act through expression of fractalkine (CX3CL1), which induces a neuroprotective microglia phenotype [<xref ref-type="bibr" rid="CR313">313</xref>] and immunomodulates microglia through paracrine effects [<xref ref-type="bibr" rid="CR314">314</xref>]. MSC are also known to express multiple neural genes and transcription factors and differentiate into neural cells after culture in a suitable media [<xref ref-type="bibr" rid="CR315">315</xref>]. The overall safety profile from clinical applications is promising; however, it lacks long-term data [<xref ref-type="bibr" rid="CR316">316</xref>].</p>
<p id="Par71">A few clinical papers on stem cells use in autism have been published so far; for a summary, please see Supplementary Table <xref ref-type="media" rid="MOESM1">1</xref>. Firstly, a 14-year-old autistic boy [<xref ref-type="bibr" rid="CR317">317</xref>] treated with autologous bone marrow-derived mononuclear stem cells (BM-MNC) was described. The patient had been diagnosed with severe autism with co-existing self-injurious behavior. Brain MRI was normal, PET CT scan showed reduced metabolic activity in several regions, while on EEG bilateral episodic sharp and slow wave abnormalities were seen. The patient received 56 × 10<sup>6</sup> MNC intrathecally along with intensified rehabilitation. At 6 months, he was evaluated with CARS and PET CT. CARS showed substantial improvement as the boy scored 23.5 points (19-point change from the baseline), which is considered as “non-autistic.” PET CT showed increased uptake in several regions which was considered to be improvement in comparison with previous result. At 12 months, the investigators reported on further improvement, especially concerning social sphere; however, the patient was not tested with tools dedicated to evaluate autistic children. The subsequent study by Sharma et al. [<xref ref-type="bibr" rid="CR318">318</xref>] was an open-label, proof-of-concept study with 32 patients and similar study plan; however, the patients were evaluated with Indian Scale for Assessment of Autism, Clinical Global Impression scale (CGI), and scales designed to measure independence in daily living. In CGI-II scores, all patients but one were considered as improved, including 11 who were evaluated as “very much improved.” The improvements were noted on all evaluated domains and were most pronounced in social sphere. The adverse effects related to the procedure included an increase in hyperactivity (transient in six patients, lasting over 6 months in one patient) and generalized tonic–clonic seizures in three patients that could be controlled with medications. Another study [<xref ref-type="bibr" rid="CR319">319</xref>] used cord blood MNC along with Wharton’s jelly-derived MSC (WJ-MSC) in one of three study arms. The study employed both an intravenous and intrathecal administration route. No serious adverse effects were observed. ASD children treated with WJ-MSC yielded better results on CARS, ABC, and CGI at 24 weeks after treatment. The results were compared with patients who received cord blood-derived MNC and rehabilitation only. Unfortunately, there were no patients who received WJ-MSC without MNC. An open-labeled study for children with ASD by Bradstreet et al. [<xref ref-type="bibr" rid="CR320">320</xref>] used a controversial stem cell source—hematopoietic stem cells derived from fetal liver (delivered intravenously) and neuroprogenitors from fetal brain tissue (delivered subcutaneously). No serious adverse effects were noted. An improvement was noted on ABC and Autism Treatment Evaluation Checklist, especially concerning speech, social, and sensory domains. Lymphocyte subpopulations were assessed at baseline, 6, and 12 months after treatment. A significant up-regulation of CD3<sup>+</sup> and CD4<sup>+</sup> T cells with reduced B-cell count was observed. Recently, a case series of three patients treated with human embryonic stem cells was published [<xref ref-type="bibr" rid="CR321">321</xref>]. The patients received cells intramuscularly (once/day with a dose of approximately 4 × 10<sup>6</sup>), intravenously (twice/week with a dose of approximately 16 × 10<sup>6</sup>), and via other routes such as intrathecal administration (weekly, different dosages). Treatment was planned in 4 cycles within 4–8-month intervals. The patients were a 3-year-old boy with ASD and no other co-morbidities, a 4-year-old boy with co-existing developmental delay, and a 10-year-old boy who was also diagnosed with pediatric acute-onset neuropsychiatric syndrome, Lyme disease, heavy metal toxicity, and obsessive-compulsive disorder. The investigator concluded that patients improved significantly in eye contact, communication, cognitive skills, and writing. No information about psychological tools used to assess children were given. PET-CT examination revealed significant improvement in brain blood perfusion in all treated patients. All those results should be interpreted with caution as improvements in communication or cognitive skills are typical for young children and should be expected also in ASD individuals. For a summary of currently ongoing or unpublished clinical trials, please refer to Supplementary Table <xref ref-type="media" rid="MOESM2">2</xref>.</p>
<p id="Par72">Cord blood (CB) is a unique biological material known to contain several populations of cells including progenitor stem cells, MSC, endothelial precursor cells, and unrestricted somatic stem cells [<xref ref-type="bibr" rid="CR322">322</xref>, <xref ref-type="bibr" rid="CR323">323</xref>]. CB was also found to contain neurotropic and immunomodulatory factors along with several anti-inflammatory cytokines [<xref ref-type="bibr" rid="CR324">324</xref>, <xref ref-type="bibr" rid="CR325">325</xref>]. The first clinical use of CB was carried out in 1988 in a setting of allogeneic HSCT in a patient with Fanconi anemia [<xref ref-type="bibr" rid="CR326">326</xref>]. Recent advances and in-depth studies of CB biology have shown that this material can be employed in brain injuries [<xref ref-type="bibr" rid="CR327">327</xref>]. Autologous cord blood infusion has already been shown to be safe and promising in cerebral palsy and acquired brain disorders [<xref ref-type="bibr" rid="CR328">328</xref>, <xref ref-type="bibr" rid="CR329">329</xref>]. Preclinical scientific rationale support CB immunomodulatory properties and potential to correct neuronal activity [<xref ref-type="bibr" rid="CR330">330</xref>, <xref ref-type="bibr" rid="CR331">331</xref>]. A breakthrough clinical trial has shown promising potential for CB and hematopoietic stem cells in ASD [<xref ref-type="bibr" rid="CR332">332</xref>]. A phase I, open-label trial included 25 children aged 2–6 years with a confirmed ASD diagnosis and banked autologous CB. The procedure turned out to be safe and well tolerated. Improvements were noted in communication skills, expressive vocabulary, eye-tracking measures, and overall assessment of ASD severity. Interestingly, greater improvements were seen in children with higher nonverbal IQ. Further studies are planned to explore this therapeutic method, including the use of allogeneic CB.</p>
</sec>
<sec id="Sec9">
<title>Future directions</title>
<p id="Par73">The overall data suggests that there is substantial evidence for immune system dysregulation in at least some children with ASD. The challenge lies in defining the exact connection between ASD symptoms and the immunological background. The graphic idea of this association is presented presented on Figure <xref ref-type="bibr" rid="CR1">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>A graphic “vision” of this article</p></caption><graphic id="MO1" xlink:href="12035_2017_822_Fig1_HTML"></graphic></fig></p>
<p id="Par74">Studies based on newborn screening are interesting as they refer to early markers of ASD. However, they might also be misleading. Discrepancies between results of various studies may be due to methodological differences and heterogeneity of studied populations. Six studies were based on dried bloodspots from neonatal screening [<xref ref-type="bibr" rid="CR65">65</xref>–<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR70">70</xref>], two on amniotic fluid [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR72">72</xref>], and two on mid-gestational serum [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR71">71</xref>] (Table <xref ref-type="table" rid="Tab1">1</xref>).</p>
<p id="Par75">An additional problem arises from ASD over diagnosis. In many cases, achieving a diagnosis of ASD is desirable as it facilitates parents’ ability to gain early support for children with developmental disorders [<xref ref-type="bibr" rid="CR333">333</xref>]. Also, different periods of time (1991–2017) and advancements in ASD diagnostic ability and criteria make it difficult to compare results from early and current studies. The variety of psychological tools is of note as well, as an ASD diagnosis was not always confirmed with Autism Diagnostic Observation Schedule (ADOS) and Autism Diagnostic Interview–Revised (ADI-R), and several studies did not mention screening the control group for developmental disorders.</p>
<p id="Par76">Out of 57 investigations that focused on cytokine and chemokine abnormalities, a detailed diagnosis of ASD was given only by 11 authors [<xref ref-type="bibr" rid="CR140">140</xref>–<xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR153">153</xref>, <xref ref-type="bibr" rid="CR157">157</xref>, <xref ref-type="bibr" rid="CR159">159</xref>, <xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR179">179</xref>, <xref ref-type="bibr" rid="CR180">180</xref>, <xref ref-type="bibr" rid="CR183">183</xref>], thus clinical picture of studied subjects might have varied greatly. Patients included in the analysis could have been diagnosed with autistic disorder, Asperger syndrome, or PDD-NOS (Table <xref ref-type="table" rid="Tab2">2</xref>).</p>
<p id="Par77">Moreover, the age of subjects often greatly varied; some studies included both pediatric and adult populations, which could alter results in a significant manner. A majority of the studies were carried out on young children. Some included only preschool age [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR158">158</xref>, <xref ref-type="bibr" rid="CR175">175</xref>, <xref ref-type="bibr" rid="CR177">177</xref>, <xref ref-type="bibr" rid="CR178">178</xref>], while others expanded inclusion criteria up to about 11 years [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR157">157</xref>, <xref ref-type="bibr" rid="CR162">162</xref>, <xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR165">165</xref>, <xref ref-type="bibr" rid="CR168">168</xref>, <xref ref-type="bibr" rid="CR170">170</xref>, <xref ref-type="bibr" rid="CR172">172</xref>, <xref ref-type="bibr" rid="CR181">181</xref>]. Several studies focused solely on older children aged about 7–13 years [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR139">139</xref>, <xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR146">146</xref>, <xref ref-type="bibr" rid="CR153">153</xref>, <xref ref-type="bibr" rid="CR160">160</xref>, <xref ref-type="bibr" rid="CR164">164</xref>, <xref ref-type="bibr" rid="CR166">166</xref>]. However, some investigators included wide-ranging age groups with not only children but also teenagers [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR154">154</xref>, <xref ref-type="bibr" rid="CR156">156</xref>, <xref ref-type="bibr" rid="CR159">159</xref>, <xref ref-type="bibr" rid="CR167">167</xref>, <xref ref-type="bibr" rid="CR169">169</xref>, <xref ref-type="bibr" rid="CR171">171</xref>, <xref ref-type="bibr" rid="CR180">180</xref>, <xref ref-type="bibr" rid="CR183">183</xref>] and adults [<xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR151">151</xref>]. Only three studies were carried out solely on teenagers or adults [<xref ref-type="bibr" rid="CR140">140</xref>, <xref ref-type="bibr" rid="CR176">176</xref>, <xref ref-type="bibr" rid="CR182">182</xref>].</p>
<p id="Par78">While mainly all control subjects were age matched, only 33 studies compared gender-matched groups, which is highly important as biomarker profiles have been found to be gender specific [<xref ref-type="bibr" rid="CR140">140</xref>].</p>
<p id="Par79">Another source of bias could be different methodological approaches, as studies on peripheral blood used both plasma and serum, while investigations with PB-MNC were carried out with different stimulation conditions.</p>
<p id="Par80">Multiple drugs are known to alter the cytokine profile, but 24 groups of investigators stated that patients either did not take any medication or were taking drugs that would not compromise study results [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR160">160</xref>, <xref ref-type="bibr" rid="CR162">162</xref>, <xref ref-type="bibr" rid="CR164">164</xref>–<xref ref-type="bibr" rid="CR166">166</xref>, <xref ref-type="bibr" rid="CR169">169</xref>–<xref ref-type="bibr" rid="CR171">171</xref>, <xref ref-type="bibr" rid="CR174">174</xref>, <xref ref-type="bibr" rid="CR176">176</xref>, <xref ref-type="bibr" rid="CR181">181</xref>, <xref ref-type="bibr" rid="CR182">182</xref>, <xref ref-type="bibr" rid="CR185">185</xref>]. Several have stated that study subjects were taking psychotropic, antiepileptic, or other drugs that might be relevant [<xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR151">151</xref>–<xref ref-type="bibr" rid="CR153">153</xref>, <xref ref-type="bibr" rid="CR159">159</xref>, <xref ref-type="bibr" rid="CR168">168</xref>, <xref ref-type="bibr" rid="CR183">183</xref>]; however, almost half did not include any information on medication, which greatly impairs result interpretation.</p>
<p id="Par81">Furthermore, ASD frequently occurs together with epilepsy, intellectual disability, ADHD, anxiety and behavior disorder, and in the course of several other diseases. The difference in cytokine profiles could be substantial as described by Jácome et al. [<xref ref-type="bibr" rid="CR135">135</xref>] who compared ASD children with and without epilepsy. The exact data about ASD co-morbidities was frequently overlooked by investigators. Out of 57 summarized research studies on cytokine and chemokine abnormalities, 30 studies did not include any data on epilepsy, 47 on intellectual disability, and 49 on ADHD. For details, please see Table <xref ref-type="table" rid="Tab2">2</xref>.</p>
<p id="Par82">Further in-depth studies into ASD immunology could find that different behavioral traits are etiologically distinct and thus different approaches and therapeutic interventions should be undertaken. One third of conducted studies did not attempt to correlate biochemical abnormalities with behavioral traits. Observed concentrations of cytokines, chemokines, and growth factors were most frequently associated with ASD severity, impaired social interactions, and repetitive behaviors and interests. Only 3 studies, out of 26 that included psychological data, failed to detect any correlations (Table <xref ref-type="table" rid="Tab3">3</xref>).</p>
<p id="Par83">Out of multiple examined proteins, IL-1 and IL-6 turned out to be particularly interesting due to repeatability of the results concerning associated behavioral abnormalities. Probably, it could be partially attributed to the number of conducted studies in comparison to other examined molecules. IL-1 was explored by 14 groups of investigators [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR137">137</xref>, <xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR150">150</xref>–<xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR165">165</xref>, <xref ref-type="bibr" rid="CR166">166</xref>, <xref ref-type="bibr" rid="CR168">168</xref>, <xref ref-type="bibr" rid="CR176">176</xref>, <xref ref-type="bibr" rid="CR180">180</xref>], and IL-6 by 16 of 26 [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR150">150</xref>–<xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR166">166</xref>, <xref ref-type="bibr" rid="CR167">167</xref>, <xref ref-type="bibr" rid="CR170">170</xref>–<xref ref-type="bibr" rid="CR172">172</xref>, <xref ref-type="bibr" rid="CR176">176</xref>, <xref ref-type="bibr" rid="CR180">180</xref>]. IL-1, a key cytokine in the regulation of inflammatory pathway, was found relevant in several behavioral domains, including core ASD symptoms. It was found to be positively correlated with impaired social sphere in two [<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR155">155</xref>] of five studies [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR166">166</xref>, <xref ref-type="bibr" rid="CR177">177</xref>]. All studies evaluated social interactions based on ADOS and ADI-R apart from Napolioni et al. [<xref ref-type="bibr" rid="CR138">138</xref>] who employed SRS. It is worth noticing that one study analyzed cytokines on mRNA level [<xref ref-type="bibr" rid="CR166">166</xref>], while all the others examined protein concentration with enzyme-linked immunosorbent assays. It has not escaped our notice that Careaga et al. study [<xref ref-type="bibr" rid="CR150">150</xref>] and Enstrom et al. study [<xref ref-type="bibr" rid="CR155">155</xref>] were conducted on children with mean age of 3, while those who did not find any correlation to social sphere were carried out on older children [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR166">166</xref>] or adults [<xref ref-type="bibr" rid="CR138">138</xref>]. Surprisingly, no overwhelming evidence over IL-1 association with severity has been found. However, out of 24 studies that explored IL-1 links with behavioral abnormalities, only 4 tried to link it with ASD severity [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR180">180</xref>] and 1 succeeded [<xref ref-type="bibr" rid="CR152">152</xref>]. A related point to consider is poor methodological quality of that study: wide age range (2–21 years), inclusion of children with PDD (6/29 patients), and no exact data on medication taken by subjects. On the other hand, other studies had either small [<xref ref-type="bibr" rid="CR135">135</xref>] or heterogeneous study groups [<xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR181">181</xref>], along with children with Rett syndrome [<xref ref-type="bibr" rid="CR180">180</xref>]. Regression turned out to be associated in two [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR145">145</xref>] of four [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR163">163</xref>] conducted studies in this area. The topic is worth exploring since one of the studies that denied abovementioned connection was carried out after stimulation [<xref ref-type="bibr" rid="CR144">144</xref>] and the other one included children with PDD-NOS [<xref ref-type="bibr" rid="CR163">163</xref>]. IL-6, a complex cytokine involved in inflammation and neural functions, was found to be up-regulated in relation to social impairment in half [<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR167">167</xref>] of the conducted studies [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR166">166</xref>, <xref ref-type="bibr" rid="CR167">167</xref>, <xref ref-type="bibr" rid="CR176">176</xref>]. Analogically to IL-1, IL-6 was found significant in younger children [<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR155">155</xref>] or in a large pediatric study group [<xref ref-type="bibr" rid="CR167">167</xref>]. No correlation with cognition has been made by the same investigators who explored also IL-1 [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR166">166</xref>, <xref ref-type="bibr" rid="CR177">177</xref>]. Intriguingly, three [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR171">171</xref>] of four [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR171">171</xref>] studies reported up-regulation of IL-6 in association with disease severity. Single studies have linked up-regulation of IL-1 and IL-6 with repetitive behaviors and interests [<xref ref-type="bibr" rid="CR145">145</xref>], impaired communication [<xref ref-type="bibr" rid="CR155">155</xref>], development [<xref ref-type="bibr" rid="CR150">150</xref>], adaptive skills [<xref ref-type="bibr" rid="CR138">138</xref>], aggression [<xref ref-type="bibr" rid="CR150">150</xref>], hyperactivity and irritability [<xref ref-type="bibr" rid="CR151">151</xref>], or lower IQ [<xref ref-type="bibr" rid="CR138">138</xref>]. Despite vast studies of both IL-1 and IL-6, no associations with cognitive sphere have been reported so far. It is worth underlying that up-regulation of IL-1 or IL-6 and their connection to social sphere was significant in young individuals [<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR155">155</xref>]. It would be beneficial to examine large groups of children before psychological interventions, just after establishing diagnosis. We could suspect that those children would manifest the most prominent behavioral abnormalities and thus become an aim of further in-depth studies.</p>
<p id="Par84">The search for potential biomarkers and their correlation with phenotypic variability should be the point of focus in ASD research and make a ground for future targeted therapies. Singh [<xref ref-type="bibr" rid="CR334">334</xref>] hypothesized that an autoimmune autistic disorder might be identified and treated accordingly. However, his hypothesis involved mainly virus-induced autoimmunity. Several other interesting factors such as leptin, osteopontin, cell adhesion molecules, markers of oxidative stress, and neurotransmitters were reported to be relevant in ASD [<xref ref-type="bibr" rid="CR335">335</xref>–<xref ref-type="bibr" rid="CR340">340</xref>].</p>
<p id="Par85">Not every study was in favor of an ASD immune pathogenesis. Stern et al. [<xref ref-type="bibr" rid="CR117">117</xref>] concluded that only 2 out of 24 examined individuals had altered immune function, out of which 1 had common variable immune deficiency and routine immunologic examination would not benefit this group of patients. However, it is worth noticing that Stern et al. [<xref ref-type="bibr" rid="CR117">117</xref>] also included children with PDD and the age of included patients varied from 3 to 17 years. For a full list of excluded correlations and a summary of studies conducted on peripheral blood, please refer to Table <xref ref-type="table" rid="Tab3">3</xref>.</p>
<p id="Par86">Taken together, the presented data suggest a strong link between autism and immune dysfunction. Caution in drawing a conclusion should be preserved due to the lack of consistency in the studied populations, as the variety of co-existing symptoms and neurological comorbidities makes it difficult to completely synthesize all conducted studies. The association between immune system dysfunction and behavioral abnormalities, in at least a subset of individuals with ASD, suggests a potential role for immunomodulatory therapies as a causative treatment. Several investigators have already reported on the first clinical uses of stem cells in patients with ASD with promising results [<xref ref-type="bibr" rid="CR317">317</xref>–<xref ref-type="bibr" rid="CR319">319</xref>, <xref ref-type="bibr" rid="CR332">332</xref>]. Cellular therapies that take advantage of immunomodulatory properties of stem cells could address neurodevelopmental abnormalities on a cellular level. A summary of ongoing or unpublished clinical trials is presented in Supplementary Table <xref ref-type="media" rid="MOESM2">2</xref>.</p>
<p id="Par87">It is noteworthy that in the future, we may be able to redefine ASD on the basis of molecular, immunological, and biochemical background and determine patients who could benefit from immunomodulatory approach.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Electronic supplementary material</title>
<sec id="Sec10">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12035_2017_822_MOESM1_ESM.docx"><label>Supplementary Table 1</label><caption><p>(DOCX 17 kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12035_2017_822_MOESM2_ESM.docx"><label>Supplementary Table 2</label><caption><p>(DOCX 17 kb)</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn>
<p>
<bold>Electronic supplementary material</bold>
</p>
<p>The online version of this article (10.1007/s12035-017-0822-x) contains supplementary material, which is available to authorized users.</p>
</fn>
</fn-group>
<notes notes-type="COI-statement">
<title>Compliance with ethical standards</title>
<sec id="FPar1">
<title>Conflict of interests</title>
<p id="Par88">D.G. is a part-time employee of the Polish Stem Cell Bank. Other authors have no conflicts of interest to declare.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<mixed-citation publication-type="other">World Health Organization (2013) International statistical classification of diseases and related health problems, 10th revision (ICD-10). World Health Organization, Geneva, 1992</mixed-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<mixed-citation publication-type="other">American Psychiatric Association Neurodevelopmental disorders. In: Diagnostic and statistical manual of mental disorders, 5th edn. 10.1176/appi.books.9780890425596.dsm01. Accessed 29 May 2017</mixed-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coury</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Swedo</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Thurm</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Veenstra-VanderWeele</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Carbone</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Lounds Taylor</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Treating the whole person with autism: the proceedings of the Autism Speaks National Autism Conference</article-title>
<source/>Curr Probl Pediatr Adolesc Health Care
          <year>2014</year>
<volume>44</volume>
<issue>2</issue>
<fpage>26</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="pmid">24491508</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lubetsky</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Handen</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Lubetsky</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McGonigle</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Systems of care for individuals with autism spectrum disorder and serious behavioral disturbance through the lifespan</article-title>
<source/>Child Adolesc Psychiatr Clin N Am
          <year>2014</year>
<volume>23</volume>
<issue>1</issue>
<fpage>97</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="pmid">24231170</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kennedy</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Juárez</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Greenslade</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tally</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Children with severe developmental disabilities and behavioral disorders have increased special healthcare needs</article-title>
<source/>Dev Med Child Neurol
          <year>2007</year>
<volume>49</volume>
<issue>12</issue>
<fpage>926</fpage>
<lpage>930</lpage>
<pub-id pub-id-type="pmid">18039240</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators, Centers for Disease Control and Prevention</collab>
</person-group>
<article-title>Prevalence of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2010</article-title>
<source/>MMWR Surveill Summ
          <year>2014</year>
<volume>63</volume>
<issue>2</issue>
<fpage>1</fpage>
<lpage>21</lpage>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baxter</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Brugha</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Erskine</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Scheurer</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Vos</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>JG</given-names>
</name>
</person-group>
<article-title>The epidemiology and global burden of autism spectrum disorders</article-title>
<source/>Psychol Med
          <year>2015</year>
<volume>45</volume>
<issue>3</issue>
<fpage>601</fpage>
<lpage>613</lpage>
<pub-id pub-id-type="pmid">25108395</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brynskikh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kipnis</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Adaptive immunity affects learning behavior in mice</article-title>
<source/>Brain Behav Immun
          <year>2008</year>
<volume>22</volume>
<issue>6</issue>
<fpage>861</fpage>
<lpage>869</lpage>
<pub-id pub-id-type="pmid">18249087</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stubbs</surname>
<given-names>EG</given-names>
</name>
</person-group>
<article-title>Autistic children exhibit undetectable hemagglutination inhibition antibody titers despite previous rubella vaccination</article-title>
<source/>J Autism Child Schizophr
          <year>1976</year>
<volume>6</volume>
<issue>3</issue>
<fpage>269</fpage>
<lpage>274</lpage>
<pub-id pub-id-type="pmid">1036494</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Onore</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Schwartzer</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Careaga</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Maternal immune activation leads to activated inflammatory macrophages in offspring</article-title>
<source/>Brain Behav Immun
          <year>2014</year>
<volume>38</volume>
<fpage>220</fpage>
<lpage>226</lpage>
<pub-id pub-id-type="pmid">24566386</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<mixed-citation publication-type="other">Luan R, Cheng H, Li L, Zhao Q, Liu H, Wu Z, Zhao L, Yang J et al (2015) Maternal lipopolysaccharide exposure promotes immunological functional changes in adult offspring CD4+ T cells. Am J Reprod Immunol 73(6):522–535. 10.1111/aji.12364</mixed-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsiao</surname>
<given-names>EY</given-names>
</name>
<name>
<surname>McBride</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mazmanian</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Patterson</surname>
<given-names>PH</given-names>
</name>
</person-group>
<article-title>Modeling an autism risk factor in mice leads to permanent immune dysregulation</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2012</year>
<volume>109</volume>
<issue>31</issue>
<fpage>12776</fpage>
<lpage>12781</lpage>
<pub-id pub-id-type="pmid">22802640</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lucchina</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Depino</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Altered peripheral and central inflammatory responses in a mouse model of autism</article-title>
<source/>Autism Res
          <year>2014</year>
<volume>7</volume>
<issue>2</issue>
<fpage>273</fpage>
<lpage>289</lpage>
<pub-id pub-id-type="pmid">24124122</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<mixed-citation publication-type="other">Krakowiak P, Walker CK, Tancredi D, Hertz-Picciotto I, Van de Water J (2016) Autism-specific maternal anti-fetal brain autoantibodies are associated with metabolic conditions. Autism Res. 10.1002/aur.1657</mixed-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fox-Edmiston</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Maternal anti-fetal brain IgG autoantibodies and autism spectrum disorder: current knowledge and its implications for potential therapeutics</article-title>
<source/>CNS Drugs
          <year>2015</year>
<volume>29</volume>
<issue>9</issue>
<fpage>715</fpage>
<lpage>724</lpage>
<pub-id pub-id-type="pmid">26369920</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mazur-Kolecka</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>IL</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Kaczmarski</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Flory</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Frackowiak</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Autoantibodies against neuronal progenitors in sera from children with autism</article-title>
<source/>Brain Dev
          <year>2014</year>
<volume>36</volume>
<issue>4</issue>
<fpage>322</fpage>
<lpage>329</lpage>
<pub-id pub-id-type="pmid">23838310</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nordahl</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Braunschweig</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Iosif</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Amaral</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Maternal autoantibodies are associated with abnormal brain enlargement in a subgroup of children with autism spectrum disorder</article-title>
<source/>Brain Behav Immun
          <year>2013</year>
<volume>30</volume>
<fpage>61</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="pmid">23395715</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<mixed-citation publication-type="other">Rossi CC, Fuentes J, Van de Water J, Amaral DG (2013) Brief report: Antibodies reacting to brain tissue in Basque Spanish children with autism spectrum disorder and their mothers. J Autism Dev Disord. 10.1007/s10803-013-1859-y</mixed-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rout</surname>
<given-names>UK</given-names>
</name>
<name>
<surname>Mungan</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Dhossche</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Presence of GAD65 autoantibodies in the serum of children with autism or ADHD</article-title>
<source/>Eur Child Adolesc Psychiatry
          <year>2012</year>
<volume>21</volume>
<issue>3</issue>
<fpage>141</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="pmid">22323074</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singer</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Gause</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Gillin</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>AW</given-names>
</name>
</person-group>
<article-title>Antibodies against fetal brain in sera of mothers with autistic children</article-title>
<source/>J Neuroimmunol
          <year>2008</year>
<volume>194</volume>
<issue>1-2</issue>
<fpage>165</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="pmid">18093664</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Braunschweig</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cabanlit</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Amaral</surname>
<given-names>DG</given-names>
</name>
</person-group>
<article-title>Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism</article-title>
<source/>Brain Behav Immun
          <year>2008</year>
<volume>22</volume>
<issue>6</issue>
<fpage>806</fpage>
<lpage>816</lpage>
<pub-id pub-id-type="pmid">18262386</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<mixed-citation publication-type="other">Bauman MD, Iosif AM, Ashwood P, Braunschweig D, Lee A, Schumann CM, Van de Water J, Amaral DG (2013) Maternal antibodies from mothers of children with autism alter brain growth and social behavior development in the rhesus monkey. Transl Psychiatry 3(7):e278. 10.1038/tp.2013.47</mixed-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Camacho</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ariza</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Noctor</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Martínez-Cerdeño</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Embryonic intraventricular exposure to autism-specific maternal autoantibodies produces alterations in autistic-like stereotypical behaviors in offspring mice</article-title>
<source/>Behav Brain Res
          <year>2014</year>
<volume>1</volume>
<issue>266</issue>
<fpage>46</fpage>
<lpage>51</lpage>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Lawrence</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Aberrant immune responses in a mouse with behavioral disorders</article-title>
<source/>PLoS One
          <year>2011</year>
<volume>6</volume>
<issue>7</issue>
<fpage>e20912</fpage>
<pub-id pub-id-type="pmid">21799730</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Surcel</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Hinkka-Yli-Salomäki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cheslack-Postava</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sourander</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Maternal thyroid autoantibody and elevated risk of autism in a national birth cohort</article-title>
<source/>Prog Neuropsychopharmacol Biol Psychiatry
          <year>2015</year>
<volume>57</volume>
<fpage>86</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="pmid">25445476</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khaiman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Onnuam</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Photchanakaew</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chonchaiya</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Suphapeetiporn</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Risk factors for autism spectrum disorder in the Thai population</article-title>
<source/>Eur J Pediatr
          <year>2015</year>
<volume>174</volume>
<issue>10</issue>
<fpage>1365</fpage>
<lpage>1372</lpage>
<pub-id pub-id-type="pmid">26226890</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andersen</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Laurberg</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Olsen</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Attention deficit hyperactivity disorder and autism spectrum disorder in children born to mothers with thyroid dysfunction: a Danish nationwide cohort study</article-title>
<source/>BJOG
          <year>2014</year>
<volume>121</volume>
<issue>11</issue>
<fpage>1365</fpage>
<lpage>1374</lpage>
<pub-id pub-id-type="pmid">24605987</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyall</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hertz-Picciotto</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Maternal immune-mediated conditions, autism spectrum disorders, and developmental delay</article-title>
<source/>J Autism Dev Disord
          <year>2014</year>
<volume>44</volume>
<issue>7</issue>
<fpage>1546</fpage>
<lpage>1555</lpage>
<pub-id pub-id-type="pmid">24337796</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Jing</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bowers</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Maternal diabetes and the risk of autism spectrum disorders in the offspring: a systematic review and meta-analysis</article-title>
<source/>J Autism Dev Disord
          <year>2014</year>
<volume>44</volume>
<issue>4</issue>
<fpage>766</fpage>
<lpage>775</lpage>
<pub-id pub-id-type="pmid">24057131</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyall</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pauls</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Spiegelman</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ascherio</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Santangelo</surname>
<given-names>SL</given-names>
</name>
</person-group>
<article-title>Pregnancy complications and obstetric suboptimality in association with autism spectrum disorders in children of the Nurses’ Health Study II</article-title>
<source/>Autism Res
          <year>2012</year>
<volume>5</volume>
<issue>1</issue>
<fpage>21</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="pmid">21972225</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keil</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Daniels</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Forssen</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Hultman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cnattingius</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Söderberg</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Feychting</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sparen</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Parental autoimmune diseases associated with autism spectrum disorders in offspring</article-title>
<source/>Epidemiology
          <year>2010</year>
<volume>21</volume>
<issue>6</issue>
<fpage>805</fpage>
<lpage>808</lpage>
<pub-id pub-id-type="pmid">20798635</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mostafa</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Shehab</surname>
<given-names>AA</given-names>
</name>
</person-group>
<article-title>The link of C4B null allele to autism and to a family history of autoimmunity in Egyptian autistic children</article-title>
<source/>J Neuroimmunol
          <year>2010</year>
<volume>223</volume>
<issue>1-2</issue>
<fpage>115</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="pmid">20452682</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atladóttir</surname>
<given-names>HO</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Thorsen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mortensen</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Deleuran</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Eaton</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Parner</surname>
<given-names>ET</given-names>
</name>
</person-group>
<article-title>Association of family history of autoimmune diseases and autism spectrum disorders</article-title>
<source/>Pediatrics
          <year>2009</year>
<volume>124</volume>
<issue>2</issue>
<fpage>687</fpage>
<lpage>694</lpage>
<pub-id pub-id-type="pmid">19581261</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mouridsen</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Rich</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Isager</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nedergaard</surname>
<given-names>NJ</given-names>
</name>
</person-group>
<article-title>Autoimmune diseases in parents of children with infantile autism: a case-control study</article-title>
<source/>Dev Med Child Neurol
          <year>2007</year>
<volume>49</volume>
<issue>6</issue>
<fpage>429</fpage>
<lpage>432</lpage>
<pub-id pub-id-type="pmid">17518928</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Croen</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Grether</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Odouli</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study</article-title>
<source/>Arch Pediatr Adolesc Med
          <year>2005</year>
<volume>159</volume>
<issue>2</issue>
<fpage>151</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="pmid">15699309</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lauritsen</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Mortensen</surname>
<given-names>PB</given-names>
</name>
</person-group>
<article-title>Effects of familial risk factors and place of birth on the risk of autism: a nationwide register-based study</article-title>
<source/>J Child Psychol Psychiatry
          <year>2005</year>
<volume>46</volume>
<issue>9</issue>
<fpage>963</fpage>
<lpage>971</lpage>
<pub-id pub-id-type="pmid">16108999</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Comi</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>VH</given-names>
</name>
<name>
<surname>Law</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Peeden</surname>
<given-names>JN</given-names>
</name>
</person-group>
<article-title>Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism</article-title>
<source/>J Child Neurol
          <year>1999</year>
<volume>14</volume>
<issue>6</issue>
<fpage>388</fpage>
<lpage>394</lpage>
<pub-id pub-id-type="pmid">10385847</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Family history of autoimmune diseases is associated with an increased risk of autism in children: a systematic review and meta-analysis</article-title>
<source/>Neurosci Biobehav Rev
          <year>2015</year>
<volume>55</volume>
<fpage>322</fpage>
<lpage>332</lpage>
<pub-id pub-id-type="pmid">25981892</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<mixed-citation publication-type="other">Chen SW, Zhong XS, Jiang LN, Zheng XY, Xiong YQ, Ma SJ, Qiu M, Huo ST et al (2016) Maternal autoimmune diseases and the risk of autism spectrum disorders in offspring: a systematic review and meta-analysis. Behav Brain Res 296:61–69. 10.1016/j.bbr.2015.08.035</mixed-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mostafa</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Shehab</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Al-Ayadhi</surname>
<given-names>LY</given-names>
</name>
</person-group>
<article-title>The link between some alleles on human leukocyte antigen system and autism in children</article-title>
<source/>J Neuroimmunol
          <year>2013</year>
<volume>255</volume>
<issue>1-2</issue>
<fpage>70</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="pmid">23110937</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trajkovski</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Spiroski</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>DNA typing of HLA-A, -C, -B, AND -DRB1 in the children with autism in the Republic of Macedonia</article-title>
<source/>Bratisl Lek Listy
          <year>2015</year>
<volume>116</volume>
<issue>1</issue>
<fpage>14</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="pmid">25666956</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Zachary</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Leffell</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Newschaffer</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Matteson</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Tyler</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>AW</given-names>
</name>
</person-group>
<article-title>HLA-DR4 in families with autism</article-title>
<source/>Pediatr Neurol
          <year>2006</year>
<volume>35</volume>
<issue>5</issue>
<fpage>303</fpage>
<lpage>307</lpage>
<pub-id pub-id-type="pmid">17074598</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torres</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Sweeten</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Cutler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bedke</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Fillmore</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stubbs</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Odell</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>The association and linkage of the HLA-A2 class I allele with autism</article-title>
<source/>Hum Immunol
          <year>2006</year>
<volume>67</volume>
<issue>4-5</issue>
<fpage>346</fpage>
<lpage>351</lpage>
<pub-id pub-id-type="pmid">16720216</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torres</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Maciulis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stubbs</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Cutler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Odell</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>The transmission disequilibrium test suggests that HLA-DR4 and DR13 are linked to autism spectrum disorder</article-title>
<source/>Hum Immunol
          <year>2002</year>
<volume>63</volume>
<issue>4</issue>
<fpage>311</fpage>
<lpage>316</lpage>
<pub-id pub-id-type="pmid">12039413</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warren</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Odell</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Burger</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Maciulis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Daniels</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>AR</given-names>
</name>
</person-group>
<article-title>Strong association of the third hypervariable region of HLA-DR beta 1 with autism</article-title>
<source/>J Neuroimmunol
          <year>1996</year>
<volume>67</volume>
<issue>2</issue>
<fpage>97</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="pmid">8765331</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<mixed-citation publication-type="other">Puangpetch A, Suwannarat P, Chamnanphol M, Koomdee N, Ngamsamut N, Limsila P, Sukasem C (2015) Significant association of HLA-B alleles and genotypes in Thai children with autism spectrum disorders: a case-control study. Dis Markers: 724935. 10.1155/2015/724935</mixed-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<mixed-citation publication-type="other">Al-Hakbany M, Awadallah S, Al-Ayadhi L (2014) The relationship of HLA class I and II alleles and haplotypes with autism: a case control study. Autism Res Treat: 242048. 10.1155/2014/242048</mixed-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chien</surname>
<given-names>YL</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Gau</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Chien</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Chao</surname>
<given-names>YL</given-names>
</name>
</person-group>
<article-title>Association of HLA-DRB1 alleles and neuropsychological function in autism</article-title>
<source/>Psychiatr Genet
          <year>2012</year>
<volume>22</volume>
<issue>1</issue>
<fpage>46</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="pmid">21716163</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<mixed-citation publication-type="other">Guerini FR, Bolognesi E, Chiappedi M, Ghezzo A, Canevini MP, Mensi MM, Vignoli A, Agliardi C et al (2015) An HLA-G(∗)14bp insertion/deletion polymorphism associates with the development of autistic spectrum disorders. Brain Behav Immun 44:207–212. 10.1016/j.bbi.2014.10.002.</mixed-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Buyske</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mars</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Sreenath</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stenroos</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>GH</given-names>
</name>
</person-group>
<article-title>HLA-DR4 as a risk allele for autism acting in mothers of probands possibly during pregnancy</article-title>
<source/>Arch Pediatr Adolesc Med
          <year>2009</year>
<volume>163</volume>
<issue>6</issue>
<fpage>542</fpage>
<lpage>546</lpage>
<pub-id pub-id-type="pmid">19487610</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<mixed-citation publication-type="other">Torres AR, Sweeten TL, Johnson RC, Odell D, Westover JB, Bray-Ward P, Ward DC, Davies CJ et al (2016) Common genetic variants found in HLA and KIR immune genes in autism spectrum disorder. Front Neurosci 10:463</mixed-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piras</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Haapanen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Napolioni</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Sacco</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Persico</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Anti-brain antibodies are associated with more severe cognitive and behavioral profiles in Italian children with autism spectrum disorder</article-title>
<source/>Brain Behav Immun
          <year>2014</year>
<volume>38</volume>
<fpage>91</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="pmid">24389156</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braunschweig</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Duncanson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Boyce</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pessah</surname>
<given-names>IN</given-names>
</name>
<name>
<surname>Hertz-Picciotto</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Behavioral correlates of maternal antibody status among children with autism</article-title>
<source/>J Autism Dev Disord
          <year>2012</year>
<volume>42</volume>
<issue>7</issue>
<fpage>1435</fpage>
<lpage>1445</lpage>
<pub-id pub-id-type="pmid">22012245</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mostafa</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Al-Ayadhi</surname>
<given-names>LY</given-names>
</name>
</person-group>
<article-title>The relationship between the increased frequency of serum antineuronal antibodies and the severity of autism in children</article-title>
<source/>Eur J Paediatr Neurol
          <year>2012</year>
<volume>16</volume>
<issue>5</issue>
<fpage>464</fpage>
<lpage>468</lpage>
<pub-id pub-id-type="pmid">22226851</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossi</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Amaral</surname>
<given-names>DG</given-names>
</name>
</person-group>
<article-title>Detection of plasma autoantibodies to brain tissue in young children with and without autism spectrum disorders</article-title>
<source/>Brain Behav Immun
          <year>2011</year>
<volume>25</volume>
<issue>6</issue>
<fpage>1123</fpage>
<lpage>1135</lpage>
<pub-id pub-id-type="pmid">21420487</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wills</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Martinez Cerdeño</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Amaral</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Further characterization of autoantibodies to GABAergic neurons in the central nervous system produced by a subset of children with autism</article-title>
<source/>Mol Autism
          <year>2011</year>
<volume>2</volume>
<fpage>5</fpage>
<pub-id pub-id-type="pmid">21521495</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<mixed-citation publication-type="other">Goines P, Haapanen L, Boyce R, Duncanson P, Braunschweig D, Delwiche L, Hansen R, Hertz-Picciotto I et al (2011) Autoantibodies to cerebellum in children with autism associate with behavior. Brain Behav Immun 25(3):514–523. 10.1016/j.bbi.2010.11.017</mixed-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wills</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cabanlit</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Amaral</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Detection of autoantibodies to neural cells of the cerebellum in the plasma of subjects with autism spectrum disorders</article-title>
<source/>Brain Behav Immun
          <year>2009</year>
<volume>23</volume>
<issue>1</issue>
<fpage>64</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="pmid">18706993</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<mixed-citation publication-type="other">Cabanlit M, Wills S, Goines P, Ashwood P, Van de Water J (2007) Brain-specific autoantibodies in the plasma of subjects with autistic spectrum disorder. Ann N Y Acad Sci 1107:92–103. 10.1196/annals.1381.010</mixed-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<mixed-citation publication-type="other">Connolly AM, Chez M, Streif EM, Keeling RM, Golumbek PT, Kwon JM, Riviello JJ, Robinson RG et al (2006) Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. Biol Psychiatry 59(4):354–363</mixed-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singer</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>PN</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>DY</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>AW</given-names>
</name>
</person-group>
<article-title>Antibrain antibodies in children with autism and their unaffected siblings</article-title>
<source/>J Neuroimmunol
          <year>2006</year>
<volume>178</volume>
<issue>1-2</issue>
<fpage>149</fpage>
<lpage>155</lpage>
<pub-id pub-id-type="pmid">16842863</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>VK</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Odell</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Antibodies to myelin basic protein in children with autistic behavior</article-title>
<source/>Brain Behav Immun
          <year>1993</year>
<volume>7</volume>
<issue>1</issue>
<fpage>97</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="pmid">7682457</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mostafa</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Al-Ayadhi</surname>
<given-names>LY</given-names>
</name>
</person-group>
<article-title>Increased serum levels of anti-ganglioside M1 auto-antibodies in autistic children: relation to the disease severity</article-title>
<source/>J Neuroinflammation
          <year>2011</year>
<volume>8</volume>
<fpage>39</fpage>
<pub-id pub-id-type="pmid">21513576</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<mixed-citation publication-type="other">Jones KL, Croen LA, Yoshida CK, Heuer L, Hansen R, Zerbo O, DeLorenze GN, Kharrazi M et al (2017) Autism with intellectual disability is associated with increased levels of maternal cytokines and chemokines during gestation. Mol Psychiatry 22(2):273–279. 10.1038/mp.2016.77</mixed-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krakowiak</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Goines</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Tancredi</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Hertz-Picciotto</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Neonatal cytokine profiles associated with autism spectrum disorder</article-title>
<source/>Biol Psychiatry
          <year>2017</year>
<volume>81</volume>
<issue>5</issue>
<fpage>442</fpage>
<lpage>451</lpage>
<pub-id pub-id-type="pmid">26392128</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<mixed-citation publication-type="other">Zerbo O, Yoshida C, Grether JK, Van de Water J, Ashwood P, Delorenze GN, Hansen RL, Kharrazi M et al (2014) Neonatal cytokines and chemokines and risk of autism spectrum disorder: the Early Markers for Autism (EMA) study: a case-control study. J Neuroinflammation 11:113. 10.1186/1742-2094-11-113</mixed-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdallah</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Mortensen</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Greaves-Lord</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bonefeld-Jørgensen</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Nørgaard-Pedersen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hougaard</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Grove</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Neonatal levels of neurotrophic factors and risk of autism spectrum disorders</article-title>
<source/>Acta Psychiatr Scand
          <year>2013</year>
<volume>128</volume>
<issue>1</issue>
<fpage>61</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="pmid">23039165</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdallah</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Grove</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bonefeld-Jørgensen</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Nørgaard-Pedersen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hougaard</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Mortensen</surname>
<given-names>EL</given-names>
</name>
</person-group>
<article-title>Neonatal chemokine levels and risk of autism spectrum disorders: findings from a Danish historic birth cohort follow-up study</article-title>
<source/>Cytokine
          <year>2013</year>
<volume>61</volume>
<issue>2</issue>
<fpage>370</fpage>
<lpage>376</lpage>
<pub-id pub-id-type="pmid">23267761</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdallah</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Pearce</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Greaves-Lord</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nørgaard-Pedersen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hougaard</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Mortensen</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Grove</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Amniotic fluid MMP-9 and neurotrophins in autism spectrum disorders: an exploratory study</article-title>
<source/>Autism Res
          <year>2012</year>
<volume>5</volume>
<issue>6</issue>
<fpage>428</fpage>
<lpage>433</lpage>
<pub-id pub-id-type="pmid">23008271</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdallah</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mortensen</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Atladóttir</surname>
<given-names>HÓ</given-names>
</name>
<name>
<surname>Nørgaard-Pedersen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bonefeld-Jørgensen</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Grove</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hougaard</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Neonatal levels of cytokines and risk of autism spectrum disorders: an exploratory register-based historic birth cohort study utilizing the Danish Newborn Screening Biobank</article-title>
<source/>J Neuroimmunol
          <year>2012</year>
<volume>252</volume>
<issue>1–2</issue>
<fpage>75</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="pmid">22917523</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<mixed-citation publication-type="other">Goines PE, Croen LA, Braunschweig D, Yoshida CK, Grether J, Hansen R, Kharrazi M, Ashwood P et al (2011) Increased midgestational IFN-γ, IL-4 and IL-5 in women bearing a child with autism: a case-control study. Mol Autism 2:13. 10.1186/2040-2392-2-13</mixed-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<mixed-citation publication-type="other">Nelson PG, Kuddo T, Song EY, Dambrosia JM, Kohler S, Satyanarayana G, Vandunk C, Grether JK et al (2006) Selected neurotrophins, neuropeptides, and cytokines: developmental trajectory and concentrations in neonatal blood of children with autism or Down syndrome. Int J Dev Neurosci 24(1):73–80</mixed-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Ansary</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hassan</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Qasem</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>UN</given-names>
</name>
</person-group>
<article-title>Identification of biomarkers of impaired sensory profiles among autistic patients</article-title>
<source/>PLoS One
          <year>2016</year>
<volume>11</volume>
<issue>11</issue>
<fpage>e0164153</fpage>
<pub-id pub-id-type="pmid">27824861</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rose</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Potential cytokine biomarkers in autism spectrum disorders</article-title>
<source/>Biomark Med
          <year>2014</year>
<volume>8</volume>
<issue>9</issue>
<fpage>1171</fpage>
<lpage>1181</lpage>
<pub-id pub-id-type="pmid">25402586</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>Autism biomarkers: challenges, pitfalls and possibilities</article-title>
<source/>J Autism Dev Disord
          <year>2015</year>
<volume>45</volume>
<issue>4</issue>
<fpage>1103</fpage>
<lpage>1113</lpage>
<pub-id pub-id-type="pmid">25193140</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chatterjee</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chiasson</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Bounds</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>BM</given-names>
</name>
</person-group>
<article-title>Regulation of the anti-inflammatory cytokines interleukin-4 and interleukin-10 during pregnancy</article-title>
<source/>Front Immunol
          <year>2014</year>
<volume>5</volume>
<fpage>253</fpage>
<pub-id pub-id-type="pmid">24904596</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmes</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Wallace</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Gilmore</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>McFaul</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>HD</given-names>
</name>
</person-group>
<article-title>Plasma levels of the immunomodulatory cytokine interleukin-10 during normal human pregnancy: a longitudinal study</article-title>
<source/>Cytokine
          <year>2003</year>
<volume>21</volume>
<issue>6</issue>
<fpage>265</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="pmid">12823999</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stubbs</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>Depressed lymphocyte responsiveness in autistic children</article-title>
<source/>J Autism Child Schizophr
          <year>1977</year>
<volume>7</volume>
<issue>1</issue>
<fpage>49</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="pmid">139400</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warren</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Margaretten</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Pace</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Foster</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Immune abnormalities in patients with autism</article-title>
<source/>J Autism Dev Disord
          <year>1986</year>
<volume>16</volume>
<issue>2</issue>
<fpage>189</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="pmid">2941410</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denney</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Frei</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Gaffney</surname>
<given-names>GR</given-names>
</name>
</person-group>
<article-title>Lymphocyte subsets and interleukin-2 receptors in autistic children</article-title>
<source/>J Autism Dev Disord
          <year>1996</year>
<volume>26</volume>
<issue>1</issue>
<fpage>87</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="pmid">8819772</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yonk</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Burger</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Odell</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>White</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>VK</given-names>
</name>
</person-group>
<article-title>CD4+ helper T cell depression in autism</article-title>
<source/>Immunol Lett
          <year>1990</year>
<volume>25</volume>
<issue>4</issue>
<fpage>341</fpage>
<lpage>345</lpage>
<pub-id pub-id-type="pmid">1979061</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Corbett</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Kantor</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schulman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Amaral</surname>
<given-names>DG</given-names>
</name>
</person-group>
<article-title>In search of cellular immunophenotypes in the blood of children with autism</article-title>
<source/>PLoS One
          <year>2011</year>
<volume>6</volume>
<issue>5</issue>
<fpage>e19299</fpage>
<pub-id pub-id-type="pmid">21573236</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferrante</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Saresella</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Guerini</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Marzorati</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Musetti</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Cazzullo</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>Significant association of HLA A2-DR11 with CD4 naive decrease in autistic children</article-title>
<source/>Biomed Pharmacother
          <year>2003</year>
<volume>57</volume>
<issue>8</issue>
<fpage>372</fpage>
<lpage>374</lpage>
<pub-id pub-id-type="pmid">14568232</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warren</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Yonk</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Burger</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Odell</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>WL</given-names>
</name>
</person-group>
<article-title>DR-positive T cells in autism: association with decreased plasma levels of the complement C4B protein</article-title>
<source/>Neuropsychobiology
          <year>1995</year>
<volume>31</volume>
<issue>2</issue>
<fpage>53</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="pmid">7760985</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warren</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Yonk</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Burger</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Odell</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>White</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>VK</given-names>
</name>
</person-group>
<article-title>Deficiency of suppressor-inducer (CD4+CD45RA+) T cells in autism</article-title>
<source/>Immunol Invest
          <year>1990</year>
<volume>19</volume>
<issue>3</issue>
<fpage>245</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="pmid">2142123</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mostafa</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Shehab</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Fouad</surname>
<given-names>NR</given-names>
</name>
</person-group>
<article-title>Frequency of CD4+CD25high regulatory T cells in the peripheral blood of Egyptian children with autism</article-title>
<source/>J Child Neurol
          <year>2010</year>
<volume>25</volume>
<issue>3</issue>
<fpage>328</fpage>
<lpage>335</lpage>
<pub-id pub-id-type="pmid">19713552</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<mixed-citation publication-type="other">Ahmad SF, Zoheir KM, Ansari MA, Nadeem A, Bakheet SA, Al-Ayadhi LY, Alzahrani MZ, Al-Shabanah OA, Al-Harbi MM, Attia SM (2017) Dysregulation of Th1, Th2, Th17, and T regulatory cell-related transcription factor signaling in children with autism. Mol Neurobiol 54(6):4390–4400. 10.1007/s12035-016-9977-0</mixed-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aggarwal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rashanravan</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism</article-title>
<source/>J Neuroimmunol
          <year>1998</year>
<volume>85</volume>
<issue>1</issue>
<fpage>106</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="pmid">9627004</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Ayadhi</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Mostafa</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Elevated serum levels of macrophage-derived chemokine and thymus and activation-regulated chemokine in autistic children</article-title>
<source/>J Neuroinflammation
          <year>2013</year>
<volume>10</volume>
<fpage>72</fpage>
<pub-id pub-id-type="pmid">23782855</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>López-Cacho</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Gallardo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Posada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Aguerri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Calzada</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mayayo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lahoz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cárdaba</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Characterization of immune cell phenotypes in adults with autism spectrum disorders</article-title>
<source/>J Investig Med
          <year>2016</year>
<volume>64</volume>
<issue>7</issue>
<fpage>1179</fpage>
<lpage>1185</lpage>
<pub-id pub-id-type="pmid">27296457</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<mixed-citation publication-type="other">Saresella M, Marventano I, Guerini FR, Mancuso R, Ceresa L, Zanzottera M, Rusconi B, Maggioni E et al (2009) An autistic endophenotype results in complex immune dysfunction in healthy siblings of autistic children. Biol Psychiatry 66(10):978–984. 10.1016/j.biopsych.2009.06.020</mixed-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<mixed-citation publication-type="other">Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K (2015) The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp (Warsz) 63(6):435–449. 10.1007/s00005-015-0344-z</mixed-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Ayadhi</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Mostafa</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Elevated serum levels of interleukin-17A in children with autism</article-title>
<source/>J Neuroinflammation
          <year>2012</year>
<volume>9</volume>
<fpage>158</fpage>
<pub-id pub-id-type="pmid">22748016</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akintunde</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Krakowiak</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Heuer</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hertz-Picciotto</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Increased production of IL-17 in children with autism spectrum disorders and co-morbid asthma</article-title>
<source/>J Neuroimmunol
          <year>2015</year>
<volume>286</volume>
<fpage>33</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">26298322</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<mixed-citation publication-type="other">Choi GB, Yim YS, Wong H, Kim S, Kim H, Kim SV, Hoeffer CA, Littman DR et al (2016) The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. Science 351(6276):933–939. 10.1126/science.aad0314</mixed-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Onore</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Enstrom</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Krakowiak</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hertz-Picciotto</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Decreased cellular IL-23 but not IL-17 production in children with autism spectrum disorders</article-title>
<source/>J Neuroimmunol
          <year>2009</year>
<volume>216</volume>
<issue>1-2</issue>
<fpage>126</fpage>
<lpage>129</lpage>
<pub-id pub-id-type="pmid">19800697</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enstrom</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Onore</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hertz-Picciotto</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Croen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Van De Water</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Detection of IL-17 and IL-23 in plasma samples of children with autism</article-title>
<source/>Am J Biochem Biotechnol
          <year>2003</year>
<volume>4</volume>
<issue>2</issue>
<fpage>114</fpage>
<lpage>120</lpage>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Jo</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Heo</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Aberrant IgG isotype generation in mice with abnormal behaviors</article-title>
<source/>J Immunotoxicol
          <year>2016</year>
<volume>13</volume>
<issue>1</issue>
<fpage>92</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="pmid">25691089</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Caparulo</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Shaywitz</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Childhood autism. Cerebrospinal fluid examination and immunoglobulin levels</article-title>
<source/>J Am Acad Child Psychiatry
          <year>1977</year>
<volume>16</volume>
<issue>1</issue>
<fpage>174</fpage>
<lpage>179</lpage>
<pub-id pub-id-type="pmid">845339</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warren</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Odell</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Burger</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Maciulis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Daniels</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>AR</given-names>
</name>
</person-group>
<article-title>Brief report: immunoglobulin A deficiency in a subset of autistic subjects</article-title>
<source/>J Autism Dev Disord
          <year>1997</year>
<volume>27</volume>
<issue>2</issue>
<fpage>187</fpage>
<lpage>192</lpage>
<pub-id pub-id-type="pmid">9105969</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wasilewska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kaczmarski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stasiak-Barmuta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tobolczyk</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kowalewska</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Low serum IgA and increased expression of CD23 on B lymphocytes in peripheral blood in children with regressive autism aged 3–6 years old</article-title>
<source/>Arch Med Sci
          <year>2012</year>
<volume>8</volume>
<issue>2</issue>
<fpage>324</fpage>
<lpage>331</lpage>
<pub-id pub-id-type="pmid">22662007</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santaella</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Varela</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Linares</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Disdier</surname>
<given-names>OM</given-names>
</name>
</person-group>
<article-title>Prevalence of autism spectrum disorders in relatives of patients with selective immunoglobulin A deficiency</article-title>
<source/>P R Health Sci J
          <year>2008</year>
<volume>27</volume>
<issue>3</issue>
<fpage>204</fpage>
<lpage>208</lpage>
<pub-id pub-id-type="pmid">18782963</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<mixed-citation publication-type="other">Heuer L, Ashwood P, Schauer J, Goines P, Krakowiak P, Hertz-Picciotto I, Hansen R, Croen LA et al (2008) Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms. Autism Res 1(5):275–283. 10.1002/aur.42</mixed-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heuer</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Decreased levels of total immunoglobulin in children with autism are not a result of B cell dysfunction</article-title>
<source/>J Neuroimmunol
          <year>2012</year>
<volume>251</volume>
<issue>1-2</issue>
<fpage>94</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="pmid">22854260</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trajkovski</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ajdinski</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Spiroski</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Plasma concentration of immunoglobulin classes and subclasses in children with autism in the Republic of Macedonia: retrospective study</article-title>
<source/>Croat Med J
          <year>2004</year>
<volume>45</volume>
<issue>6</issue>
<fpage>746</fpage>
<lpage>749</lpage>
<pub-id pub-id-type="pmid">15578810</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trajkovski</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Petlichovski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Efinska-Mladenovska</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Trajkov</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Arsov</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Strezova</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ajdinski</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Spiroski</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Higher plasma concentration of food-specific antibodies in persons with autistic disorder in comparison to their siblings</article-title>
<source/>Focus Autism Other Dev Disabl
          <year>2008</year>
<volume>23</volume>
<fpage>176</fpage>
<lpage>185</lpage>
</element-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<mixed-citation publication-type="other">Spiroski M, Trajkovski V, Trajkov D, Petlichkovski A, Efinska-Mladenovska O, Hristomanova S, Djulejic E, Paneva M et al (2009) Family analysis of immunoglobulin classes and subclasses in children with autistic disorder. Bosn J Basic Med Sci 9(4):283–289</mixed-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<mixed-citation publication-type="other">Croonenberghs J, Wauters A, Devreese K, Verkerk R, Scharpe S, Bosmans E, Egyed B, Deboutte D et al (2002) Increased serum albumin, gamma globulin, immunoglobulin IgG, and IgG2 and IgG4 in autism. Psychol Med 32(8):1457–1463</mixed-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enstrom</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Krakowiak</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Onore</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pessah</surname>
<given-names>IN</given-names>
</name>
<name>
<surname>Hertz-Picciotto</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Increased IgG4 levels in children with autism disorder</article-title>
<source/>Brain Behav Immun
          <year>2009</year>
<volume>23</volume>
<issue>3</issue>
<fpage>389</fpage>
<lpage>395</lpage>
<pub-id pub-id-type="pmid">19136055</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<mixed-citation publication-type="other">Hollander E, DelGiudice-Asch G, Simon L, Schmeidler J, Cartwright C, DeCaria CM, Kwon J, Cunningham-Rundles C et al (1999) B lymphocyte antigen D8/17 and repetitive behaviors in autism. Am J Psychiatry 156(2):317–320</mixed-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harel</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mukamel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zeharia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kodman</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Prais</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Uziel</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zabriskie</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Amir</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Presence of D8/17 B-cell marker in patients with poststreptococcal reactive arthritis</article-title>
<source/>Rheumatol Int
          <year>2007</year>
<volume>27</volume>
<issue>8</issue>
<fpage>695</fpage>
<lpage>698</lpage>
<pub-id pub-id-type="pmid">17221172</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<mixed-citation publication-type="other">Weisz JL, McMahon WM, Moore JC, Augustine NH, Bohnsack JF, Bale JF, Johnson MB, Morgan JF et al (2004) D8/17 and CD19 expression on lymphocytes of patients with acute rheumatic fever and Tourette's disorder. Clin Diagn Lab Immunol 11(2):330–336</mixed-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<mixed-citation publication-type="other">Niehaus DJ, Knowles JA, van Kradenberg J, du Toit W, Kaminer D, Seedat S, Daniels W, Cotton M et al (1999) D8/17 in obsessive-compulsive disorder and trichotillomania. S Afr Med J 89(7):755–756</mixed-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<mixed-citation publication-type="other">Swedo SE, Leonard HL, Mittleman BB, Allen AJ, Rapoport JL, Dow SP, Kanter ME, Chapman F et al (1997) Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Am J Psychiatry 154(1):110–112</mixed-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<mixed-citation publication-type="other">Sharpe MA, Gist TL, Baskin DS (2013) B-lymphocytes from a population of children with autism spectrum disorder and their unaffected siblings exhibit hypersensitivity to thimerosal. J Toxicol. 10.1155/2013/801517</mixed-citation>
</ref>
<ref id="CR116">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Malik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sheikh</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Merz</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ted Brown</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Abnormal cell properties and down-regulated FAK-Src complex signaling in B lymphoblasts of autistic subjects</article-title>
<source/>Am J Pathol
          <year>2011</year>
<volume>179</volume>
<issue>1</issue>
<fpage>66</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="pmid">21703394</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stern</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Francoeur</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Primeau</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Sommerville</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Fombonne</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mazer</surname>
<given-names>BD</given-names>
</name>
</person-group>
<article-title>Immune function in autistic children</article-title>
<source/>Ann Allergy Asthma Immunol
          <year>2005</year>
<volume>95</volume>
<issue>6</issue>
<fpage>558</fpage>
<lpage>565</lpage>
<pub-id pub-id-type="pmid">16400896</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cooper</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Fehniger</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Caligiuri</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>The biology of human natural killer-cell subsets</article-title>
<source/>Trends Immunol
          <year>2001</year>
<volume>22</volume>
<issue>11</issue>
<fpage>633</fpage>
<lpage>640</lpage>
<pub-id pub-id-type="pmid">11698225</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papamichail</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Gritzapis</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Baxevanis</surname>
<given-names>CN</given-names>
</name>
</person-group>
<article-title>Natural killer lymphocytes: biology, development, and function</article-title>
<source/>Cancer Immunol Immunother
          <year>2004</year>
<volume>53</volume>
<issue>3</issue>
<fpage>176</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="pmid">14685782</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zitvogel</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Dendritic and natural killer cells cooperate in the control/switch of innate immunity</article-title>
<source/>J Exp Med
          <year>2002</year>
<volume>195</volume>
<issue>3</issue>
<fpage>F9</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">11828015</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enk</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mandelboim</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>The role of natural cytotoxicity receptors in various pathologies: emphasis on type I diabetes</article-title>
<source/>Front Immunol
          <year>2014</year>
<volume>5</volume>
<fpage>4</fpage>
<pub-id pub-id-type="pmid">24478773</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galuppo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Giacoppo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sessa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bramanti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mazzon</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Are natural killer cells involved in multiple sclerosis etiology? Evidences from NKp46/NCR1 receptor modulation in an observational study</article-title>
<source/>J Neurol Sci
          <year>2014</year>
<volume>345</volume>
<issue>1-2</issue>
<fpage>248</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="pmid">25115502</pub-id>
</element-citation>
</ref>
<ref id="CR123">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sperner-Unterweger</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Whitworth</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kemmler</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hilbe</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Thaler</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fleischhacker</surname>
<given-names>WW</given-names>
</name>
</person-group>
<article-title>T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients</article-title>
<source/>Schizophr Res
          <year>1999</year>
<volume>38</volume>
<issue>1</issue>
<fpage>61</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="pmid">10427611</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lit</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gilbert</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>FR</given-names>
</name>
</person-group>
<article-title>A subgroup of Tourette’s patients overexpress specific natural killer cell genes in blood: a preliminary report</article-title>
<source/>Am J Med Genet B Neuropsychiatr Genet
          <year>2007</year>
<volume>144B</volume>
<issue>7</issue>
<fpage>958</fpage>
<lpage>963</lpage>
<pub-id pub-id-type="pmid">17503477</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fiumara</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sciotto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Barone</surname>
<given-names>R</given-names>
</name>
<name>
<surname>D'Asero</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Munda</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Parano</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pavone</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Peripheral lymphocyte subsets and other immune aspects in Rett syndrome</article-title>
<source/>Pediatr Neurol
          <year>1999</year>
<volume>21</volume>
<issue>3</issue>
<fpage>619</fpage>
<lpage>621</lpage>
<pub-id pub-id-type="pmid">10513687</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warren</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Foster</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Margaretten</surname>
<given-names>NC</given-names>
</name>
</person-group>
<article-title>Reduced natural killer cell activity in autism</article-title>
<source/>J Am Acad Child Adolesc Psychiatry
          <year>1987</year>
<volume>26</volume>
<issue>3</issue>
<fpage>333</fpage>
<lpage>335</lpage>
<pub-id pub-id-type="pmid">3597287</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<label>127.</label>
<mixed-citation publication-type="other">Enstrom AM, Lit L, Onore CE, Gregg JP, Hansen RL, Pessah IN, Hertz-Picciotto I, Van de Water JA et al (2009) Altered gene expression and function of peripheral blood natural killer cells in children with autism. Brain Behav Immun 23(1):124–133</mixed-citation>
</ref>
<ref id="CR128">
<label>128.</label>
<mixed-citation publication-type="other">Vojdani A, Mumper E, Granpeesheh D, Mielke L, Traver D, Bock K, Hirani K, Neubrander J et al (2008) Low natural killer cell cytotoxic activity in autism: the role of glutathione, IL-2 and IL-15. J Neuroimmunol 205(1-2):148–154</mixed-citation>
</ref>
<ref id="CR129">
<label>129.</label>
<mixed-citation publication-type="other">Gregg JP, Lit L, Baron CA, Hertz-Picciotto I, Walker W, Davis RA, Croen LA, Ozonoff S et al (2008) Gene expression changes in children with autism. Genomics 91(1):22–29</mixed-citation>
</ref>
<ref id="CR130">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torres</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Westover</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Gibbons</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>Activating killer-cell immunoglobulin-like receptors (KIR) and their cognate HLA ligands are significantly increased in autism</article-title>
<source/>Brain Behav Immun
          <year>2012</year>
<volume>26</volume>
<issue>7</issue>
<fpage>1122</fpage>
<lpage>1127</lpage>
<pub-id pub-id-type="pmid">22884899</pub-id>
</element-citation>
</ref>
<ref id="CR131">
<label>131.</label>
<mixed-citation publication-type="other">Guerini FR, Bolognesi E, Chiappedi M, Manca S, Ghezzo A, Agliardi C, Zanette M, Littera R et al (2014) Activating KIR molecules and their cognate ligands prevail in children with a diagnosis of ASD and in their mothers. Brain Behav Immun 36:54–60</mixed-citation>
</ref>
<ref id="CR132">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ivarsson</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Michaëlsson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fauriat</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Activating killer cell Ig-like receptors in health and disease</article-title>
<source/>Front Immunol
          <year>2014</year>
<volume>5</volume>
<fpage>184</fpage>
<pub-id pub-id-type="pmid">24795726</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuśnierczyk</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Killer cell immunoglobulin-like receptor gene associations with autoimmune and allergic diseases, recurrent spontaneous abortion, and neoplasms</article-title>
<source/>Front Immunol
          <year>2013</year>
<volume>4</volume>
<fpage>8</fpage>
<pub-id pub-id-type="pmid">23372569</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siniscalco</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mijatovic</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bosmans</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cirillo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kruzliak</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lombardi</surname>
<given-names>VC</given-names>
</name>
<name>
<surname>De Meirleir</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Antonucci</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Decreased numbers of CD57+CD3− cells identify potential innate immune differences in patients with autism spectrum disorder</article-title>
<source/>In Vivo
          <year>2016</year>
<volume>30</volume>
<issue>2</issue>
<fpage>83</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="pmid">26912817</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<label>135.</label>
<mixed-citation publication-type="other">Jácome IMC, Morales Chacòn LM, Vera Cuesta H, Maragoto Rizo C, Whilby Santiesteban M, Ramos Hernandez L, Noris García E, González Fraguela ME et al (2016) Peripheral inflammatory markers contributing to comorbidities in autism. Behav Sci (Basel) 6(4). 10.3390/bs6040029</mixed-citation>
</ref>
<ref id="CR136">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pecorelli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cervellati</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Belmonte</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Montagner</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Waldon</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hayek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gambari</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Valacchi</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Cytokines profile and peripheral blood mononuclear cells morphology in Rett and autistic patients</article-title>
<source/>Cytokine
          <year>2016</year>
<volume>77</volume>
<fpage>180</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="pmid">26471937</pub-id>
</element-citation>
</ref>
<ref id="CR137">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rose</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Unique immune profiles in children with autism who experience gastrointestinal co-morbidity (Abstract # 1787)</article-title>
<source/>Brain Behav Immun
          <year>2016</year>
<volume>57</volume>
<fpage>e23</fpage>
<lpage>e24</lpage>
</element-citation>
</ref>
<ref id="CR138">
<label>138.</label>
<mixed-citation publication-type="other">Napolioni V, Ober-Reynolds B, Szelinger S, Corneveaux JJ, Pawlowski T, Ober-Reynolds S, Kirwan J, Persico AM et al (2013) Plasma cytokine profiling in sibling pairs discordant for autism spectrum disorder. J Neuroinflammation 10:38. 10.1186/1742-2094-10-38</mixed-citation>
</ref>
<ref id="CR139">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manzardo</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Henkhaus</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dhillon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>MG</given-names>
</name>
</person-group>
<article-title>Plasma cytokine levels in children with autistic disorder and unrelated siblings</article-title>
<source/>Int J Dev Neurosci
          <year>2012</year>
<volume>30</volume>
<issue>2</issue>
<fpage>121</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="pmid">22197967</pub-id>
</element-citation>
</ref>
<ref id="CR140">
<label>140.</label>
<mixed-citation publication-type="other">Schwarz E, Guest PC, Rahmoune H, Wang L, Levin Y, Ingudomnukul E, Ruta L, Kent L et al (2011) Sex-specific serum biomarker patterns in adults with Asperger’s syndrome. Mol Psychiatry 16(12):1213–1220. 10.1038/mp.2010.102</mixed-citation>
</ref>
<ref id="CR141">
<label>141.</label>
<mixed-citation publication-type="other">Suzuki K, Matsuzaki H, Iwata K, Kameno Y, Shimmura C, Kawai S, Yoshihara Y, Wakuda T et al (2011) Plasma cytokine profiles in subjects with high-functioning autism spectrum disorders. PLoS One 6(5):e20470. 10.1371/journal.pone.0020470</mixed-citation>
</ref>
<ref id="CR142">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bryn</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Aass</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Skjeldal</surname>
<given-names>OH</given-names>
</name>
<name>
<surname>Isaksen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Saugstad</surname>
<given-names>OD</given-names>
</name>
<name>
<surname>Ormstad</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Cytokine profile in autism spectrum disorders in children</article-title>
<source/>J Mol Neurosci
          <year>2017</year>
<volume>61</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">27730473</pub-id>
</element-citation>
</ref>
<ref id="CR143">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tostes</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Teixeira</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Gattaz</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>Brandão</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Raposo</surname>
<given-names>NR</given-names>
</name>
</person-group>
<article-title>Altered neurotrophin, neuropeptide, cytokines and nitric oxide levels in autism</article-title>
<source/>Pharmacopsychiatry
          <year>2012</year>
<volume>45</volume>
<issue>6</issue>
<fpage>241</fpage>
<lpage>243</lpage>
<pub-id pub-id-type="pmid">22426848</pub-id>
</element-citation>
</ref>
<ref id="CR144">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Krakowiak</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hertz-Picciotto</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pessah</surname>
<given-names>IN</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Altered T cell responses in children with autism</article-title>
<source/>Brain Behav Immun
          <year>2011</year>
<volume>25</volume>
<issue>5</issue>
<fpage>840</fpage>
<lpage>849</lpage>
<pub-id pub-id-type="pmid">20833247</pub-id>
</element-citation>
</ref>
<ref id="CR145">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Krakowiak</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hertz-Picciotto</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pessah</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome</article-title>
<source/>Brain Behav Immun
          <year>2011</year>
<volume>25</volume>
<issue>1</issue>
<fpage>40</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="pmid">20705131</pub-id>
</element-citation>
</ref>
<ref id="CR146">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sheikh</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Spivack</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Expression of inflammatory cytokines, Bcl2 and cathepsin D are altered in lymphoblasts of autistic subjects</article-title>
<source/>Immunobiology
          <year>2011</year>
<volume>216</volume>
<issue>1-2</issue>
<fpage>80</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="pmid">20399529</pub-id>
</element-citation>
</ref>
<ref id="CR147">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schauer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pessah</surname>
<given-names>IN</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Preliminary evidence of the in vitro effects of BDE-47 on innate immune responses in children with autism spectrum disorders</article-title>
<source/>J Neuroimmunol
          <year>2009</year>
<volume>208</volume>
<issue>1-2</issue>
<fpage>130</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="pmid">19211157</pub-id>
</element-citation>
</ref>
<ref id="CR148">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Molloy</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Meinzen-Derr</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schleifer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dienger</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Manning-Courtney</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Altaye</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wills-Karp</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Elevated cytokine levels in children with autism spectrum disorder</article-title>
<source/>J Neuroimmunol
          <year>2006</year>
<volume>172</volume>
<issue>1-2</issue>
<fpage>198</fpage>
<lpage>205</lpage>
<pub-id pub-id-type="pmid">16360218</pub-id>
</element-citation>
</ref>
<ref id="CR149">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>VK</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Odell</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Changes of soluble interleukin-2, interleukin-2 receptor, T8 antigen, and interleukin-1 in the serum of autistic children</article-title>
<source/>Clin Immunol Immunopathol
          <year>1991</year>
<volume>61</volume>
<issue>3</issue>
<fpage>448</fpage>
<lpage>455</lpage>
<pub-id pub-id-type="pmid">1934632</pub-id>
</element-citation>
</ref>
<ref id="CR150">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Careaga</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Amaral</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Immune endophenotypes in children with autism spectrum disorder</article-title>
<source/>Biol Psychiatry
          <year>2017</year>
<volume>81</volume>
<issue>5</issue>
<fpage>434</fpage>
<lpage>441</lpage>
<pub-id pub-id-type="pmid">26493496</pub-id>
</element-citation>
</ref>
<ref id="CR151">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jyonouchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Davidow</surname>
<given-names>AL</given-names>
</name>
</person-group>
<article-title>Cytokine profiles by peripheral blood monocytes are associated with changes in behavioral symptoms following immune insults in a subset of ASD subjects: an inflammatory subtype?</article-title>
<source/>J Neuroinflammation
          <year>2014</year>
<volume>11</volume>
<fpage>187</fpage>
<pub-id pub-id-type="pmid">25344730</pub-id>
</element-citation>
</ref>
<ref id="CR152">
<label>152.</label>
<mixed-citation publication-type="other">Ricci S, Businaro R, Ippoliti F, Lo Vasco VR, Massoni F, Onofri E, Troili GM, Pontecorvi V et al (2013) Altered cytokine and BDNF levels in autism spectrum disorder. Neurotox Res 24(4):491–501. 10.1007/s12640-013-9393-4</mixed-citation>
</ref>
<ref id="CR153">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jyonouchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Streck</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Toruner</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Immunological characterization and transcription profiling of peripheral blood (PB) monocytes in children with autism spectrum disorders (ASD) and specific polysaccharide antibody deficiency (SPAD): case study</article-title>
<source/>J Neuroinflammation
          <year>2012</year>
<volume>9</volume>
<fpage>4</fpage>
<pub-id pub-id-type="pmid">22226452</pub-id>
</element-citation>
</ref>
<ref id="CR154">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jyonouchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Streck</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Toruner</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Children with autism spectrum disorders (ASD) who exhibit chronic gastrointestinal (GI) symptoms and marked fluctuation of behavioral symptoms exhibit distinct innate immune abnormalities and transcriptional profiles of peripheral blood (PB) monocytes</article-title>
<source/>J Neuroimmunol
          <year>2011</year>
<volume>238</volume>
<issue>1-2</issue>
<fpage>73</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="pmid">21803429</pub-id>
</element-citation>
</ref>
<ref id="CR155">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enstrom</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Onore</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Differential monocyte responses to TLR ligands in children with autism spectrum disorders</article-title>
<source/>Brain Behav Immun
          <year>2010</year>
<volume>24</volume>
<issue>1</issue>
<fpage>64</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="pmid">19666104</pub-id>
</element-citation>
</ref>
<ref id="CR156">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jyonouchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cushing-Ruby</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Quraishi</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Impact of innate immunity in a subset of children with autism spectrum disorders: a case control study</article-title>
<source/>J Neuroinflammation
          <year>2008</year>
<volume>5</volume>
<fpage>52</fpage>
<pub-id pub-id-type="pmid">19025588</pub-id>
</element-citation>
</ref>
<ref id="CR157">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jyonouchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ruby</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zimmerman-Bier</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Evaluation of an association between gastrointestinal symptoms and cytokine production against common dietary proteins in children with autism spectrum disorders</article-title>
<source/>J Pediatr
          <year>2005</year>
<volume>146</volume>
<issue>5</issue>
<fpage>605</fpage>
<lpage>610</lpage>
<pub-id pub-id-type="pmid">15870662</pub-id>
</element-citation>
</ref>
<ref id="CR158">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jyonouchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ruby</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zimmerman-Bier</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention</article-title>
<source/>Neuropsychobiology
          <year>2005</year>
<volume>51</volume>
<issue>2</issue>
<fpage>77</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="pmid">15741748</pub-id>
</element-citation>
</ref>
<ref id="CR159">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jyonouchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression</article-title>
<source/>J Neuroimmunol
          <year>2001</year>
<volume>120</volume>
<issue>1-2</issue>
<fpage>170</fpage>
<lpage>179</lpage>
<pub-id pub-id-type="pmid">11694332</pub-id>
</element-citation>
</ref>
<ref id="CR160">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>VK</given-names>
</name>
</person-group>
<article-title>Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism</article-title>
<source/>J Neuroimmunol
          <year>1996</year>
<volume>66</volume>
<issue>1-2</issue>
<fpage>143</fpage>
<lpage>145</lpage>
<pub-id pub-id-type="pmid">8964908</pub-id>
</element-citation>
</ref>
<ref id="CR161">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sweeten</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Posey</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>McDougle</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>High blood monocyte counts and neopterin levels in children with autistic disorder</article-title>
<source/>Am J Psychiatry
          <year>2003</year>
<volume>160</volume>
<issue>9</issue>
<fpage>1691</fpage>
<lpage>1693</lpage>
<pub-id pub-id-type="pmid">12944347</pub-id>
</element-citation>
</ref>
<ref id="CR162">
<label>162.</label>
<mixed-citation publication-type="other">Ahmad SF, Nadeem A, Ansari MA, Bakheet SA, Attia SM, Zoheir KM, Al-Ayadhi LY, Alzahrani MZ et al (2017) Imbalance between the anti- and pro-inflammatory milieu in blood leukocytes of autistic children. Mol Immunol 82:57–65. 10.1016/j.molimm.2016.12.019</mixed-citation>
</ref>
<ref id="CR163">
<label>163.</label>
<mixed-citation publication-type="other">Guloksuz SA, Abali O, Aktas Cetin E, Bilgic Gazioglu S, Deniz G, Yildirim A, Kawikova I, Guloksuz S, Leckman JF (2017) Elevated plasma concentrations of S100 calcium-binding protein B and tumor necrosis factor alpha in children with autism spectrum disorders. Rev Bras Psiquiatr 39(3):195–200. 10.1590/1516-4446-2015-1843</mixed-citation>
</ref>
<ref id="CR164">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Cheung</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Sze</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Yeung</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>AS</given-names>
</name>
</person-group>
<article-title>Distinct cytokine and chemokine profiles in autism spectrum disorders</article-title>
<source/>Front Immunol
          <year>2017</year>
<volume>8</volume>
<fpage>11</fpage>
<pub-id pub-id-type="pmid">28167942</pub-id>
</element-citation>
</ref>
<ref id="CR165">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Ansary</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Ben Bacha</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Al-Ayadhi</surname>
<given-names>LY</given-names>
</name>
</person-group>
<article-title>Proinflammatory and proapoptotic markers in relation to mono and di-cations in plasma of autistic patients from Saudi Arabia</article-title>
<source/>J Neuroinflammation
          <year>2011</year>
<volume>8</volume>
<fpage>142</fpage>
<pub-id pub-id-type="pmid">21999440</pub-id>
</element-citation>
</ref>
<ref id="CR166">
<label>166.</label>
<mixed-citation publication-type="other">Makinodan M, Iwata K, Ikawa D, Yamashita Y, Yamamuro K, Toritsuka M, Kimoto S, Okumura K et al (2017) Tumor necrosis factor-alpha expression in peripheral blood mononuclear cells correlates with early childhood social interaction in autism spectrum disorder. Neurochem Int 104:1–5. 10.1016/j.neuint.2016.12.005.</mixed-citation>
</ref>
<ref id="CR167">
<label>167.</label>
<mixed-citation publication-type="other">Ferguson BJ, Marler S, Altstein LL, Lee EB, Mazurek MO, McLaughlin A, Macklin EA, McDonnell E et al (2016) Associations between cytokines, endocrine stress response, and gastrointestinal symptoms in autism spectrum disorder. Brain Behav Immun 58:57–62. 10.1016/j.bbi.2016.05.009</mixed-citation>
</ref>
<ref id="CR168">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbosa</surname>
<given-names>IG</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Rocha</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Sousa</surname>
<given-names>LF</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Simões-E-Silva</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Kummer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Teixeira</surname>
<given-names>AL</given-names>
</name>
</person-group>
<article-title>Plasma levels of alarmin IL-33 are unchanged in autism spectrum disorder: a preliminary study</article-title>
<source/>J Neuroimmunol
          <year>2015</year>
<volume>278</volume>
<fpage>69</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="pmid">25595254</pub-id>
</element-citation>
</ref>
<ref id="CR169">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tonhajzerova</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ondrejka</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mestanik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mikolka</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hrtanek</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mestanikova</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bujnakova</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mokra</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Inflammatory activity in autism spectrum disorder</article-title>
<source/>Adv Exp Med Biol
          <year>2015</year>
<volume>861</volume>
<fpage>93</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="pmid">26022900</pub-id>
</element-citation>
</ref>
<ref id="CR170">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsilioni</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Taliou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Theoharides</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Children with autism spectrum disorders, who improved with a luteolin-containing dietary formulation, show reduced serum levels of TNF and IL-6</article-title>
<source/>Transl Psychiatry
          <year>2015</year>
<volume>5</volume>
<fpage>e647</fpage>
<pub-id pub-id-type="pmid">26418275</pub-id>
</element-citation>
</ref>
<ref id="CR171">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Sang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>YJ</given-names>
</name>
</person-group>
<article-title>The combined role of serotonin and interleukin-6 as biomarker for autism</article-title>
<source/>Neuroscience
          <year>2015</year>
<volume>284</volume>
<fpage>290</fpage>
<lpage>296</lpage>
<pub-id pub-id-type="pmid">25453766</pub-id>
</element-citation>
</ref>
<ref id="CR172">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Ansary</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Al-Ayadhi</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>GABAergic/glutamatergic imbalance relative to excessive neuroinflammation in autism spectrum disorders</article-title>
<source/>J Neuroinflammation
          <year>2014</year>
<volume>11</volume>
<fpage>189</fpage>
<pub-id pub-id-type="pmid">25407263</pub-id>
</element-citation>
</ref>
<ref id="CR173">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Ansary</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Al-Ayadhi</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Neuroinflammation in autism spectrum disorders</article-title>
<source/>J Neuroinflammation
          <year>2012</year>
<volume>9</volume>
<fpage>265</fpage>
<pub-id pub-id-type="pmid">23231720</pub-id>
</element-citation>
</ref>
<ref id="CR174">
<label>174.</label>
<mixed-citation publication-type="other">Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de Water J (2011) Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disorders. J Neuroimmunol 232(1-2):196–199. 10.1016/j.jneuroim.2010.10.025</mixed-citation>
</ref>
<ref id="CR175">
<label>175.</label>
<mixed-citation publication-type="other">Onore C, Van de Water J, Ashwood P (2012) Decreased levels of EGF in plasma of children with autism spectrum disorder. Autism Res Treat: 205362. 10.1155/2012/205362</mixed-citation>
</ref>
<ref id="CR176">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emanuele</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Orsi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Boso</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Broglia</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Brondino</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Barale</surname>
<given-names>F</given-names>
</name>
<name>
<surname>di Nemi</surname>
<given-names>SU</given-names>
</name>
<name>
<surname>Politi</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Low-grade endotoxemia in patients with severe autism</article-title>
<source/>Neurosci Lett
          <year>2010</year>
<volume>471</volume>
<issue>3</issue>
<fpage>162</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="pmid">20097267</pub-id>
</element-citation>
</ref>
<ref id="CR177">
<label>177.</label>
<mixed-citation publication-type="other">Ashwood P, Enstrom A, Krakowiak P, Hertz-Picciotto I, Hansen RL, Croen LA, Ozonoff S, Pessah IN et al (2008) Decreased transforming growth factor beta1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol 204(1-2):149–153. 10.1016/j.jneuroim.2008.07.006</mixed-citation>
</ref>
<ref id="CR178">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enstrom</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Onore</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hertz-Picciotto</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Croen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Detection of IL-17 and IL-23 in plasma samples of children with autism</article-title>
<source/>Am J Biochem Biotechnol
          <year>2008</year>
<volume>4</volume>
<issue>2</issue>
<fpage>114</fpage>
<lpage>120</lpage>
<pub-id pub-id-type="pmid">27688738</pub-id>
</element-citation>
</ref>
<ref id="CR179">
<label>179.</label>
<mixed-citation publication-type="other">Grigorenko EL, Han SS, Yrigollen CM, Leng L, Mizue Y, Anderson GM, Mulder EJ, de Bildt A et al (2008) Macrophage migration inhibitory factor and autism spectrum disorders. Pediatrics 122(2):e438–e445. 10.1542/peds.2007-3604</mixed-citation>
</ref>
<ref id="CR180">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Ayadhi</surname>
<given-names>LY</given-names>
</name>
</person-group>
<article-title>Pro-inflammatory cytokines in autistic children in central Saudi Arabia</article-title>
<source/>Neurosciences (Riyadh)
          <year>2005</year>
<volume>10</volume>
<issue>2</issue>
<fpage>155</fpage>
<lpage>158</lpage>
<pub-id pub-id-type="pmid">22473229</pub-id>
</element-citation>
</ref>
<ref id="CR181">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sweeten</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Posey</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Shankar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McDougle</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>High nitric oxide production in autistic disorder: a possible role for interferon-gamma</article-title>
<source/>Biol Psychiatry
          <year>2004</year>
<volume>55</volume>
<issue>4</issue>
<fpage>434</fpage>
<lpage>437</lpage>
<pub-id pub-id-type="pmid">14960298</pub-id>
</element-citation>
</ref>
<ref id="CR182">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Croonenberghs</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bosmans</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Deboutte</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kenis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Maes</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Activation of the inflammatory response system in autism</article-title>
<source/>Neuropsychobiology
          <year>2002</year>
<volume>45</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">11803234</pub-id>
</element-citation>
</ref>
<ref id="CR183">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jyonouchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Itokazu</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder</article-title>
<source/>Neuropsychobiology
          <year>2002</year>
<volume>46</volume>
<issue>2</issue>
<fpage>76</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="pmid">12378124</pub-id>
</element-citation>
</ref>
<ref id="CR184">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jyonouchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Waynne</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>An association between IL-1β production and mitochondrial functions in patients with autism spectrum disorders (abstract 671)</article-title>
<source/>J Allergy Clin Immunol
          <year>2017</year>
<volume>139</volume>
<issue>2</issue>
<fpage>AB213</fpage>
</element-citation>
</ref>
<ref id="CR185">
<label>185.</label>
<mixed-citation publication-type="other">Kajizuka M, Miyachi T, Matsuzaki H, Iwata K, Shinmura C, Suzuki K, Suda S, Tsuchiya KJ et al (2010) Serum levels of platelet-derived growth factor BB homodimers are increased in male children with autism. Prog Neuropsychopharmacol Biol Psychiatry 34(1):154–158. 10.1016/j.pnpbp.2009.10.017</mixed-citation>
</ref>
<ref id="CR186">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ginhoux</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Monocytes and macrophages: developmental pathways and tissue homeostasis</article-title>
<source/>Nat Rev Immunol
          <year>2014</year>
<volume>14</volume>
<issue>6</issue>
<fpage>392</fpage>
<lpage>404</lpage>
<pub-id pub-id-type="pmid">24854589</pub-id>
</element-citation>
</ref>
<ref id="CR187">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swirski</surname>
<given-names>FK</given-names>
</name>
<name>
<surname>Hilgendorf</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Robbins</surname>
<given-names>CS</given-names>
</name>
</person-group>
<article-title>From proliferation to proliferation: monocyte lineage comes full circle</article-title>
<source/>Semin Immunopathol
          <year>2014</year>
<volume>36</volume>
<issue>2</issue>
<fpage>137</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="pmid">24435095</pub-id>
</element-citation>
</ref>
<ref id="CR188">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amoruso</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sola</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Obeng</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Fresu</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Sainaghi</surname>
<given-names>PP</given-names>
</name>
<name>
<surname>Pirisi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brunelleschi</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Relation among anti-rheumatic drug therapy, CD14(+)CD16(+) blood monocytes and disease activity markers (DAS28 and US7 scores) in rheumatoid arthritis: a pilot study</article-title>
<source/>Pharmacol Res
          <year>2016</year>
<volume>107</volume>
<fpage>308</fpage>
<lpage>314</lpage>
<pub-id pub-id-type="pmid">27045818</pub-id>
</element-citation>
</ref>
<ref id="CR189">
<label>189.</label>
<mixed-citation publication-type="other">Saresella M, Marventano I, Calabrese E, Piancone F, Rainone V, Gatti A, Alberoni M, Nemni R et al (2014) A complex proinflammatory role for peripheral monocytes in Alzheimer’s disease. J Alzheimers Dis 38(2):403–413. 10.3233/JAD-131160.</mixed-citation>
</ref>
<ref id="CR190">
<label>190.</label>
<mixed-citation publication-type="other">Grozdanov V, Bliederhaeuser C, Ruf WP, Roth V, Fundel-Clemens K, Zondler L, Brenner D, Martin-Villalba A et al (2014) Inflammatory dysregulation of blood monocytes in Parkinson’s disease patients. Acta Neuropathol 128(5):651–663. 10.1007/s00401-014-1345-4</mixed-citation>
</ref>
<ref id="CR191">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benarroch</surname>
<given-names>EE</given-names>
</name>
</person-group>
<article-title>Microglia: multiple roles in surveillance, circuit shaping, and response to injury</article-title>
<source/>Neurology
          <year>2013</year>
<volume>81</volume>
<issue>12</issue>
<fpage>1079</fpage>
<lpage>1088</lpage>
<pub-id pub-id-type="pmid">23946308</pub-id>
</element-citation>
</ref>
<ref id="CR192">
<label>192.</label>
<mixed-citation publication-type="other">Koyama R, Ikegaya Y (2015) Microglia in the pathogenesis of autism spectrum disorders. Neurosci Res. 10.1016/j.neures.2015.06.005</mixed-citation>
</ref>
<ref id="CR193">
<label>193.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takano</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Role of microglia in autism: recent advances</article-title>
<source/>Dev Neurosci
          <year>2015</year>
<volume>37</volume>
<issue>3</issue>
<fpage>195</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="pmid">25998072</pub-id>
</element-citation>
</ref>
<ref id="CR194">
<label>194.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Réus</surname>
<given-names>GZ</given-names>
</name>
<name>
<surname>Fries</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Stertz</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Badawy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Passos</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Barichello</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kapczinski</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Quevedo</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders</article-title>
<source/>Neuroscience
          <year>2015</year>
<volume>300</volume>
<fpage>141</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="pmid">25981208</pub-id>
</element-citation>
</ref>
<ref id="CR195">
<label>195.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamuro</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kimoto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Kishimoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Makinodan</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Potential primary roles of glial cells in the mechanisms of psychiatric disorders</article-title>
<source/>Front Cell Neurosci
          <year>2015</year>
<volume>9</volume>
<fpage>154</fpage>
<pub-id pub-id-type="pmid">26029044</pub-id>
</element-citation>
</ref>
<ref id="CR196">
<label>196.</label>
<mixed-citation publication-type="other">Suzuki K, Sugihara G, Ouchi Y, Nakamura K, Futatsubashi M, Takebayashi K, Yoshihara Y, Omata K et al (2013) Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry 70(1):49–58</mixed-citation>
</ref>
<ref id="CR197">
<label>197.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morgan</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Chana</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Abramson</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Semendeferi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Courchesne</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Everall</surname>
<given-names>IP</given-names>
</name>
</person-group>
<article-title>Abnormal microglial-neuronal spatial organization in the dorsolateral prefrontal cortex in autism</article-title>
<source/>Brain Res
          <year>2012</year>
<volume>1456</volume>
<fpage>72</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">22516109</pub-id>
</element-citation>
</ref>
<ref id="CR198">
<label>198.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morgan</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Chana</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pardo</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Achim</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Semendeferi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Buckwalter</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Courchesne</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Everall</surname>
<given-names>IP</given-names>
</name>
</person-group>
<article-title>Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism</article-title>
<source/>Biol Psychiatry
          <year>2010</year>
<volume>68</volume>
<issue>4</issue>
<fpage>368</fpage>
<lpage>376</lpage>
<pub-id pub-id-type="pmid">20674603</pub-id>
</element-citation>
</ref>
<ref id="CR199">
<label>199.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tetreault</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Hakeem</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Allman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wold</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Allman</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Microglia in the cerebral cortex in autism</article-title>
<source/>J Autism Dev Disord
          <year>2012</year>
<volume>42</volume>
<issue>12</issue>
<fpage>2569</fpage>
<lpage>2584</lpage>
<pub-id pub-id-type="pmid">22466688</pub-id>
</element-citation>
</ref>
<ref id="CR200">
<label>200.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Kern</surname>
<given-names>JK</given-names>
</name>
</person-group>
<article-title>Evidence of microglial activation in autism and its possible role in brain underconnectivity</article-title>
<source/>Neuron Glia Biol
          <year>2011</year>
<volume>7</volume>
<issue>2-4</issue>
<fpage>205</fpage>
<lpage>213</lpage>
<pub-id pub-id-type="pmid">22874006</pub-id>
</element-citation>
</ref>
<ref id="CR201">
<label>201.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belmonte</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Beckel-Mitchener</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boulanger</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Carper</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Webb</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Autism and abnormal development of brain connectivity</article-title>
<source/>J Neurosci
          <year>2004</year>
<volume>24</volume>
<issue>42</issue>
<fpage>9228</fpage>
<lpage>9231</lpage>
<pub-id pub-id-type="pmid">15496656</pub-id>
</element-citation>
</ref>
<ref id="CR202">
<label>202.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Tvrdik</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Peden</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Spangrude</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Capecchi</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Hematopoietic origin of pathological grooming in Hoxb8 mutant mice</article-title>
<source/>Cell
          <year>2010</year>
<volume>141</volume>
<issue>5</issue>
<fpage>775</fpage>
<lpage>785</lpage>
<pub-id pub-id-type="pmid">20510925</pub-id>
</element-citation>
</ref>
<ref id="CR203">
<label>203.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laskaris</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Di Biase</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Everall</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Chana</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Christopoulos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Skafidas</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cropley</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Pantelis</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Microglial activation and progressive brain changes in schizophrenia</article-title>
<source/>Br J Pharmacol
          <year>2016</year>
<volume>173</volume>
<issue>4</issue>
<fpage>666</fpage>
<lpage>680</lpage>
<pub-id pub-id-type="pmid">26455353</pub-id>
</element-citation>
</ref>
<ref id="CR204">
<label>204.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chew</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Fusar-Poli</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schmitz</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Oligodendroglial alterations and the role of microglia in white matter injury: relevance to schizophrenia</article-title>
<source/>Dev Neurosci
          <year>2013</year>
<volume>35</volume>
<issue>2-3</issue>
<fpage>102</fpage>
<lpage>129</lpage>
<pub-id pub-id-type="pmid">23446060</pub-id>
</element-citation>
</ref>
<ref id="CR205">
<label>205.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wohleb</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Delpech</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Dynamic cross-talk between microglia and peripheral monocytes underlies stress-induced neuroinflammation and behavioral consequences</article-title>
<source/>Prog Neuropsychopharmacol Biol Psychiatry
          <year>2017</year>
<volume>79</volume>
<issue>Pt A</issue>
<fpage>40</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">27154755</pub-id>
</element-citation>
</ref>
<ref id="CR206">
<label>206.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pepe</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Calderazzi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>De Maglie</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Villa</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Vegeto</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Heterogeneous induction of microglia M2a phenotype by central administration of interleukin-4</article-title>
<source/>J Neuroinflammation
          <year>2014</year>
<volume>11</volume>
<fpage>211</fpage>
<pub-id pub-id-type="pmid">25551794</pub-id>
</element-citation>
</ref>
<ref id="CR207">
<label>207.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Blehm</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Santoro</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>The potential pathogenetic link between peripheral immune activation and the central innate immune response in neuropsychiatric systemic lupus erythematosus</article-title>
<source/>Med Hypotheses
          <year>2004</year>
<volume>62</volume>
<issue>3</issue>
<fpage>325</fpage>
<lpage>335</lpage>
<pub-id pub-id-type="pmid">14975498</pub-id>
</element-citation>
</ref>
<ref id="CR208">
<label>208.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ameis</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Catani</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Altered white matter connectivity as a neural substrate for social impairment in autism spectrum disorder</article-title>
<source/>Cortex
          <year>2015</year>
<volume>62</volume>
<fpage>158</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="pmid">25433958</pub-id>
</element-citation>
</ref>
<ref id="CR209">
<label>209.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Owen</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Desai</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Arnett</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Marco</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Mukherjee</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Autism and sensory processing disorders: shared white matter disruption in sensory pathways but divergent connectivity in social-emotional pathways</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<issue>7</issue>
<fpage>e103038</fpage>
<pub-id pub-id-type="pmid">25075609</pub-id>
</element-citation>
</ref>
<ref id="CR210">
<label>210.</label>
<mixed-citation publication-type="other">Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM, Ji L, Brown T et al (2009) Elevated immune response in the brain of autistic patients. J Neuroimmunol 207(1-2):111–116</mixed-citation>
</ref>
<ref id="CR211">
<label>211.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vargas</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Nascimbene</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Krishnan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Pardo</surname>
<given-names>CA</given-names>
</name>
</person-group>
<article-title>Neuroglial activation and neuroinflammation in the brain of patients with autism</article-title>
<source/>Ann Neurol
          <year>2005</year>
<volume>57</volume>
<issue>1</issue>
<fpage>67</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">15546155</pub-id>
</element-citation>
</ref>
<ref id="CR212">
<label>212.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sheikh</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Malik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dobkin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation</article-title>
<source/>J Neuroinflammation
          <year>2011</year>
<volume>8</volume>
<fpage>52</fpage>
<pub-id pub-id-type="pmid">21595886</pub-id>
</element-citation>
</ref>
<ref id="CR213">
<label>213.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zimmerman</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Jyonouchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Comi</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Connors</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Milstien</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Varsou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Heyes</surname>
<given-names>MP</given-names>
</name>
</person-group>
<article-title>Cerebrospinal fluid and serum markers of inflammation in autism</article-title>
<source/>Pediatr Neurol
          <year>2005</year>
<volume>33</volume>
<issue>3</issue>
<fpage>195</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="pmid">16139734</pub-id>
</element-citation>
</ref>
<ref id="CR214">
<label>214.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tani</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fernell</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Långström</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Decrease in 6R-5,6,7,8-tetrahydrobiopterin content in cerebrospinal fluid of autistic patients</article-title>
<source/>Neurosci Lett
          <year>1994</year>
<volume>181</volume>
<issue>1-2</issue>
<fpage>169</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="pmid">7898761</pub-id>
</element-citation>
</ref>
<ref id="CR215">
<label>215.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>HX</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>JG</given-names>
</name>
</person-group>
<article-title>High plasma neopterin levels in Chinese children with autism spectrum disorders</article-title>
<source/>Int J Dev Neurosci
          <year>2015</year>
<volume>41</volume>
<fpage>92</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="pmid">25660944</pub-id>
</element-citation>
</ref>
<ref id="CR216">
<label>216.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Messahel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pheasant</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Pall</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ahmed-Choudury</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sungum-Paliwal</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Vostanis</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Urinary levels of neopterin and biopterin in autism</article-title>
<source/>Neurosci Lett
          <year>1998</year>
<volume>241</volume>
<fpage>17</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="pmid">9502205</pub-id>
</element-citation>
</ref>
<ref id="CR217">
<label>217.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harrison</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Pheasant</surname>
<given-names>AE</given-names>
</name>
</person-group>
<article-title>Analysis of urinary pterins in autism</article-title>
<source/>Biochem Soc Trans
          <year>1995</year>
<volume>23</volume>
<issue>4</issue>
<fpage>603S</fpage>
<pub-id pub-id-type="pmid">8654788</pub-id>
</element-citation>
</ref>
<ref id="CR218">
<label>218.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eto</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bandy</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Butterworth</surname>
<given-names>CE</given-names>
<suffix>Jr</suffix>
</name>
</person-group>
<article-title>Plasma and urinary levels of biopterin, neopterin, and related pterins and plasma levels of folate in infantile autism</article-title>
<source/>J Autism Dev Disord
          <year>1992</year>
<volume>22</volume>
<issue>2</issue>
<fpage>295</fpage>
<lpage>308</lpage>
<pub-id pub-id-type="pmid">1624410</pub-id>
</element-citation>
</ref>
<ref id="CR219">
<label>219.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>DeLatorre</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Slattery</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Melnyk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chowdhury</surname>
<given-names>N</given-names>
</name>
<name>
<surname>James</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Metabolic effects of sapropterin treatment in autism spectrum disorder: a preliminary study</article-title>
<source/>Transl Psychiatry
          <year>2013</year>
<volume>3</volume>
<fpage>e237</fpage>
<pub-id pub-id-type="pmid">23462988</pub-id>
</element-citation>
</ref>
<ref id="CR220">
<label>220.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klaiman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Huffman</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Masaki</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>GR</given-names>
</name>
</person-group>
<article-title>Tetrahydrobiopterin as a treatment for autism spectrum disorders: a double-blind, placebo-controlled trial</article-title>
<source/>J Child Adolesc Psychopharmacol
          <year>2013</year>
<volume>23</volume>
<issue>5</issue>
<fpage>320</fpage>
<lpage>328</lpage>
<pub-id pub-id-type="pmid">23782126</pub-id>
</element-citation>
</ref>
<ref id="CR221">
<label>221.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Huffman</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>GR</given-names>
</name>
</person-group>
<article-title>Tetrahydrobiopterin as a novel therapeutic intervention for autism</article-title>
<source/>Neurotherapeutics
          <year>2010</year>
<volume>7</volume>
<issue>3</issue>
<fpage>241</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="pmid">20643376</pub-id>
</element-citation>
</ref>
<ref id="CR222">
<label>222.</label>
<mixed-citation publication-type="other">Danfors T, von Knorring AL, Hartvig P, Langstrom B, Moulder R, Stromberg B, Torstenson R, Wester U et al (2005) Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. J Clin Psychopharmacol 25(5):485–489</mixed-citation>
</ref>
<ref id="CR223">
<label>223.</label>
<mixed-citation publication-type="other">Fernell E, Watanabe Y, Adolfsson I, Tani Y, Bergström M, Hartvig P, Lilja A, von Knorring AL et al (1997) Possible effects of tetrahydrobiopterin treatment in six children with autism—clinical and positron emission tomography data: a pilot study. Dev Med Child Neurol 39(5):313–318</mixed-citation>
</ref>
<ref id="CR224">
<label>224.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Komori</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Matsuishi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yamashita</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ohtaki</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Cerebrospinal fluid biopterin and biogenic amine metabolites during oral R-THBP therapy for infantile autism</article-title>
<source/>J Autism Dev Disord
          <year>1995</year>
<volume>25</volume>
<issue>2</issue>
<fpage>183</fpage>
<lpage>193</lpage>
<pub-id pub-id-type="pmid">7559284</pub-id>
</element-citation>
</ref>
<ref id="CR225">
<label>225.</label>
<mixed-citation publication-type="other">Schnetz-Boutaud NC, Anderson BM, Brown KD, Wright HH, Abramson RK, Cuccaro ML, Gilbert JR, Pericak-Vance MA et al (2009) Examination of tetrahydrobiopterin pathway genes in autism. Genes Brain Behav 8(8):753–757. 10.1111/j.1601-183X.2009.00521.x</mixed-citation>
</ref>
<ref id="CR226">
<label>226.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Suckling</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Powis</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Aberrant NF-kappaB expression in autism spectrum condition: a mechanism for neuroinflammation</article-title>
<source/>Front Psychiatry
          <year>2011</year>
<volume>2</volume>
<fpage>27</fpage>
<pub-id pub-id-type="pmid">21629840</pub-id>
</element-citation>
</ref>
<ref id="CR227">
<label>227.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chez</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Dowling</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Khanna</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kominsky</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children</article-title>
<source/>Pediatr Neurol
          <year>2007</year>
<volume>36</volume>
<issue>6</issue>
<fpage>361</fpage>
<lpage>365</lpage>
<pub-id pub-id-type="pmid">17560496</pub-id>
</element-citation>
</ref>
<ref id="CR228">
<label>228.</label>
<mixed-citation publication-type="other">Song R, Yu D, Yoon J, Park J (2015) Valproic acid attenuates the expression of pro-inflammatory cytokines lipopolysaccharide-treated canine peripheral blood mononuclear cells (in vitro) and in a canine endotoxemia model (in vivo). Vet Immunol Immunopathol. 10.1016/j.vetimm.2015.06.012</mixed-citation>
</ref>
<ref id="CR229">
<label>229.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Widjaja</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Careaga</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bent</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hendren</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Change in plasma cytokine levels during risperidone treatment in children with autism</article-title>
<source/>J Child Adolesc Psychopharmacol
          <year>2014</year>
<volume>24</volume>
<issue>10</issue>
<fpage>586</fpage>
<lpage>589</lpage>
<pub-id pub-id-type="pmid">24828014</pub-id>
</element-citation>
</ref>
<ref id="CR230">
<label>230.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suda</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Katsura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kanamaru</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Katayama</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Valproic acid attenuates ischemia-reperfusion injury in the rat brain through inhibition of oxidative stress and inflammation</article-title>
<source/>Eur J Pharmacol
          <year>2013</year>
<volume>707</volume>
<issue>1-3</issue>
<fpage>26</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="pmid">23541723</pub-id>
</element-citation>
</ref>
<ref id="CR231">
<label>231.</label>
<mixed-citation publication-type="other">Ximenes JC, de Oliveira Gonçalves D, Siqueira RM, Neves KR, Santos Cerqueira G, Correia AO, Félix FH, Leal LK et al (2013) Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory properties. Naunyn Schmiedebergs Arch Pharmacol 386(7):575–587. 10.1007/s00210-013-0853-4</mixed-citation>
</ref>
<ref id="CR232">
<label>232.</label>
<mixed-citation publication-type="other">Pardo CA, Farmer CA, Thurm A, Shebl FM, Ilieva J, Kalra S, Swedo S (2017) Serum and cerebrospinal fluid immune mediators in children with autistic disorder: a longitudinal study. Mol Autism. 8(1). 10.1186/s13229-016-0115-7</mixed-citation>
</ref>
<ref id="CR233">
<label>233.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsiao</surname>
<given-names>EY</given-names>
</name>
</person-group>
<article-title>Gastrointestinal issues in autism spectrum disorder</article-title>
<source/>Harv Rev Psychiatry
          <year>2014</year>
<volume>22</volume>
<issue>2</issue>
<fpage>104</fpage>
<lpage>111</lpage>
<pub-id pub-id-type="pmid">24614765</pub-id>
</element-citation>
</ref>
<ref id="CR234">
<label>234.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wakefield</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms</article-title>
<source/>J Neuroimmunol
          <year>2006</year>
<volume>173</volume>
<issue>1-2</issue>
<fpage>126</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="pmid">16494951</pub-id>
</element-citation>
</ref>
<ref id="CR235">
<label>235.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Anthony</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Torrente</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wakefield</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: mucosal immune activation and reduced counter regulatory interleukin-10</article-title>
<source/>J Clin Immunol
          <year>2004</year>
<volume>24</volume>
<issue>6</issue>
<fpage>664</fpage>
<lpage>673</lpage>
<pub-id pub-id-type="pmid">15622451</pub-id>
</element-citation>
</ref>
<ref id="CR236">
<label>236.</label>
<mixed-citation publication-type="other">Luna RA, Oezguen N, Balderas M, Venkatachalam A, Runge JK, Versalovic J, Veenstra-VanderWeele J, Anderson GM et al (2016) Distinct microbiome-neuroimmune signatures correlate with functional abdominal pain in children with autism spectrum disorder. Cell Mol Gastroenterol Hepatol 3(2):218–230. 10.1016/j.jcmgh.2016.11.008</mixed-citation>
</ref>
<ref id="CR237">
<label>237.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeFelice</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Ruchelli</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Markowitz</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Strogatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Kadivar</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mulberg</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>KA</given-names>
</name>
</person-group>
<article-title>Intestinal cytokines in children with pervasive developmental disorders</article-title>
<source/>Am J Gastroenterol
          <year>2003</year>
<volume>98</volume>
<issue>8</issue>
<fpage>1777</fpage>
<lpage>1782</lpage>
<pub-id pub-id-type="pmid">12907332</pub-id>
</element-citation>
</ref>
<ref id="CR238">
<label>238.</label>
<mixed-citation publication-type="other">Furlano RI, Anthony A, Day R, Brown A, McGarvey L, Thomson MA, Davies SE, Berelowitz M et al (2001) Colonic CD8 and gamma delta T-cell infiltration with epithelial damage in children with autism. J Pediatr 138(3):366–372</mixed-citation>
</ref>
<ref id="CR239">
<label>239.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Anthony</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pellicer</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Torrente</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Walker-Smith</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Wakefield</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology</article-title>
<source/>J Clin Immunol
          <year>2003</year>
<volume>23</volume>
<issue>6</issue>
<fpage>504</fpage>
<lpage>517</lpage>
<pub-id pub-id-type="pmid">15031638</pub-id>
</element-citation>
</ref>
<ref id="CR240">
<label>240.</label>
<mixed-citation publication-type="other">Torrente F, Ashwood P, Day R, Machado N, Furlano RI, Anthony A, Davies SE, Wakefield AJ et al (2002) Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Mol Psychiatry 7(4):375–382 334</mixed-citation>
</ref>
<ref id="CR241">
<label>241.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bashir</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Al-Ayadhi</surname>
<given-names>LY</given-names>
</name>
</person-group>
<article-title>Effect of camel milk on thymus and activation-regulated chemokine in autistic children: double-blind study</article-title>
<source/>Pediatr Res
          <year>2014</year>
<volume>75</volume>
<issue>4</issue>
<fpage>559</fpage>
<lpage>563</lpage>
<pub-id pub-id-type="pmid">24375082</pub-id>
</element-citation>
</ref>
<ref id="CR242">
<label>242.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shenoy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chatila</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome</article-title>
<source/>J Pediatr
          <year>2000</year>
<volume>136</volume>
<issue>5</issue>
<fpage>682</fpage>
<lpage>687</lpage>
<pub-id pub-id-type="pmid">10802504</pub-id>
</element-citation>
</ref>
<ref id="CR243">
<label>243.</label>
<mixed-citation publication-type="other">Feasby T, Banwell B, Benstead T, Bril V, Brouwers M, Freedman M, Hahn A, Hume H et al (2007) Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 21(2 Suppl 1):S57–107</mixed-citation>
</ref>
<ref id="CR244">
<label>244.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plioplys</surname>
<given-names>AV</given-names>
</name>
</person-group>
<article-title>Intravenous immunoglobulin treatment of children with autism</article-title>
<source/>J Child Neurol.
          <year>1998</year>
<volume>13</volume>
<issue>2</issue>
<fpage>79</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="pmid">9512308</pub-id>
</element-citation>
</ref>
<ref id="CR245">
<label>245.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aggarwal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Heads</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics</article-title>
<source/>J Autism Dev Disord
          <year>1996</year>
<volume>26</volume>
<issue>4</issue>
<fpage>439</fpage>
<lpage>452</lpage>
<pub-id pub-id-type="pmid">8863094</pub-id>
</element-citation>
</ref>
<ref id="CR246">
<label>246.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DelGiudice-Asch</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Schmeidler</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cunningham-Rundles</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hollander</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism</article-title>
<source/>J Autism Dev Disord
          <year>1999</year>
<volume>29</volume>
<issue>2</issue>
<fpage>157</fpage>
<lpage>160</lpage>
<pub-id pub-id-type="pmid">10382136</pub-id>
</element-citation>
</ref>
<ref id="CR247">
<label>247.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boris</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Goldblatt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Edelson</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Improvement in children with autism treated with intravenous gamma globulin</article-title>
<source/>J Nutr Environ Med
          <year>2005</year>
<volume>15</volume>
<fpage>169</fpage>
<lpage>176</lpage>
</element-citation>
</ref>
<ref id="CR248">
<label>248.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Melmed</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Barstow</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Enriquez</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Ranger-Moore</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ostrem</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Oral human immunoglobulin for children with autism and gastrointestinal dysfunction: a prospective, open-label study</article-title>
<source/>J Autism Dev Disord
          <year>2006</year>
<volume>36</volume>
<issue>8</issue>
<fpage>1053</fpage>
<lpage>1064</lpage>
<pub-id pub-id-type="pmid">16845577</pub-id>
</element-citation>
</ref>
<ref id="CR249">
<label>249.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Handen</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Melmed</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Aman</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Burnham</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Bruss</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>McDougle</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>A double-blind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder</article-title>
<source/>J Autism Dev Disord
          <year>2009</year>
<volume>39</volume>
<issue>5</issue>
<fpage>796</fpage>
<lpage>805</lpage>
<pub-id pub-id-type="pmid">19148734</pub-id>
</element-citation>
</ref>
<ref id="CR250">
<label>250.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Svecova</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>IVIG therapy in pemphigus vulgaris has corticosteroid-sparing and immunomodulatory effects</article-title>
<source/>Australas J Dermatol
          <year>2016</year>
<volume>57</volume>
<issue>2</issue>
<fpage>141</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="pmid">26581165</pub-id>
</element-citation>
</ref>
<ref id="CR251">
<label>251.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cantarini</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rigante</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Vitale</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Napodano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sakkas</surname>
<given-names>LI</given-names>
</name>
<name>
<surname>Bogdanos</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Shoenfeld</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future</article-title>
<source/>Immunol Res
          <year>2015</year>
<volume>61</volume>
<issue>3</issue>
<fpage>326</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="pmid">25550086</pub-id>
</element-citation>
</ref>
<ref id="CR252">
<label>252.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klehmet</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Goehler</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ulm</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kohler</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Meisel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Meisel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Harms</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Effective treatment with intravenous immunoglobulins reduces autoreactive T-cell response in patients with CIDP</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2015</year>
<volume>86</volume>
<issue>6</issue>
<fpage>686</fpage>
<lpage>691</lpage>
<pub-id pub-id-type="pmid">25074566</pub-id>
</element-citation>
</ref>
<ref id="CR253">
<label>253.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Issekutz</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Rowter</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Miescher</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Käsermann</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Intravenous IgG (IVIG) and subcutaneous IgG (SCIG) preparations have comparable inhibitory effect on T cell activation, which is not dependent on IgG sialylation, monocytes or B cells</article-title>
<source/>Clin Immunol
          <year>2015</year>
<volume>160</volume>
<issue>2</issue>
<fpage>123</fpage>
<lpage>132</lpage>
<pub-id pub-id-type="pmid">25982320</pub-id>
</element-citation>
</ref>
<ref id="CR254">
<label>254.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durandy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kaveri</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Kuijpers</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Basta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Miescher</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ravetch</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Rieben</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Intravenous immunoglobulins—understanding properties and mechanisms</article-title>
<source/>Clin Exp Immunol
          <year>2009</year>
<volume>158</volume>
<issue>Suppl 1</issue>
<fpage>2</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="pmid">19883419</pub-id>
</element-citation>
</ref>
<ref id="CR255">
<label>255.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dussault</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ducas</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Racine</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jacques</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Paré</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Côté</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Néron</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Immunomodulation of human B cells following treatment with intravenous immunoglobulins involves increased phosphorylation of extracellular signal-regulated kinases 1 and 2</article-title>
<source/>Int Immunol.
          <year>2008</year>
<volume>20</volume>
<issue>11</issue>
<fpage>1369</fpage>
<lpage>1379</lpage>
<pub-id pub-id-type="pmid">18689724</pub-id>
</element-citation>
</ref>
<ref id="CR256">
<label>256.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duffy</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Shankardass</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McAnulty</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Eksioglu</surname>
<given-names>YZ</given-names>
</name>
<name>
<surname>Coulter</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rotenberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Als</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Corticosteroid therapy in regressive autism: a retrospective study of effects on the Frequency Modulated Auditory Evoked Response (FMAER), language, and behavior</article-title>
<source/>BMC Neurol
          <year>2014</year>
<volume>14</volume>
<fpage>70</fpage>
<pub-id pub-id-type="pmid">24885033</pub-id>
</element-citation>
</ref>
<ref id="CR257">
<label>257.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Golla</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sweeney</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Corticosteroid therapy in regressive autism: Preliminary findings from a retrospective study</article-title>
<source/>BMC Med
          <year>2014</year>
<volume>12</volume>
<fpage>79</fpage>
<pub-id pub-id-type="pmid">24884537</pub-id>
</element-citation>
</ref>
<ref id="CR258">
<label>258.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stefanatos</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Grover</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Geller</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Case study: corticosteroid treatment of language regression in pervasive developmental disorder</article-title>
<source/>J Am Acad Child Adolesc Psychiatry
          <year>1995</year>
<volume>34</volume>
<issue>8</issue>
<fpage>1107</fpage>
<lpage>1111</lpage>
<pub-id pub-id-type="pmid">7545148</pub-id>
</element-citation>
</ref>
<ref id="CR259">
<label>259.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buitelaar</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>van Engeland</surname>
<given-names>H</given-names>
</name>
<name>
<surname>de Kogel</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>H</given-names>
</name>
<name>
<surname>van Hooff</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>van Ree</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>The use of adrenocorticotrophic hormone (4–9) analog ORG 2766 in autistic children: effects on the organization of behavior</article-title>
<source/>Biol Psychiatry
          <year>1992</year>
<volume>31</volume>
<issue>11</issue>
<fpage>1119</fpage>
<lpage>1129</lpage>
<pub-id pub-id-type="pmid">1326339</pub-id>
</element-citation>
</ref>
<ref id="CR260">
<label>260.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>LeClerc</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Easley</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Pharmacological therapies for autism spectrum disorder: a review</article-title>
<source/>P T
          <year>2015</year>
<volume>40</volume>
<issue>6</issue>
<fpage>389</fpage>
<lpage>397</lpage>
<pub-id pub-id-type="pmid">26045648</pub-id>
</element-citation>
</ref>
<ref id="CR261">
<label>261.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Obuchowicz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bielecka-Wajdman</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Paul-Samojedny</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nowacka</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Different influence of antipsychotics on the balance between pro- and anti-inflammatory cytokines depends on glia activation: an in vitro study</article-title>
<source/>Cytokine
          <year>2017</year>
<volume>94</volume>
<fpage>37</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="pmid">28411046</pub-id>
</element-citation>
</ref>
<ref id="CR262">
<label>262.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacDowell</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>García-Bueno</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Madrigal</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Parellada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Arango</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Micó</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Leza</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation</article-title>
<source/>Int J Neuropsychopharmacol
          <year>2013</year>
<volume>16</volume>
<issue>1</issue>
<fpage>121</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="pmid">22176740</pub-id>
</element-citation>
</ref>
<ref id="CR263">
<label>263.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Monji</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mizoguchi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Horikawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sato-Kasai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yoshiga</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kanba</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Pretreatment of aripiprazole and minocycline, but not haloperidol, suppresses oligodendrocyte damage from interferon-γ-stimulated microglia in co-culture model</article-title>
<source/>Schizophr Res
          <year>2013</year>
<volume>151</volume>
<issue>1-3</issue>
<fpage>20</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="pmid">24100191</pub-id>
</element-citation>
</ref>
<ref id="CR264">
<label>264.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sugino</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Futamura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mitsumoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Marunaka</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice</article-title>
<source/>Prog Neuropsychopharmacol Biol Psychiatry
          <year>2009</year>
<volume>33</volume>
<issue>2</issue>
<fpage>303</fpage>
<lpage>307</lpage>
<pub-id pub-id-type="pmid">19138716</pub-id>
</element-citation>
</ref>
<ref id="CR265">
<label>265.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kato</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Monji</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hashioka</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kanba</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro</article-title>
<source/>Schizophr Res
          <year>2007</year>
<volume>92</volume>
<issue>1-3</issue>
<fpage>108</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="pmid">17363222</pub-id>
</element-citation>
</ref>
<ref id="CR266">
<label>266.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sobiś</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rykaczewska-Czerwińska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Świętochowska</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gorczyca</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity</article-title>
<source/>Pharmacol Rep
          <year>2015</year>
<volume>67</volume>
<issue>2</issue>
<fpage>353</fpage>
<lpage>359</lpage>
<pub-id pub-id-type="pmid">25712663</pub-id>
</element-citation>
</ref>
<ref id="CR267">
<label>267.</label>
<mixed-citation publication-type="other">Cazzullo CL, Sacchetti E, Galluzzo A, Panariello A, Adorni A, Pegoraro M, Bosis S, Colombo F et al (2002) Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 26(1):33–39</mixed-citation>
</ref>
<ref id="CR268">
<label>268.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erbağci</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Herken</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Köylüoglu</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Yilmaz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tarakçioglu</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment</article-title>
<source/>Mediators Inflamm
          <year>2001</year>
<volume>10</volume>
<issue>3</issue>
<fpage>109</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="pmid">11545247</pub-id>
</element-citation>
</ref>
<ref id="CR269">
<label>269.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Go</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Jun</surname>
<given-names>TY</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>YK</given-names>
</name>
</person-group>
<article-title>Effect of risperidone on serum cytokines</article-title>
<source/>Int J Neurosci
          <year>2001</year>
<volume>111</volume>
<issue>1-2</issue>
<fpage>11</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="pmid">11913333</pub-id>
</element-citation>
</ref>
<ref id="CR270">
<label>270.</label>
<mixed-citation publication-type="other">Tobiasova Z, van der Lingen KH, Scahill L, Leckman JF, Zhang Y, Chae W, McCracken JT, McDougle CJ et al (2011) Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13. J Child Adolesc Psychopharmacol 21(6):555–564. 10.1089/cap.2010.0134</mixed-citation>
</ref>
<ref id="CR271">
<label>271.</label>
<mixed-citation publication-type="other">Troost PW, Lahuis BE, Steenhuis MP, Ketelaars CE, Buitelaar JK, van Engeland H, Scahill L, Minderaa RB et al (2005) Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 44(11):1137–1144</mixed-citation>
</ref>
<ref id="CR272">
<label>272.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soares</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shiozawa</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Trevizol</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Paula</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Lowenthal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cordeiro</surname>
<given-names>Q</given-names>
</name>
</person-group>
<article-title>Effects of augmentation agents in autistic disorder patients treated with risperidone: a systematic review and a meta-analysis</article-title>
<source/>Trends Psychiatry Psychother
          <year>2016</year>
<volume>38</volume>
<issue>2</issue>
<fpage>114</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="pmid">27409138</pub-id>
</element-citation>
</ref>
<ref id="CR273">
<label>273.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghanizadeh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tordjman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jaafari</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Aripiprazole for treating irritability in children &amp; adolescents with autism: a systematic review</article-title>
<source/>Indian J Med Res
          <year>2015</year>
<volume>142</volume>
<issue>3</issue>
<fpage>269</fpage>
<lpage>275</lpage>
<pub-id pub-id-type="pmid">26458342</pub-id>
</element-citation>
</ref>
<ref id="CR274">
<label>274.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deb</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Farmah</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Arshad</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Deb</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Unwin</surname>
<given-names>GL</given-names>
</name>
</person-group>
<article-title>The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder—a systematic review</article-title>
<source/>Res Dev Disabil.
          <year>2014</year>
<volume>35</volume>
<issue>3</issue>
<fpage>711</fpage>
<lpage>725</lpage>
<pub-id pub-id-type="pmid">24405794</pub-id>
</element-citation>
</ref>
<ref id="CR275">
<label>275.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arikawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kakinuma</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Noguchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Todaka</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Donepezil, an acetylcholinesterase inhibitor, attenuates LPS-induced inflammatory response in murine macrophage cell line RAW 264.7 through inhibition of nuclear factor kappa B translocation</article-title>
<source/>Eur J Pharmacol
          <year>2016</year>
<volume>789</volume>
<fpage>17</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="pmid">27373848</pub-id>
</element-citation>
</ref>
<ref id="CR276">
<label>276.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Donepezil regulates 1-methyl-4-phenylpyridinium-induced microglial polarization in Parkinson’s disease</article-title>
<source/>ACS Chem Neurosci
          <year>2015</year>
<volume>6</volume>
<issue>10</issue>
<fpage>1708</fpage>
<lpage>1714</lpage>
<pub-id pub-id-type="pmid">26114860</pub-id>
</element-citation>
</ref>
<ref id="CR277">
<label>277.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hwang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Suk</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Microglia signaling as a target of donepezil</article-title>
<source/>Neuropharmacology
          <year>2010</year>
<volume>58</volume>
<issue>7</issue>
<fpage>1122</fpage>
<lpage>1129</lpage>
<pub-id pub-id-type="pmid">20153342</pub-id>
</element-citation>
</ref>
<ref id="CR278">
<label>278.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karvat</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kimchi</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Acetylcholine elevation relieves cognitive rigidity and social deficiency in a mouse model of autism</article-title>
<source/>Neuropsychopharmacology
          <year>2014</year>
<volume>39</volume>
<issue>4</issue>
<fpage>831</fpage>
<lpage>840</lpage>
<pub-id pub-id-type="pmid">24096295</pub-id>
</element-citation>
</ref>
<ref id="CR279">
<label>279.</label>
<mixed-citation publication-type="other">Kim JW, Seung H, Kwon KJ, Ko MJ, Lee EJ, HA O, Choi CS, Kim KC et al (2014) Subchronic treatment of donepezil rescues impaired social, hyperactive, and stereotypic behavior in valproic acid-induced animal model of autism. PLoS One 9(8):e104927. 10.1371/journal.pone.0104927</mixed-citation>
</ref>
<ref id="CR280">
<label>280.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richardson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gard</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Klugman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Isaac</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tabet</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Blood pro-inflammatory cytokines in Alzheimer’s disease in relation to the use of acetylcholinesterase inhibitors</article-title>
<source/>Int J Geriatr Psychiatry
          <year>2013</year>
<volume>28</volume>
<issue>12</issue>
<fpage>1312</fpage>
<lpage>1317</lpage>
<pub-id pub-id-type="pmid">23585364</pub-id>
</element-citation>
</ref>
<ref id="CR281">
<label>281.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hardan</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Handen</surname>
<given-names>BL</given-names>
</name>
</person-group>
<article-title>A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder</article-title>
<source/>J Child Adolesc Psychopharmacol
          <year>2002</year>
<volume>12</volume>
<issue>3</issue>
<fpage>237</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="pmid">12427297</pub-id>
</element-citation>
</ref>
<ref id="CR282">
<label>282.</label>
<mixed-citation publication-type="other">Sahu JK, Gulati S, Sapra S, Arya R, Chauhan S, Chowdhury MR, Gupta N, Kabra M et al (2013) Effectiveness and safety of donepezil in boys with fragile X syndrome: a double-blind, randomized, controlled pilot study. J Child Neurol 28(5):570–575. 10.1177/0883073812449381</mixed-citation>
</ref>
<ref id="CR283">
<label>283.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Handen</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>McAuliffe-Bellin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Hardan</surname>
<given-names>AY</given-names>
</name>
</person-group>
<article-title>Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures</article-title>
<source/>J Child Adolesc Psychopharmacol
          <year>2011</year>
<volume>21</volume>
<issue>1</issue>
<fpage>43</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="pmid">21309696</pub-id>
</element-citation>
</ref>
<ref id="CR284">
<label>284.</label>
<mixed-citation publication-type="other">Mattei D, Djodari-Irani A, Hadar R, Pelz A, de Cossío LF, Goetz T, Matyash M, Kettenmann H et al (2014) Minocycline rescues decrease in neurogenesis, increase in microglia cytokines and deficits in sensorimotor gating in an animal model of schizophrenia. Brain Behav Immun 38:175–184. 10.1016/j.bbi.2014.01.019</mixed-citation>
</ref>
<ref id="CR285">
<label>285.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pardo</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Buckley</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thurm</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Azhagiri</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Neville</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Swedo</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>A pilot open-label trial of minocycline in patients with autism and regressive features</article-title>
<source/>J Neurodev Disord
          <year>2013</year>
<volume>5</volume>
<issue>1</issue>
<fpage>9</fpage>
<pub-id pub-id-type="pmid">23566357</pub-id>
</element-citation>
</ref>
<ref id="CR286">
<label>286.</label>
<mixed-citation publication-type="other">Ghaleiha A, Alikhani R, Kazemi MR, Mohammadi MR, Mohammadinejad P, Zeinoddini A, Hamedi M, Shahriari M et al (2016) Minocycline as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind placebo-controlled trial. J Child Adolesc Psychopharmacol 26(9):784–791</mixed-citation>
</ref>
<ref id="CR287">
<label>287.</label>
<mixed-citation publication-type="other"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link> - accessed 2017/09/30</mixed-citation>
</ref>
<ref id="CR288">
<label>288.</label>
<mixed-citation publication-type="other">Tohmi M, Tsuda N, Zheng Y, Mizuno M, Sotoyama H, Shibuya M, Kawamura M, Kakita A et al (2007) The cellular and behavioral consequences of interleukin-1 alpha penetration through the blood–brain barrier of neonatal rats: a critical period for efficacy. Neuroscience 150(1):234–250</mixed-citation>
</ref>
<ref id="CR289">
<label>289.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zalcman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dyck</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Nance</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Interleukin-2 and -6 induce behavioral-activating effects in mice</article-title>
<source/>Brain Res
          <year>1998</year>
<volume>811</volume>
<issue>1-2</issue>
<fpage>111</fpage>
<lpage>121</lpage>
<pub-id pub-id-type="pmid">9804916</pub-id>
</element-citation>
</ref>
<ref id="CR290">
<label>290.</label>
<mixed-citation publication-type="other">Raison CL, Borisov AS, Majer M, Drake DF, Pagnoni G, Woolwine BJ, Vogt GJ, Massung B et al (2009) Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry 65(4):296–303. 10.1016/j.biopsych.2008.08.010</mixed-citation>
</ref>
<ref id="CR291">
<label>291.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Grossberg</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>The effects of interferon-alpha on the production and action of other cytokines</article-title>
<source/>Semin Oncol
          <year>1998</year>
<volume>25</volume>
<issue>1 Suppl 1</issue>
<fpage>23</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="pmid">9482537</pub-id>
</element-citation>
</ref>
<ref id="CR292">
<label>292.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scagnolari</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Antonelli</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Antiviral activity of the interferon α family: biological and pharmacological aspects of the treatment of chronic hepatitis C</article-title>
<source/>Expert Opin Biol Ther
          <year>2013</year>
<volume>13</volume>
<issue>5</issue>
<fpage>693</fpage>
<lpage>711</lpage>
<pub-id pub-id-type="pmid">23350850</pub-id>
</element-citation>
</ref>
<ref id="CR293">
<label>293.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tarhini</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Gogas</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kirkwood</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>IFN-α in the treatment of melanoma</article-title>
<source/>J Immunol
          <year>2012</year>
<volume>189</volume>
<issue>8</issue>
<fpage>3789</fpage>
<lpage>3793</lpage>
<pub-id pub-id-type="pmid">23042723</pub-id>
</element-citation>
</ref>
<ref id="CR294">
<label>294.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kovacs</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kovacs</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Eszlari</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gonda</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Juhasz</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Psychological side effects of immune therapies: symptoms and pathomechanism</article-title>
<source/>Curr Opin Pharmacol
          <year>2016</year>
<volume>29</volume>
<fpage>97</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="pmid">27456240</pub-id>
</element-citation>
</ref>
<ref id="CR295">
<label>295.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Louis</surname>
<given-names>CU</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grupp</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Mackall</surname>
<given-names>CL</given-names>
</name>
</person-group>
<article-title>Current concepts in the diagnosis and management of cytokine release syndrome</article-title>
<source/>Blood
          <year>2014</year>
<volume>124</volume>
<issue>2</issue>
<fpage>188</fpage>
<lpage>195</lpage>
<pub-id pub-id-type="pmid">24876563</pub-id>
</element-citation>
</ref>
<ref id="CR296">
<label>296.</label>
<mixed-citation publication-type="other">Wu H, Wang X, Gao J, Liang S, Hao Y, Sun C, Xia W, Cao Y, Wu L (2017) Fingolimod (FTY720) attenuates social deficits, learning and memory impairments, neuronal loss and neuroinflammation in the rat model of autism. Life Sci 173:43–54. 10.1016/j.lfs.2017.01.012</mixed-citation>
</ref>
<ref id="CR297">
<label>297.</label>
<mixed-citation publication-type="other">Caprnda M, Kubatka P, Gazdikova K, Gasparova I, Valentova V, Stollarova N, La Rocca G, Kobyliak N, Dragasek J, Mozos I, Prosecky R, Siniscalco D, Büsselberg D, Rodrigo L, Kruzliak P (2017) Immunomodulatory effects of stem cells: therapeutic option for neurodegenerative disorders. Biomed Pharmacother 91:60–69. 10.1016/j.biopha.2017.04.034</mixed-citation>
</ref>
<ref id="CR298">
<label>298.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nauta</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Fibbe</surname>
<given-names>WE</given-names>
</name>
</person-group>
<article-title>Immunomodulatory properties of mesenchymal stromal cells</article-title>
<source/>Blood
          <year>2007</year>
<volume>110</volume>
<issue>10</issue>
<fpage>3499</fpage>
<lpage>3506</lpage>
<pub-id pub-id-type="pmid">17664353</pub-id>
</element-citation>
</ref>
<ref id="CR299">
<label>299.</label>
<mixed-citation publication-type="other">Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop DJ, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315–317. 10.1080/14653240600855905</mixed-citation>
</ref>
<ref id="CR300">
<label>300.</label>
<mixed-citation publication-type="other">Lee M, Jeong SY, Ha J, Kim M, Jin HJ, Kwon SJ, Chang JW, Choi SJ, Oh W, Yang YS, Kim JS, Jeon HB (2014) Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo. Biochem Biophys Res Commun 446(4):983–989. 10.1016/j.bbrc.2014.03.051</mixed-citation>
</ref>
<ref id="CR301">
<label>301.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patterson</surname>
<given-names>PH</given-names>
</name>
</person-group>
<article-title>Modeling autistic features in animals</article-title>
<source/>Pediatr Res
          <year>2011</year>
<volume>69</volume>
<issue>5 Pt 2</issue>
<fpage>34R</fpage>
<lpage>40R</lpage>
<pub-id pub-id-type="pmid">20940665</pub-id>
</element-citation>
</ref>
<ref id="CR302">
<label>302.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Inhibition of IL-6 trans-signaling in the brain increases sociability in the BTBR mouse model of autism</article-title>
<source/>Biochim Biophys Acta
          <year>2016</year>
<volume>1862</volume>
<issue>10</issue>
<fpage>1918</fpage>
<lpage>1925</lpage>
<pub-id pub-id-type="pmid">27460706</pub-id>
</element-citation>
</ref>
<ref id="CR303">
<label>303.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Careaga</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schwartzer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Inflammatory profiles in the BTBR mouse: how relevant are they to autism spectrum disorders?</article-title>
<source/>Brain Behav Immun
          <year>2015</year>
<volume>43</volume>
<fpage>11</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="pmid">24937468</pub-id>
</element-citation>
</ref>
<ref id="CR304">
<label>304.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Onore</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Careaga</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Babineau</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Schwartzer</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Inflammatory macrophage phenotype in BTBR T+tf/J mice</article-title>
<source/>Front Neurosci
          <year>2013</year>
<volume>7</volume>
<fpage>158</fpage>
<pub-id pub-id-type="pmid">24062633</pub-id>
</element-citation>
</ref>
<ref id="CR305">
<label>305.</label>
<mixed-citation publication-type="other">Segal-Gavish H, Karvat G, Barak N, Barzilay R, Ganz J, Edry L, Aharony I, Offen D et al (2016) Mesenchymal stem cell transplantation promotes neurogenesis and ameliorates autism related behaviors in BTBR mice. Autism Res 9(1):17–32. 10.1002/aur.1530</mixed-citation>
</ref>
<ref id="CR306">
<label>306.</label>
<mixed-citation publication-type="other">Perets N, Segal-Gavish H, Gothelf Y, Barzilay R, Barhum Y, Abramov N, Hertz S, Morozov D et al (2017) Long term beneficial effect of neurotrophic factors-secreting mesenchymal stem cells transplantation in the BTBR mouse model of autism. Behav Brain Res 331:254–260. 10.1016/j.bbr.2017.03.047</mixed-citation>
</ref>
<ref id="CR307">
<label>307.</label>
<mixed-citation publication-type="other">Barzilay R, Ganz J, Sadan O, Ben-Zur T, Bren Z, Hinden N, Taler M, Lev N et al (2013) Mesenchymal stem cells protect from sub-chronic phencyclidine insult in vivo and counteract changes in astrocyte gene expression in vitro. Eur Neuropsychopharmacol 23(9):1115–1123. 10.1016/j.euroneuro.2012.10.002</mixed-citation>
</ref>
<ref id="CR308">
<label>308.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barzilay</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sadan</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Melamed</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Offen</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Comparative characterization of bone marrow-derived mesenchymal stromal cells from four different rat strains</article-title>
<source/>Cytotherapy
          <year>2009</year>
<volume>11</volume>
<issue>4</issue>
<fpage>435</fpage>
<lpage>442</lpage>
<pub-id pub-id-type="pmid">19521891</pub-id>
</element-citation>
</ref>
<ref id="CR309">
<label>309.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ha</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mahmood</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Ra</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Suh</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>KA</given-names>
</name>
</person-group>
<article-title>Human adipose-derived stem cells ameliorate repetitive behavior, social deficit and anxiety in a VPA-induced autism mouse model</article-title>
<source/>Behav Brain Res
          <year>2017</year>
<volume>317</volume>
<fpage>479</fpage>
<lpage>484</lpage>
<pub-id pub-id-type="pmid">27717813</pub-id>
</element-citation>
</ref>
<ref id="CR310">
<label>310.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hegyi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Környei</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ferenczi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fekete</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kudlik</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kovács</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Madarász</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Uher</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Regulation of mouse microglia activation and effector functions by bone marrow-derived mesenchymal stem cells</article-title>
<source/>Stem Cells Dev
          <year>2014</year>
<volume>23</volume>
<issue>21</issue>
<fpage>2600</fpage>
<lpage>2612</lpage>
<pub-id pub-id-type="pmid">24870815</pub-id>
</element-citation>
</ref>
<ref id="CR311">
<label>311.</label>
<mixed-citation publication-type="other">Zanier ER, Pischiutta F, Riganti L, Marchesi F, Turola E, Fumagalli S, Perego C, Parotto E et al (2014) Bone marrow mesenchymal stromal cells drive protective M2 microglia polarization after brain trauma. Neurotherapeutics 11(3):679–695. 10.1007/s13311-014-0277-y</mixed-citation>
</ref>
<ref id="CR312">
<label>312.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ao</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Intracerebral transplantation of adipose-derived mesenchymal stem cells alternatively activates microglia and ameliorates neuropathological deficits in Alzheimer’s disease mice</article-title>
<source/>Cell Transplant
          <year>2013</year>
<volume>22</volume>
<issue>Suppl 1</issue>
<fpage>S113</fpage>
<lpage>S126</lpage>
<pub-id pub-id-type="pmid">24070198</pub-id>
</element-citation>
</ref>
<ref id="CR313">
<label>313.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giunti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Parodi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Usai</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vergani</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Casazza</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bruzzone</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mancardi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Uccelli</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Mesenchymal stem cells shape microglia effector functions through the release of CX3CL1</article-title>
<source/>Stem Cells
          <year>2012</year>
<volume>30</volume>
<issue>9</issue>
<fpage>2044</fpage>
<lpage>2053</lpage>
<pub-id pub-id-type="pmid">22821677</pub-id>
</element-citation>
</ref>
<ref id="CR314">
<label>314.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ooi</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Dheen</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Tay</surname>
<given-names>SS</given-names>
</name>
</person-group>
<article-title>Paracrine effects of mesenchymal stem cells-conditioned medium on microglial cytokines expression and nitric oxide production</article-title>
<source/>Neuroimmunomodulation
          <year>2015</year>
<volume>22</volume>
<issue>4</issue>
<fpage>233</fpage>
<lpage>242</lpage>
<pub-id pub-id-type="pmid">25341618</pub-id>
</element-citation>
</ref>
<ref id="CR315">
<label>315.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blondheim</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Ben-Zur</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human mesenchymal stem cells express neural genes, suggesting a neural predisposition</article-title>
<source/>Stem Cells Dev
          <year>2006</year>
<volume>15</volume>
<issue>2</issue>
<fpage>141</fpage>
<lpage>164</lpage>
<pub-id pub-id-type="pmid">16646662</pub-id>
</element-citation>
</ref>
<ref id="CR316">
<label>316.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lalu</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>McIntyre</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pugliese</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fergusson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Winston</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Granton</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Canadian Critical Care Trials Group. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>7</volume>
<issue>10</issue>
<fpage>e47559</fpage>
</element-citation>
</ref>
<ref id="CR317">
<label>317.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Badhe</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gokulchandran</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kulkarni</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mishra</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Shetty</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sane</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>An improved case of autism as revealed by PET CT scan in patient transplanted with autologous bone marrow derived mononuclear cells</article-title>
<source/>J Stem Cell Res Ther
          <year>2013</year>
<volume>3</volume>
<fpage>139</fpage>
</element-citation>
</ref>
<ref id="CR318">
<label>318.</label>
<mixed-citation publication-type="other">Sharma A, Gokulchandran N, Sane H, Nagrajan A, Paranjape A, Kulkarni P, Shetty A, Mishra P, Kali M, Biju H, Badhe P (2013) Autologous bone marrow mononuclear cell therapy for autism: an open label proof of concept study. Stem Cells Int: 623875. 10.1155/2013/623875</mixed-citation>
</ref>
<ref id="CR319">
<label>319.</label>
<mixed-citation publication-type="other">Lv YT, Zhang Y, Liu M, Qiuwaxi JN, Ashwood P, Cho SC, Huan Y, Ge RC et al (2013) Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. J Transl Med 11:196. 10.1186/1479-5876-11-196</mixed-citation>
</ref>
<ref id="CR320">
<label>320.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bradstreet</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Sych</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Antonucci</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Klunnik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ivankova</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Matyashchuk</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Demchuk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Siniscalco</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Efficacy of fetal stem cell transplantation in autism spectrum disorders: an open-labeled pilot study</article-title>
<source/>Cell Transplant
          <year>2014</year>
<volume>23</volume>
<issue>Suppl 1</issue>
<fpage>S105</fpage>
<lpage>S112</lpage>
<pub-id pub-id-type="pmid">25302490</pub-id>
</element-citation>
</ref>
<ref id="CR321">
<label>321.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shroff</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Human embryonic stem cells in the treatment of autism: a case series</article-title>
<source/>Innov Clin Neurosci
          <year>2017</year>
<volume>14</volume>
<issue>3-4</issue>
<fpage>12</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="pmid">28584692</pub-id>
</element-citation>
</ref>
<ref id="CR322">
<label>322.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schira</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Falkenberg</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hendricks</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Waldera-Lupa</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Kögler</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Stühler</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Characterization of regenerative phenotype of unrestricted somatic stem cells (USSC) from human umbilical cord blood (hUCB) by functional secretome analysis</article-title>
<source/>Mol Cell Proteomics
          <year>2015</year>
<volume>14</volume>
<issue>10</issue>
<fpage>2630</fpage>
<lpage>2643</lpage>
<pub-id pub-id-type="pmid">26183719</pub-id>
</element-citation>
</ref>
<ref id="CR323">
<label>323.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Divya</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Roshin</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Divya</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Rasheed</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Santhoshkumar</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Elizabeth</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>James</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pillai</surname>
<given-names>RM</given-names>
</name>
</person-group>
<article-title>Umbilical cord blood-derived mesenchymal stem cells consist of a unique population of progenitors co-expressing mesenchymal stem cell and neuronal markers capable of instantaneous neuronal differentiation</article-title>
<source/>Stem Cell Res Ther
          <year>2012</year>
<volume>3</volume>
<issue>6</issue>
<fpage>57</fpage>
<pub-id pub-id-type="pmid">23253356</pub-id>
</element-citation>
</ref>
<ref id="CR324">
<label>324.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro</article-title>
<source/>Immunology
          <year>2009</year>
<volume>126</volume>
<issue>2</issue>
<fpage>220</fpage>
<lpage>232</lpage>
<pub-id pub-id-type="pmid">18624725</pub-id>
</element-citation>
</ref>
<ref id="CR325">
<label>325.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Perez-Cruz</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Fallen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gluckman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Madrigal</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Analysis of the cytokine production by cord and adult blood</article-title>
<source/>Hum Immunol
          <year>1999</year>
<volume>60</volume>
<issue>4</issue>
<fpage>331</fpage>
<lpage>336</lpage>
<pub-id pub-id-type="pmid">10363724</pub-id>
</element-citation>
</ref>
<ref id="CR326">
<label>326.</label>
<mixed-citation publication-type="other">Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, Esperou H, Thierry D et al (1989) Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 321(17):1174–1178</mixed-citation>
</ref>
<ref id="CR327">
<label>327.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Kurtzberg</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Cord blood for brain injury</article-title>
<source/>Cytotherapy
          <year>2015</year>
<volume>17</volume>
<issue>6</issue>
<fpage>775</fpage>
<lpage>785</lpage>
<pub-id pub-id-type="pmid">25800775</pub-id>
</element-citation>
</ref>
<ref id="CR328">
<label>328.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Englander</surname>
<given-names>ZA</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Case</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mikati</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Kurtzberg</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>AW</given-names>
</name>
</person-group>
<article-title>Brain structural connectivity increases concurrent with functional improvement: evidence from diffusion tensor MRI in children with cerebral palsy during therapy</article-title>
<source/>Neuroimage Clin
          <year>2015</year>
<volume>7</volume>
<fpage>315</fpage>
<lpage>324</lpage>
<pub-id pub-id-type="pmid">25610796</pub-id>
</element-citation>
</ref>
<ref id="CR329">
<label>329.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>McLaughlin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Allison</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fitzgerald</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Waters-Pick</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kurtzberg</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Repeated autologous umbilical cord blood infusions are feasible and had no acute safety issues in young babies with congenital hydrocephalus</article-title>
<source/>Pediatr Res
          <year>2015</year>
<volume>78</volume>
<issue>6</issue>
<fpage>712</fpage>
<lpage>716</lpage>
<pub-id pub-id-type="pmid">26331765</pub-id>
</element-citation>
</ref>
<ref id="CR330">
<label>330.</label>
<mixed-citation publication-type="other">Saha A, Buntz S, Scotland P, Xu L, Noeldner P, Patel S, Wollish A, Gunaratne A et al (2016) A cord blood monocyte-derived cell therapy product accelerates brain remyelination. JCI Insight 1(13):e86667</mixed-citation>
</ref>
<ref id="CR331">
<label>331.</label>
<mixed-citation publication-type="other">Drobyshevsky A, Cotten CM, Shi Z, Luo K, Jiang R, Derrick M, Tracy ET, Gentry T et al (2015) Human umbilical cord blood cells ameliorate motor deficits in rabbits in a cerebral palsy model. Dev Neurosci 37(4-5):349–362. 10.1159/000374107.</mixed-citation>
</ref>
<ref id="CR332">
<label>332.</label>
<mixed-citation publication-type="other">Dawson G, Sun JM, Davlantis KS, Murias M, Franz L, Troy J, Simmons R, Sabatos-DeVito M et al (2017) Autologous cord blood infusions are safe and feasible in young children with autism spectrum disorder: results of a single-center phase I open-label trial. Stem Cells Transl Med 6(5):1332–1339. 10.1002/sctm.16-0474</mixed-citation>
</ref>
<ref id="CR333">
<label>333.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gillberg</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fernell</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Autism plus versus autism pure</article-title>
<source/>J Autism Dev Disord
          <year>2014</year>
<volume>44</volume>
<issue>12</issue>
<fpage>3274</fpage>
<lpage>3276</lpage>
<pub-id pub-id-type="pmid">24958434</pub-id>
</element-citation>
</ref>
<ref id="CR334">
<label>334.</label>
<mixed-citation publication-type="other">Sing (2009) Phenotypic expression of autoimmune autistic disorder (AAD): a major subset of autism Ann Clin Psychiatry 21(3):148–61</mixed-citation>
</ref>
<ref id="CR335">
<label>335.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nadeem</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Bakheet</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Al-Harbi</surname>
<given-names>NO</given-names>
</name>
<name>
<surname>Al-Ayadhi</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Attia</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Zoheir</surname>
<given-names>KM</given-names>
</name>
</person-group>
<article-title>Toll-like receptor 4 signaling is associated with upregulated NADPH oxidase expression in peripheral T cells of children with autism</article-title>
<source/>Brain Behav Immun
          <year>2017</year>
<volume>61</volume>
<fpage>146</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="pmid">28034626</pub-id>
</element-citation>
</ref>
<ref id="CR336">
<label>336.</label>
<mixed-citation publication-type="other">Patel AB, Tsilioni I, Leeman SE, Theoharides TC (2016) Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism. Proc Natl Acad Sci U S A 113(45):E7049–E7058. 10.1073/pnas.1604992113</mixed-citation>
</ref>
<ref id="CR337">
<label>337.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alabdali</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Al-Ayadhi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>El-Ansary</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Association of social and cognitive impairment and biomarkers in autism spectrum disorders</article-title>
<source/>J Neuroinflammation
          <year>2014</year>
<volume>11</volume>
<fpage>4</fpage>
<pub-id pub-id-type="pmid">24400970</pub-id>
</element-citation>
</ref>
<ref id="CR338">
<label>338.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Ayadhi</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Mostafa</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Increased serum osteopontin levels in autistic children: relation to the disease severity</article-title>
<source/>Brain Behav Immun
          <year>2011</year>
<volume>25</volume>
<issue>7</issue>
<fpage>1393</fpage>
<lpage>1398</lpage>
<pub-id pub-id-type="pmid">21521652</pub-id>
</element-citation>
</ref>
<ref id="CR339">
<label>339.</label>
<mixed-citation publication-type="other">Ikawa D, Makinodan M, Iwata K, Ohgidani M, Kato TA, Yamashita Y, Yamamuro K, Kimoto S, Toritsuka M, Yamauchi T, Fukami SI, Yoshino H, Okumura K, Tanaka T, Wanaka A, Owada Y, Tsujii M, Sugiyama T, Tsuchiya K, Mori N, Hashimoto R, Matsuzaki H, Kanba S, Kishimoto T (2017) Microglia-derived neuregulin expression in psychiatric disorders. Brain Behav Immun 61:375–385. 10.1016/j.bbi.2017.01.003</mixed-citation>
</ref>
<ref id="CR340">
<label>340.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Onore</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Nordahl</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Levels of soluble platelet endothelial cell adhesion molecule-1 and P-selectin are decreased in children with autism spectrum disorder</article-title>
<source/>Biol Psychiatry
          <year>2012</year>
<volume>72</volume>
<issue>12</issue>
<fpage>1020</fpage>
<lpage>1025</lpage>
<pub-id pub-id-type="pmid">22717029</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>